{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "%%capture\n",
    "# !pip install unsloth\n",
    "# # Also get the latest nightly Unsloth!\n",
    "# !pip uninstall unsloth -y && pip install --upgrade --no-cache-dir --no-deps git+https://github.com/unslothai/unsloth.git"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "# %pip uninstall unsloth unsloth_zoo -y\n",
    "# %pip install --upgrade --no-cache-dir \"unsloth[colab-new] @ git+https://github.com/unslothai/unsloth.git\"\n",
    "# %pip install --upgrade --no-cache-dir \"git+https://github.com/unslothai/unsloth-zoo.git\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "os.environ[\"CUDA_VISIBLE_DEVICES\"] = \"0\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ü¶• Unsloth: Will patch your computer to enable 2x faster free finetuning.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025-02-03 15:34:36.643539: I tensorflow/core/util/port.cc:153] oneDNN custom operations are on. You may see slightly different numerical results due to floating-point round-off errors from different computation orders. To turn them off, set the environment variable `TF_ENABLE_ONEDNN_OPTS=0`.\n",
      "2025-02-03 15:34:36.657643: E external/local_xla/xla/stream_executor/cuda/cuda_fft.cc:477] Unable to register cuFFT factory: Attempting to register factory for plugin cuFFT when one has already been registered\n",
      "WARNING: All log messages before absl::InitializeLog() is called are written to STDERR\n",
      "E0000 00:00:1738564476.674736 2751950 cuda_dnn.cc:8310] Unable to register cuDNN factory: Attempting to register factory for plugin cuDNN when one has already been registered\n",
      "E0000 00:00:1738564476.679759 2751950 cuda_blas.cc:1418] Unable to register cuBLAS factory: Attempting to register factory for plugin cuBLAS when one has already been registered\n",
      "2025-02-03 15:34:36.697365: I tensorflow/core/platform/cpu_feature_guard.cc:210] This TensorFlow binary is optimized to use available CPU instructions in performance-critical operations.\n",
      "To enable the following instructions: AVX2 AVX512F AVX512_VNNI FMA, in other operations, rebuild TensorFlow with the appropriate compiler flags.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Unsloth: OpenAI failed to import - ignoring for now.\n",
      "ü¶• Unsloth Zoo will now patch everything to make training faster!\n",
      "==((====))==  Unsloth 2025.1.8: Fast Llama patching. Transformers: 4.46.3.\n",
      "   \\\\   /|    GPU: NVIDIA A100-PCIE-40GB. Max memory: 39.394 GB. Platform: Linux.\n",
      "O^O/ \\_/ \\    Torch: 2.5.0+cu124. CUDA: 8.0. CUDA Toolkit: 12.4. Triton: 3.1.0\n",
      "\\        /    Bfloat16 = TRUE. FA [Xformers = 0.0.28.post2. FA2 = True]\n",
      " \"-____-\"     Free Apache license: http://github.com/unslothai/unsloth\n",
      "Unsloth: Fast downloading is enabled - ignore downloading bars which are red colored!\n"
     ]
    }
   ],
   "source": [
    "from unsloth import FastLanguageModel\n",
    "import torch\n",
    "max_seq_length = 2048 # Choose any! We auto support RoPE Scaling internally!\n",
    "dtype = None # None for auto detection. Float16 for Tesla T4, V100, Bfloat16 for Ampere+\n",
    "load_in_4bit = True # Use 4bit quantization to reduce memory usage. Can be False.\n",
    "\n",
    "# 4bit pre quantized models we support for 4x faster downloading + no OOMs.\n",
    "fourbit_models = [\n",
    "    \"unsloth/Meta-Llama-3.1-8B-bnb-4bit\",      # Llama-3.1 15 trillion tokens model 2x faster!\n",
    "    \"unsloth/Meta-Llama-3.1-8B-Instruct-bnb-4bit\",\n",
    "    \"unsloth/Meta-Llama-3.1-70B-bnb-4bit\",\n",
    "    \"unsloth/Meta-Llama-3.1-405B-bnb-4bit\",    # We also uploaded 4bit for 405b!\n",
    "    \"unsloth/Mistral-Nemo-Base-2407-bnb-4bit\", # New Mistral 12b 2x faster!\n",
    "    \"unsloth/Mistral-Nemo-Instruct-2407-bnb-4bit\",\n",
    "    \"unsloth/mistral-7b-v0.3-bnb-4bit\",        # Mistral v3 2x faster!\n",
    "    \"unsloth/mistral-7b-instruct-v0.3-bnb-4bit\",\n",
    "    \"unsloth/Phi-3.5-mini-instruct\",           # Phi-3.5 2x faster!\n",
    "    \"unsloth/Phi-3-medium-4k-instruct\",\n",
    "    \"unsloth/gemma-2-9b-bnb-4bit\",\n",
    "    \"unsloth/gemma-2-27b-bnb-4bit\",            # Gemma 2x faster!\n",
    "] # More models at https://huggingface.co/unsloth\n",
    "\n",
    "model, tokenizer = FastLanguageModel.from_pretrained(\n",
    "    # model_name = \"unsloth/Meta-Llama-3.1-8B\",\n",
    "    model_name = \"unsloth/Meta-Llama-3.1-8B\",\n",
    "    max_seq_length = max_seq_length,\n",
    "    dtype = dtype,\n",
    "    load_in_4bit = load_in_4bit,\n",
    "    # token = \"hf_...\", # use one if using gated models like meta-llama/Llama-2-7b-hf\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Unsloth: Dropout = 0 is supported for fast patching. You are using dropout = 0.05.\n",
      "Unsloth will patch all other layers, except LoRA matrices, causing a performance hit.\n",
      "Unsloth 2025.1.8 patched 32 layers with 0 QKV layers, 0 O layers and 0 MLP layers.\n"
     ]
    }
   ],
   "source": [
    "model = FastLanguageModel.get_peft_model(\n",
    "    model,\n",
    "    r = 8, # Choose any number > 0 ! Suggested 8, 16, 32, 64, 128\n",
    "    target_modules = [\"q_proj\", \"k_proj\", \"v_proj\", \"o_proj\",\n",
    "                     \"gate_proj\", \"up_proj\", \"down_proj\",],\n",
    "    lora_alpha = 16,\n",
    "    lora_dropout = 0.05, # Supports any, but = 0 is optimized\n",
    "    bias = \"none\",    # Supports any, but = \"none\" is optimized\n",
    "    # [NEW] \"unsloth\" uses 30% less VRAM, fits 2x larger batch sizes!\n",
    "    use_gradient_checkpointing = \"unsloth\", # True or \"unsloth\" for very long context\n",
    "    random_state = 3407,\n",
    "    use_rslora = False,  # We support rank stabilized LoRA\n",
    "    loftq_config = None, # And LoftQ\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "# from datasets import load_dataset\n",
    "# from datasets import Dataset, concatenate_datasets\n",
    "\n",
    "# import pandas as pd\n",
    "\n",
    "# alpaca_prompt = \"\"\"Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request.\n",
    "\n",
    "# ### Instruction:\n",
    "# {}\n",
    "\n",
    "# ### Input:\n",
    "# {}\n",
    "\n",
    "# ### Response:\n",
    "# {}\"\"\"\n",
    "\n",
    "# EOS_TOKEN = tokenizer.eos_token  # Must add EOS_TOKEN\n",
    "\n",
    "# def formatting_prompts_func(examples):\n",
    "#     instructions = examples[\"instruction\"]\n",
    "#     inputs = examples[\"input\"]\n",
    "#     outputs = examples[\"output\"]\n",
    "#     texts = []\n",
    "#     for instruction, input_text, output in zip(instructions, inputs, outputs):\n",
    "#         text = alpaca_prompt.format(instruction, input_text, output) + EOS_TOKEN\n",
    "#         texts.append(text)\n",
    "#     return { \"text\": texts }\n",
    "\n",
    "# dataset = load_dataset(\"passionMan/diabetes_v9\", split=\"train\")\n",
    "# dataset = dataset.map(formatting_prompts_func, batched=True)\n",
    "\n",
    "# dataset_df = pd.DataFrame(dataset)\n",
    "\n",
    "# long_data = dataset_df[dataset_df['dataset'].isin(['pubmedqa', 'icliniq', 'pubmed', 'chemdner', 'medal', 'mfc'])].reset_index(drop=True)\n",
    "# short_data = dataset_df[~dataset_df['dataset'].isin(['pubmedqa', 'icliniq', 'pubmed', 'chemdner', 'medal', 'mfc'])].reset_index(drop=True)\n",
    "\n",
    "# long_dataset = Dataset.from_pandas(long_data)\n",
    "# short_dataset = Dataset.from_pandas(short_data)\n",
    "\n",
    "# combined_dataset = concatenate_datasets([short_dataset, long_dataset])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "# from datasets import load_dataset\n",
    "# from datasets import Dataset, concatenate_datasets\n",
    "\n",
    "# import pandas as pd\n",
    "\n",
    "# alpaca_prompt = \"\"\"Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request.\n",
    "\n",
    "# ### Instruction:\n",
    "# {}\n",
    "\n",
    "# ### Input:\n",
    "# {}\n",
    "\n",
    "# ### Response:\n",
    "# {}\"\"\"\n",
    "\n",
    "# EOS_TOKEN = tokenizer.eos_token  # Must add EOS_TOKEN\n",
    "\n",
    "# def formatting_prompts_func(examples):\n",
    "#     instructions = examples[\"instruction\"]\n",
    "#     inputs = examples[\"input\"]\n",
    "#     outputs = examples[\"output\"]\n",
    "#     texts = []\n",
    "    \n",
    "#     for instruction, input_text, output in zip(instructions, inputs, outputs):\n",
    "#         text = alpaca_prompt.format(instruction, input_text, output) + EOS_TOKEN\n",
    "#         texts.append(text)\n",
    "\n",
    "#     return { \"text\": texts }\n",
    "\n",
    "# dataset = load_dataset(\"passionMan/diabetes_v11\", split=\"train\")\n",
    "# dataset = dataset.map(formatting_prompts_func, batched=True)\n",
    "\n",
    "# dataset_df = pd.DataFrame(dataset)\n",
    "\n",
    "# long_data = dataset_df[dataset_df['dataset'].isin(['meddialog', 'pubmed', 'ddi'])].reset_index(drop=True)\n",
    "# short_data = dataset_df[~dataset_df['dataset'].isin(['meddialog', 'pubmed', 'ddi'])].reset_index(drop=True)\n",
    "\n",
    "# def tokenize_and_set_max_length(examples):\n",
    "#     max_len = 4096 if examples[\"dataset\"] in ['meddialog', 'pubmed', 'ddi'] else 1024\n",
    "#     return tokenizer(examples[\"text\"], truncation=True, padding=\"max_length\", max_length=max_len)\n",
    "\n",
    "# long_dataset = Dataset.from_pandas(long_data).map(tokenize_and_set_max_length, batched=True)\n",
    "# short_dataset = Dataset.from_pandas(short_data).map(tokenize_and_set_max_length, batched=True)\n",
    "\n",
    "# combined_dataset = concatenate_datasets([short_dataset, long_dataset])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "# from datasets import load_dataset, Dataset\n",
    "# import pandas as pd\n",
    "\n",
    "# # Alpaca Ìè¨Îß∑ Ï†ÅÏö© ÌÖúÌîåÎ¶ø\n",
    "# alpaca_prompt = \"\"\"Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request.\n",
    "\n",
    "# ### Instruction:\n",
    "# {}\n",
    "\n",
    "# ### Input:\n",
    "# {}\n",
    "\n",
    "# ### Response:\n",
    "# {}\"\"\"\n",
    "\n",
    "# EOS_TOKEN = tokenizer.eos_token  # Must add EOS_TOKEN\n",
    "\n",
    "# # 1Ô∏è‚É£ Îç∞Ïù¥ÌÑ∞ÏÖã Î°úÎìú Î∞è Ìè¨Îß∑ Ï†ÅÏö©\n",
    "# def formatting_prompts_func(examples):\n",
    "#     texts = [\n",
    "#         alpaca_prompt.format(inst, inp, out) + EOS_TOKEN\n",
    "#         for inst, inp, out in zip(examples[\"instruction\"], examples[\"input\"], examples[\"output\"])\n",
    "#     ]\n",
    "#     return {\"text\": texts, \"task\": examples[\"task\"]}  # task Ï†ïÎ≥¥ÎèÑ Ïú†ÏßÄ\n",
    "\n",
    "# dataset = load_dataset(\"passionMan/diabetes_v11\", split=\"train\")\n",
    "# dataset = dataset.map(formatting_prompts_func, batched=True)\n",
    "\n",
    "# # 2Ô∏è‚É£ TaskÎ≥Ñ max_length ÏÑ§Ï†ï\n",
    "# task_max_length = {\n",
    "#     \"alternative_diet\": 1024,\n",
    "#     \"daily_diets\": 512,\n",
    "#     \"dfh_info\": 512,\n",
    "#     \"generation\": 3072,\n",
    "#     \"ie\": 2048,\n",
    "#     \"nli\": 2048,\n",
    "#     \"qa_objective_1\": 2048,\n",
    "#     \"qa_objective_2\": 1024,\n",
    "#     \"qa_objective_3\": 2048,\n",
    "#     \"re\": 2048,\n",
    "#     \"summarization\": 3072,  # Í∞ÄÏû• Í∏¥ ÌèâÍ∑† Í∏∏Ïù¥ Ï†ÅÏö©\n",
    "# }\n",
    "\n",
    "# # 3Ô∏è‚É£ Tokenization Î∞è max_length Ï†ÅÏö© (batched=True ÎåÄÏùë)\n",
    "# def tokenize_and_set_max_length(examples):\n",
    "#     # Í∞Å ÏÉòÌîåÎ≥Ñ max_length ÏÑ§Ï†ï ÌõÑ Í∞úÎ≥ÑÏ†ÅÏúºÎ°ú ÌÜ†ÌÅ∞Ìôî Ï†ÅÏö©\n",
    "#     tokenized_texts = [\n",
    "#         tokenizer(\n",
    "#             text,\n",
    "#             truncation=True,\n",
    "#             padding=\"max_length\",\n",
    "#             max_length=task_max_length.get(task, 1024)  # Í∏∞Î≥∏Í∞í 1024\n",
    "#         ) for text, task in zip(examples[\"text\"], examples[\"task\"])\n",
    "#     ]\n",
    "    \n",
    "#     # ÌÜ†ÌÅ∞ÌôîÎêú Í≤∞Í≥ºÎ•º Î¶¨Ïä§Ìä∏ÏóêÏÑú ÎîïÏÖîÎÑàÎ¶¨ ÌòïÌÉúÎ°ú Î≥ÄÌôò\n",
    "#     return {key: [dic[key] for dic in tokenized_texts] for key in tokenized_texts[0]}\n",
    "\n",
    "# # üîπ Dataset.map()ÏùÑ batched=TrueÎ°ú Î≥ÄÍ≤ΩÌïòÏó¨ Ï≤òÎ¶¨\n",
    "# tokenized_dataset = dataset.map(tokenize_and_set_max_length, batched=True, batch_size=4)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "cac47a60c1c3443592a581b265e5914b",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "README.md:   0%|          | 0.00/648 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "03f7755851f0411e9b79708861d58322",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "train-00000-of-00001.parquet:   0%|          | 0.00/47.5M [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "130e96c2350d4aa08f35db90d3a5c514",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "test-00000-of-00001.parquet:   0%|          | 0.00/4.80M [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "8f6e829411c7471d934b0d376bc45558",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Generating train split:   0%|          | 0/41622 [00:00<?, ? examples/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "529ff4757dec4105bdeaf5b3738c3a6f",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Generating test split:   0%|          | 0/6044 [00:00<?, ? examples/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "e73051407591408d9b0257edf11f3b6a",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Map:   0%|          | 0/41622 [00:00<?, ? examples/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "287a244409e54a298c8ce5a066d24478",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Map:   0%|          | 0/8905 [00:00<?, ? examples/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "6c22a909b7a04970bdcdc1734f0ceae2",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Map:   0%|          | 0/8672 [00:00<?, ? examples/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "49985051b4324fb687fa1880467ea290",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Map:   0%|          | 0/17577 [00:00<?, ? examples/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from datasets import load_dataset\n",
    "from datasets import Dataset, concatenate_datasets\n",
    "\n",
    "import pandas as pd\n",
    "\n",
    "alpaca_prompt = \"\"\"Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request.\n",
    "\n",
    "### Instruction:\n",
    "{}\n",
    "\n",
    "### Input:\n",
    "{}\n",
    "\n",
    "### Response:\n",
    "{}\"\"\"\n",
    "\n",
    "EOS_TOKEN = tokenizer.eos_token  # Must add EOS_TOKEN\n",
    "\n",
    "def formatting_prompts_func(examples):\n",
    "    instructions = examples[\"instruction\"]\n",
    "    inputs = examples[\"input\"]\n",
    "    outputs = examples[\"output\"]\n",
    "    texts = []\n",
    "    \n",
    "    for instruction, input_text, output in zip(instructions, inputs, outputs):\n",
    "        text = alpaca_prompt.format(instruction, input_text, output) + EOS_TOKEN\n",
    "        texts.append(text)\n",
    "\n",
    "    return { \"text\": texts }\n",
    "\n",
    "dataset = load_dataset(\"passionMan/diabetes_v13\", split=\"train\")\n",
    "dataset = dataset.map(formatting_prompts_func, batched=True)\n",
    "\n",
    "dataset_df = pd.DataFrame(dataset)\n",
    "\n",
    "long_data = dataset_df[dataset_df['dataset'].isin(['pubmed', 'bionli', 'chemdner'])].reset_index(drop=True)\n",
    "medium_data = dataset_df[dataset_df['dataset'].isin(['ddi', 'pubmedqa', 'medqa', 'meddialog'])].reset_index(drop=True)\n",
    "short_data = dataset_df[~dataset_df['dataset'].isin(['medmcqa', 'diabetes_food_hub'])].reset_index(drop=True)\n",
    "\n",
    "def tokenize_and_set_max_length(examples):\n",
    "    if examples[\"dataset\"] in [\"pubmed\", 'bionli', 'chemdner']:\n",
    "        max_len = 4096\n",
    "    elif examples[\"dataset\"] in [\"ddi\", \"pubmedqa\", \"medqa\", \"meddialog\"]:\n",
    "        max_len = 2048\n",
    "    else:\n",
    "        max_len = 1024\n",
    "    return tokenizer(examples[\"text\"], truncation=True, padding=\"max_length\", max_length=max_len)\n",
    "\n",
    "long_dataset = Dataset.from_pandas(long_data).map(tokenize_and_set_max_length, batched=True)\n",
    "medium_dataset = Dataset.from_pandas(medium_data).map(tokenize_and_set_max_length, batched=True)\n",
    "short_dataset = Dataset.from_pandas(short_data).map(tokenize_and_set_max_length, batched=True)\n",
    "\n",
    "combined_dataset = concatenate_datasets([short_dataset, medium_dataset, long_dataset])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "# from trl import SFTTrainer\n",
    "# from transformers import TrainingArguments\n",
    "# from unsloth import is_bfloat16_supported\n",
    "# from datasets import Dataset, concatenate_datasets\n",
    "# import pandas as pd\n",
    "# import numpy as np\n",
    "\n",
    "\n",
    "# def compute_weights(example):\n",
    "#     return {\"weight\": 0.4 if example['dataset'] in ['pubmedqa', 'icliniq', 'pubmed', 'chemdner', 'medal', 'mfc'] else 0.6}\n",
    "\n",
    "# weighted_dataset = combined_dataset.map(compute_weights)\n",
    "\n",
    "# weights = np.array(weighted_dataset[\"weight\"])\n",
    "# weights = weights / weights.sum()  \n",
    "\n",
    "# weighted_indices = np.random.choice(len(combined_dataset), size=len(combined_dataset), p=weights)\n",
    "# resampled_dataset = combined_dataset.select(weighted_indices)\n",
    "\n",
    "# if isinstance(resampled_dataset, dict):\n",
    "#     resampled_dataset = Dataset.from_dict(resampled_dataset)\n",
    "\n",
    "# if \"text\" not in resampled_dataset.column_names:\n",
    "#     resampled_dataset = resampled_dataset.map(lambda x: {\"text\": x[\"input\"] + \" \" + x[\"output\"]})\n",
    "\n",
    "# trainer = SFTTrainer(\n",
    "#     model=model,\n",
    "#     tokenizer=tokenizer,\n",
    "#     train_dataset=resampled_dataset,\n",
    "#     dataset_text_field=\"text\",\n",
    "#     dataset_num_proc=16, \n",
    "\n",
    "#     args=TrainingArguments(\n",
    "#         per_device_train_batch_size=32, \n",
    "#         gradient_accumulation_steps=1,  \n",
    "#         warmup_steps=300,  \n",
    "#         num_train_epochs=3, \n",
    "#         learning_rate=3e-5,  \n",
    "#         fp16=not is_bfloat16_supported(),\n",
    "#         bf16=is_bfloat16_supported(),  \n",
    "#         optim=\"adamw_8bit\",  \n",
    "#         weight_decay=0.01,  \n",
    "#         lr_scheduler_type=\"linear\",  \n",
    "#         logging_steps=100,  \n",
    "#         seed=3407,  \n",
    "#         save_steps=200,  \n",
    "#         output_dir=\"outputs/weighted_sampling9\", \n",
    "#         report_to=\"none\",  \n",
    "#     ),\n",
    "# )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "# from datasets import Dataset, concatenate_datasets\n",
    "# import numpy as np\n",
    "# from trl import SFTTrainer\n",
    "# from transformers import TrainingArguments\n",
    "# from unsloth import is_bfloat16_supported\n",
    "# import pandas as pd\n",
    "\n",
    "# def compute_weights(example):\n",
    "#     if example['dataset'] in ['daily_diets']:\n",
    "#         return {\"weight\": 0.3}\n",
    "#     elif example['dataset'] in ['alternative_diet', 'dfh_info']:\n",
    "#         return {\"weight\": 0.5}\n",
    "#     elif example['dataset'] in ['meddialog', 'pubmed']:\n",
    "#         return {\"weight\": 0.7}\n",
    "#     elif example['dataset'] in ['chemdner']:\n",
    "#         return {\"weight\": 1.2} \n",
    "#     elif example['dataset'] in ['ddi']:\n",
    "#         return {\"weight\": 2.0}\n",
    "#     elif example['dataset'] in ['bionli', 'chemdner']:\n",
    "#         return {\"weight\": 3.0}\n",
    "#     else:\n",
    "#         return {\"weight\": 1.0}\n",
    "    \n",
    "\n",
    "# if \"dataset\" in combined_dataset.column_names:\n",
    "#     weighted_dataset = combined_dataset.map(compute_weights)\n",
    "# else:\n",
    "#     print(\"Warning: 'dataset' Ïª¨ÎüºÏù¥ Ï°¥Ïû¨ÌïòÏßÄ ÏïäÏäµÎãàÎã§. Í∞ÄÏ§ëÏπò Í≥ÑÏÇ∞Ïù¥ Î∂àÍ∞ÄÎä•Ìï† Ïàò ÏûàÏäµÎãàÎã§.\")\n",
    "\n",
    "# weights = np.array(weighted_dataset[\"weight\"])\n",
    "# weights = weights / weights.sum() \n",
    "\n",
    "# weighted_indices = np.random.choice(len(combined_dataset), size=len(combined_dataset), p=weights)\n",
    "\n",
    "# if \"__index_level_0__\" in combined_dataset.column_names:\n",
    "#     combined_dataset = combined_dataset.remove_columns([\"__index_level_0__\"])\n",
    "\n",
    "# resampled_dataset = combined_dataset.select(weighted_indices)\n",
    "\n",
    "# if \"text\" not in resampled_dataset.column_names:\n",
    "#     resampled_dataset = resampled_dataset.map(lambda x: {\"text\": x[\"input\"] + \" \" + x[\"output\"]})\n",
    "\n",
    "# trainer = SFTTrainer(\n",
    "#     model=model,\n",
    "#     tokenizer=tokenizer,\n",
    "#     train_dataset=resampled_dataset,\n",
    "#     dataset_text_field=\"text\",\n",
    "#     dataset_num_proc=16, \n",
    "\n",
    "#     args=TrainingArguments(\n",
    "#         per_device_train_batch_size=32, \n",
    "#         gradient_accumulation_steps=1,  \n",
    "#         warmup_steps=300,  \n",
    "#         num_train_epochs=3, \n",
    "#         learning_rate=3e-5,  \n",
    "#         fp16=not is_bfloat16_supported(),\n",
    "#         bf16=is_bfloat16_supported(),  \n",
    "#         optim=\"adamw_8bit\",  \n",
    "#         weight_decay=0.01,  \n",
    "#         lr_scheduler_type=\"linear\",  \n",
    "#         logging_steps=100,  \n",
    "#         seed=3407,  \n",
    "#         save_steps=200,  \n",
    "#         output_dir=\"outputs/weighted_sampling11\", \n",
    "#         report_to=\"none\",  \n",
    "#     ),\n",
    "# )\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "# from datasets import Dataset\n",
    "# import numpy as np\n",
    "# from trl import SFTTrainer\n",
    "# from transformers import TrainingArguments\n",
    "# from unsloth import is_bfloat16_supported\n",
    "# import pandas as pd\n",
    "\n",
    "# # üìå 1Ô∏è‚É£ TaskÎ≥Ñ Í∞ÄÏ§ëÏπò ÏÑ§Ï†ï (Ïù¥ÎØ∏ÏßÄ ÏÜç Îç∞Ïù¥ÌÑ∞ Î∂ÑÌè¨ Î∞òÏòÅ)\n",
    "# def compute_weights(example):\n",
    "#     task_weights = {\n",
    "#         \"daily_diets\": 0.4, # 3000\n",
    "#         \"alternative_diet\": 0.5, # 3000\n",
    "#         \"dfh_info\": 0.6, # 3000\n",
    "#         \"summarization\": 4.0, \n",
    "#         \"generation\": 0.5,\n",
    "#         \"nli\": 0.9,\n",
    "#         \"qa_objective_3\": 1.0,\n",
    "#         \"qa_objective_1\": 1.0,\n",
    "#         \"qa_objective_2\": 1.0,\n",
    "#         \"re\": 1.5,\n",
    "#         \"ie\": 1.0,\n",
    "#     }\n",
    "#     return {\"weight\": task_weights.get(example[\"task\"], 1.0)}\n",
    "\n",
    "# weighted_dataset = tokenized_dataset.map(compute_weights)\n",
    "\n",
    "# weights = np.array(weighted_dataset[\"weight\"])\n",
    "# weights = weights / weights.sum() \n",
    "\n",
    "# weighted_indices = np.random.choice(len(tokenized_dataset), size=len(tokenized_dataset), p=weights)\n",
    "# resampled_dataset = tokenized_dataset.select(weighted_indices)\n",
    "# resampled_dataset = weighted_dataset.shuffle(seed=3407).select(range(len(weighted_dataset)))\n",
    "\n",
    "# trainer = SFTTrainer(\n",
    "#     model=model,\n",
    "#     tokenizer=tokenizer,\n",
    "#     train_dataset=resampled_dataset,\n",
    "#     dataset_text_field=\"text\",\n",
    "#     dataset_num_proc=8, \n",
    "\n",
    "#     args=TrainingArguments(\n",
    "#         per_device_train_batch_size=32, \n",
    "#         gradient_accumulation_steps=2,  \n",
    "#         warmup_steps=300,  \n",
    "#         num_train_epochs=3, \n",
    "#         learning_rate=3e-5,  \n",
    "#         fp16=not is_bfloat16_supported(),\n",
    "#         bf16=is_bfloat16_supported(),  \n",
    "#         optim=\"adamw_8bit\",  \n",
    "#         weight_decay=0.01,  \n",
    "#         lr_scheduler_type=\"linear\",  \n",
    "#         logging_steps=100,  \n",
    "#         seed=3407,  \n",
    "#         save_steps=200,  \n",
    "#         output_dir=\"outputs/weighted_sampling12\", \n",
    "#         report_to=\"none\",  \n",
    "#     ),\n",
    "# )\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "e70fdf781e644099aedce5d8d722295b",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Map:   0%|          | 0/35154 [00:00<?, ? examples/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
      "To disable this warning, you can either:\n",
      "\t- Avoid using `tokenizers` before the fork if possible\n",
      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n",
      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
      "To disable this warning, you can either:\n",
      "\t- Avoid using `tokenizers` before the fork if possible\n",
      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n"
     ]
    }
   ],
   "source": [
    "from datasets import Dataset, concatenate_datasets\n",
    "import numpy as np\n",
    "from trl import SFTTrainer\n",
    "from transformers import TrainingArguments\n",
    "from unsloth import is_bfloat16_supported\n",
    "import pandas as pd\n",
    "\n",
    "def compute_weights(example):\n",
    "    if example['task'] in ['daily_diets']:\n",
    "        return {\"weight\": 0.3}\n",
    "    elif example['task'] in ['alternative_diet']:\n",
    "        return {\"weight\": 0.5}\n",
    "    elif example['task'] in ['dfh_info']:\n",
    "        return {\"weight\": 0.7}\n",
    "    elif example['task'] in ['summarization', 'generation']:\n",
    "        return {\"weight\": 0.8}\n",
    "    elif example['task'] in ['ie', 'nli', 'qa_objective_1', 'qa_objective_2', 'qa_objective_3']:\n",
    "        return {\"weight\": 1.0} \n",
    "    elif example['dataset'] in ['ddi']:\n",
    "        return {\"weight\": 2.0}\n",
    "    else:\n",
    "        return {\"weight\": 1.0}\n",
    "    \n",
    "\n",
    "if \"dataset\" in combined_dataset.column_names:\n",
    "    weighted_dataset = combined_dataset.map(compute_weights)\n",
    "else:\n",
    "    print(\"Warning: 'dataset' Ïª¨ÎüºÏù¥ Ï°¥Ïû¨ÌïòÏßÄ ÏïäÏäµÎãàÎã§. Í∞ÄÏ§ëÏπò Í≥ÑÏÇ∞Ïù¥ Î∂àÍ∞ÄÎä•Ìï† Ïàò ÏûàÏäµÎãàÎã§.\")\n",
    "\n",
    "weights = np.array(weighted_dataset[\"weight\"])\n",
    "weights = weights / weights.sum() \n",
    "\n",
    "weighted_indices = np.random.choice(len(combined_dataset), size=len(combined_dataset), p=weights)\n",
    "\n",
    "if \"__index_level_0__\" in combined_dataset.column_names:\n",
    "    combined_dataset = combined_dataset.remove_columns([\"__index_level_0__\"])\n",
    "\n",
    "resampled_dataset = combined_dataset.select(weighted_indices)\n",
    "\n",
    "if \"text\" not in resampled_dataset.column_names:\n",
    "    resampled_dataset = resampled_dataset.map(lambda x: {\"text\": x[\"input\"] + \" \" + x[\"output\"]})\n",
    "\n",
    "trainer = SFTTrainer(\n",
    "    model=model,\n",
    "    tokenizer=tokenizer,\n",
    "    train_dataset=resampled_dataset,\n",
    "    dataset_text_field=\"text\",\n",
    "    dataset_num_proc=16, \n",
    "\n",
    "    args=TrainingArguments(\n",
    "        per_device_train_batch_size=32, \n",
    "        gradient_accumulation_steps=1,  \n",
    "        warmup_steps=300,  \n",
    "        num_train_epochs=3, \n",
    "        learning_rate=3e-5,  \n",
    "        fp16=not is_bfloat16_supported(),\n",
    "        bf16=is_bfloat16_supported(),  \n",
    "        optim=\"adamw_8bit\",  \n",
    "        weight_decay=0.01,  \n",
    "        lr_scheduler_type=\"linear\",  \n",
    "        logging_steps=100,  \n",
    "        seed=3407,  \n",
    "        save_steps=200,  \n",
    "        output_dir=\"outputs/weighted_sampling_v4\", \n",
    "        report_to=\"none\",  \n",
    "    ),\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
      "To disable this warning, you can either:\n",
      "\t- Avoid using `tokenizers` before the fork if possible\n",
      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n",
      "==((====))==  Unsloth - 2x faster free finetuning | Num GPUs = 1\n",
      "   \\\\   /|    Num examples = 35,154 | Num Epochs = 3\n",
      "O^O/ \\_/ \\    Batch size per device = 32 | Gradient Accumulation steps = 1\n",
      "\\        /    Total batch size = 32 | Total steps = 3,297\n",
      " \"-____-\"     Number of trainable parameters = 20,971,520\n",
      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
      "To disable this warning, you can either:\n",
      "\t- Avoid using `tokenizers` before the fork if possible\n",
      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n",
      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
      "To disable this warning, you can either:\n",
      "\t- Avoid using `tokenizers` before the fork if possible\n",
      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n",
      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
      "To disable this warning, you can either:\n",
      "\t- Avoid using `tokenizers` before the fork if possible\n",
      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "\n",
       "    <div>\n",
       "      \n",
       "      <progress value='3297' max='3297' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
       "      [3297/3297 13:00:14, Epoch 3/3]\n",
       "    </div>\n",
       "    <table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       " <tr style=\"text-align: left;\">\n",
       "      <th>Step</th>\n",
       "      <th>Training Loss</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <td>100</td>\n",
       "      <td>1.879900</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>200</td>\n",
       "      <td>1.459000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>300</td>\n",
       "      <td>1.311400</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>400</td>\n",
       "      <td>1.298100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>500</td>\n",
       "      <td>1.282400</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>600</td>\n",
       "      <td>1.296100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>700</td>\n",
       "      <td>1.263700</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>800</td>\n",
       "      <td>1.253100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>900</td>\n",
       "      <td>1.247000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1000</td>\n",
       "      <td>1.232800</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1100</td>\n",
       "      <td>1.232200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1200</td>\n",
       "      <td>1.217900</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1300</td>\n",
       "      <td>1.220600</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1400</td>\n",
       "      <td>1.198700</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1500</td>\n",
       "      <td>1.187500</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1600</td>\n",
       "      <td>1.219200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1700</td>\n",
       "      <td>1.170300</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1800</td>\n",
       "      <td>1.169300</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>1900</td>\n",
       "      <td>1.170200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2000</td>\n",
       "      <td>1.175900</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2100</td>\n",
       "      <td>1.155200</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2200</td>\n",
       "      <td>1.162100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2300</td>\n",
       "      <td>1.143100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2400</td>\n",
       "      <td>1.111900</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2500</td>\n",
       "      <td>1.123900</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2600</td>\n",
       "      <td>1.110600</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2700</td>\n",
       "      <td>1.129500</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2800</td>\n",
       "      <td>1.107500</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>2900</td>\n",
       "      <td>1.110300</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3000</td>\n",
       "      <td>1.103500</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3100</td>\n",
       "      <td>1.102300</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <td>3200</td>\n",
       "      <td>1.101600</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table><p>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/data/jaesung/anaconda3/envs/meal/lib/python3.12/site-packages/peft/utils/other.py:689: UserWarning: Unable to fetch remote file due to the following error (ReadTimeoutError(\"HTTPSConnectionPool(host='huggingface.co', port=443): Read timed out. (read timeout=10)\"), '(Request ID: 941075e6-9927-473c-b87d-b5bde650f48f)') - silently ignoring the lookup for the file config.json in unsloth/meta-llama-3.1-8b-bnb-4bit.\n",
      "  warnings.warn(\n",
      "/data/jaesung/anaconda3/envs/meal/lib/python3.12/site-packages/peft/utils/save_and_load.py:243: UserWarning: Could not find a config file in unsloth/meta-llama-3.1-8b-bnb-4bit - will assume that the vocabulary was not modified.\n",
      "  warnings.warn(\n"
     ]
    },
    {
     "ename": "",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31mThe Kernel crashed while executing code in the current cell or a previous cell. \n",
      "\u001b[1;31mPlease review the code in the cell(s) to identify a possible cause of the failure. \n",
      "\u001b[1;31mClick <a href='https://aka.ms/vscodeJupyterKernelCrash'>here</a> for more info. \n",
      "\u001b[1;31mView Jupyter <a href='command:jupyter.viewOutput'>log</a> for further details."
     ]
    }
   ],
   "source": [
    "trainer_stats = trainer.train()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "## inference"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "0f5a1c5c891b4e17a9d4ccec27ed523e",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Map:   0%|          | 0/43179 [00:00<?, ? examples/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from datasets import Dataset, concatenate_datasets\n",
    "import numpy as np\n",
    "from trl import SFTTrainer\n",
    "from transformers import TrainingArguments\n",
    "from unsloth import is_bfloat16_supported\n",
    "import pandas as pd\n",
    "\n",
    "def compute_weights(example):\n",
    "    if example['task'] in ['daily_diets']:\n",
    "        return {\"weight\": 0.3}\n",
    "    elif example['task'] in ['generation', 'alternative_diet']:\n",
    "        return {\"weight\": 0.5}\n",
    "    elif example['task'] in ['dfh_info', 'nli', 'summarization']:\n",
    "        return {\"weight\": 0.7}\n",
    "    elif example['task'] in ['ie', 'qa_objective_1', 'qa_objective_2', 'qa_objective_3']:\n",
    "        return {\"weight\": 1.0} \n",
    "    elif example['dataset'] in ['ddi']:\n",
    "        return {\"weight\": 2.0}\n",
    "    else:\n",
    "        return {\"weight\": 1.0}\n",
    "    \n",
    "\n",
    "if \"dataset\" in combined_dataset.column_names:\n",
    "    weighted_dataset = combined_dataset.map(compute_weights)\n",
    "else:\n",
    "    print(\"Warning: 'dataset' Ïª¨ÎüºÏù¥ Ï°¥Ïû¨ÌïòÏßÄ ÏïäÏäµÎãàÎã§. Í∞ÄÏ§ëÏπò Í≥ÑÏÇ∞Ïù¥ Î∂àÍ∞ÄÎä•Ìï† Ïàò ÏûàÏäµÎãàÎã§.\")\n",
    "\n",
    "weights = np.array(weighted_dataset[\"weight\"])\n",
    "weights = weights / weights.sum() \n",
    "\n",
    "weighted_indices = np.random.choice(len(combined_dataset), size=len(combined_dataset), p=weights)\n",
    "\n",
    "if \"__index_level_0__\" in combined_dataset.column_names:\n",
    "    combined_dataset = combined_dataset.remove_columns([\"__index_level_0__\"])\n",
    "\n",
    "resampled_dataset = combined_dataset.select(weighted_indices)\n",
    "\n",
    "if \"text\" not in resampled_dataset.column_names:\n",
    "    resampled_dataset = resampled_dataset.map(lambda x: {\"text\": x[\"input\"] + \" \" + x[\"output\"]})\n",
    "\n",
    "trainer = SFTTrainer(\n",
    "    model=model,\n",
    "    tokenizer=tokenizer,\n",
    "    train_dataset=resampled_dataset,\n",
    "    dataset_text_field=\"text\",\n",
    "    dataset_num_proc=16, \n",
    "\n",
    "    args=TrainingArguments(\n",
    "        per_device_train_batch_size=64, \n",
    "        gradient_accumulation_steps=1,  \n",
    "        warmup_steps=300,  \n",
    "        num_train_epochs=3, \n",
    "        learning_rate=6e-5,  \n",
    "        fp16=not is_bfloat16_supported(),\n",
    "        bf16=is_bfloat16_supported(),  \n",
    "        optim=\"adamw_8bit\",  \n",
    "        weight_decay=0.01,  \n",
    "        lr_scheduler_type=\"linear\",  \n",
    "        logging_steps=100,  \n",
    "        seed=3407,  \n",
    "        save_steps=200,  \n",
    "        output_dir=\"outputs/weighted_sampling_v1\", \n",
    "        report_to=\"none\",  \n",
    "    ),\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "==((====))==  Unsloth 2025.1.8: Fast Llama patching. Transformers: 4.46.3.\n",
      "   \\\\   /|    GPU: NVIDIA A100-PCIE-40GB. Max memory: 39.394 GB. Platform: Linux.\n",
      "O^O/ \\_/ \\    Torch: 2.5.0+cu124. CUDA: 8.0. CUDA Toolkit: 12.4. Triton: 3.1.0\n",
      "\\        /    Bfloat16 = TRUE. FA [Xformers = 0.0.28.post2. FA2 = True]\n",
      " \"-____-\"     Free Apache license: http://github.com/unslothai/unsloth\n",
      "Unsloth: Fast downloading is enabled - ignore downloading bars which are red colored!\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
      "To disable this warning, you can either:\n",
      "\t- Avoid using `tokenizers` before the fork if possible\n",
      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n",
      "huggingface/tokenizers: The current process just got forked, after parallelism has already been used. Disabling parallelism to avoid deadlocks...\n",
      "To disable this warning, you can either:\n",
      "\t- Avoid using `tokenizers` before the fork if possible\n",
      "\t- Explicitly set the environment variable TOKENIZERS_PARALLELISM=(true | false)\n"
     ]
    }
   ],
   "source": [
    "\n",
    "from unsloth import FastLanguageModel\n",
    "import torch\n",
    "max_seq_length = 2048 # Choose any! We auto support RoPE Scaling internally!\n",
    "dtype = None # None for auto detection. Float16 for Tesla T4, V100, Bfloat16 for Ampere+\n",
    "load_in_4bit = True # Use 4bit quantization to reduce memory usage. Can be False.\n",
    "\n",
    "# 4bit pre quantized models we support for 4x faster downloading + no OOMs.\n",
    "fourbit_models = [\n",
    "    \"unsloth/Meta-Llama-3.1-8B-bnb-4bit\",      # Llama-3.1 15 trillion tokens model 2x faster!\n",
    "    \"unsloth/Meta-Llama-3.1-8B-Instruct-bnb-4bit\",\n",
    "    \"unsloth/Meta-Llama-3.1-70B-bnb-4bit\",\n",
    "    \"unsloth/Meta-Llama-3.1-405B-bnb-4bit\",    # We also uploaded 4bit for 405b!\n",
    "    \"unsloth/Mistral-Nemo-Base-2407-bnb-4bit\", # New Mistral 12b 2x faster!\n",
    "    \"unsloth/Mistral-Nemo-Instruct-2407-bnb-4bit\",\n",
    "    \"unsloth/mistral-7b-v0.3-bnb-4bit\",        # Mistral v3 2x faster!\n",
    "    \"unsloth/mistral-7b-instruct-v0.3-bnb-4bit\",\n",
    "    \"unsloth/Phi-3.5-mini-instruct\",           # Phi-3.5 2x faster!\n",
    "    \"unsloth/Phi-3-medium-4k-instruct\",\n",
    "    \"unsloth/gemma-2-9b-bnb-4bit\",\n",
    "    \"unsloth/gemma-2-27b-bnb-4bit\",            # Gemma 2x faster!\n",
    "] # More models at https://huggingface.co/unsloth\n",
    "\n",
    "model, tokenizer = FastLanguageModel.from_pretrained(\n",
    "    model_name = \"/data/jaesung/llm_for_diabetes/src/model/outputs/weighted_sampling11/checkpoint-3453\",\n",
    "    max_seq_length = max_seq_length,\n",
    "    dtype = dtype,\n",
    "    load_in_4bit = load_in_4bit,\n",
    "    # token = \"hf_...\", # use one if using gated models like meta-llama/Llama-2-7b-hf\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<|begin_of_text|>Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request.\n",
      "\n",
      "### Instruction:\n",
      "Recommend a daily diet that includes a specific ingredient.\n",
      "\n",
      "### Input:\n",
      "Create a diet that includes baby bok choy(roots trimmed and roughly chopped).\n",
      "\n",
      "### Response:\n",
      "{\"Breakfast\": \"Ginger Infused Oatmeal\", \"Lunch\": \"Turkey Meatball \\u201cWonton\\u201d Soup with Bok Choy & Carrots\", \"Dinner\": \"Roasted Sweet Potatoes with Lemon-Dill Yogurt Sauce\"}<|end_of_text|>\n"
     ]
    }
   ],
   "source": [
    "\n",
    "\n",
    "FastLanguageModel.for_inference(model) # Enable native 2x faster inference\n",
    "\n",
    "# alpaca_prompt = You MUST copy from above!\n",
    "alpaca_prompt = \"\"\"Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request.\n",
    "\n",
    "### Instruction:\n",
    "{}\n",
    "\n",
    "### Input:\n",
    "{}\n",
    "\n",
    "### Response:\n",
    "{}\"\"\"\n",
    "\n",
    "\n",
    "inputs = tokenizer(\n",
    "[\n",
    "    alpaca_prompt.format(\n",
    "        \"Recommend a daily diet that includes a specific ingredient.\",\n",
    "\n",
    "        \"Create a diet that includes baby bok choy(roots trimmed and roughly chopped).\",\n",
    "\n",
    "        \"\", # output - leave this blank for generation!\n",
    "    )\n",
    "], return_tensors = \"pt\").to(\"cuda\")\n",
    "\n",
    "from transformers import TextStreamer\n",
    "text_streamer = TextStreamer(tokenizer)\n",
    "_ = model.generate(**inputs, streamer = text_streamer, max_new_tokens = 2048)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Task: daily_diets, Sampled: 50\n",
      "{'dataset': 'diabetes_food_hub', 'split_data': 'test', 'task': 'daily_diets', 'instruction': 'Recommend a daily diet that includes a specific ingredient.', 'input': 'Create a diet that includes Splenda¬Æ Monk Fruit Granulated Sweetener(for the BBQ sauce).', 'output': '{\"Breakfast\": \"Masala Omelette with Mixed Veggies\", \"Lunch\": \"Air Fryer \\\\u201cHoney\\\\u201d BBQ Cauliflower Wings\", \"Dinner\": \"Turkey Meatball \\\\u201cWonton\\\\u201d Soup with Bok Choy & Carrots\"}', 'text_length': 317, '__index_level_0__': 48548}\n",
      "{'dataset': 'diabetes_food_hub', 'split_data': 'test', 'task': 'daily_diets', 'instruction': 'Analyze and summarize the nutritional content of a daily diet.', 'input': '{\"Breakfast\": \"Greek Vegetable Pita Pizzas\", \"Lunch\": \"Peach & Cream Smoothie\", \"Dinner\": \"Turkey Meatball \\\\u201cWonton\\\\u201d Soup with Bok Choy & Carrots\"}', 'output': '{\"Daily Total\": {\"Calories\": 670.0, \"Carbohydrate (g)\": 71.0, \"Fiber (g)\": 12.0, \"Protein (g)\": 49.0, \"Fat (g)\": 25.0, \"Cholesterol (mg)\": 145.0, \"Sodium (mg)\": 1335.0, \"Potassium (mg)\": 1870.0}}', 'text_length': 403, '__index_level_0__': 46289}\n",
      "{'dataset': 'diabetes_food_hub', 'split_data': 'test', 'task': 'daily_diets', 'instruction': 'Recommend a daily diet that includes a specific ingredient.', 'input': 'Create a diet that includes canned chickpeas(rinsed and drained).', 'output': '{\"Breakfast\": \"Roasted Sweet Potatoes with Lemon-Dill Yogurt Sauce\", \"Lunch\": \"Curried Chickpea Stew with Roasted Vegetables\", \"Dinner\": \"Chicken and Cucumber Lettuce Wraps with Peanut Sauce\"}', 'text_length': 316, '__index_level_0__': 48112}\n",
      "{'dataset': 'diabetes_food_hub', 'split_data': 'test', 'task': 'daily_diets', 'instruction': 'Recommend a daily diet that includes a specific ingredient.', 'input': 'Create a diet that includes celery(small diced).', 'output': '{\"Breakfast\": \"Bean and Cheese Tostadas\", \"Lunch\": \"Green Vegetable Egg \\\\\"Tortilla\\\\\"\", \"Dinner\": \"Turkey Chili Stuffed Sweet Potatoes\"}', 'text_length': 240, '__index_level_0__': 46511}\n",
      "{'dataset': 'diabetes_food_hub', 'split_data': 'test', 'task': 'daily_diets', 'instruction': 'Recommend a daily diet that includes a specific ingredient.', 'input': 'Create a diet that includes lower sodium soy sauce.', 'output': '{\"Breakfast\": \"Strawberry Cream Cheese French Toast Casserole\", \"Lunch\": \"Turkey Meatball \\\\u201cWonton\\\\u201d Soup with Bok Choy & Carrots\", \"Dinner\": \"Greek Vegetable Pita Pizzas\"}', 'text_length': 280, '__index_level_0__': 48693}\n",
      "Task: ie, Sampled: 50\n",
      "{'dataset': 'chemdner', 'split_data': 'test', 'task': 'ie', 'instruction': 'Extract chemical substances, including pharmaceutical compounds and active ingredients, from the text.', 'input': \"To date, peroxisome proliferator-activated receptors (PPARs) are becoming the new therapeutic targets for the treatment of metabolic diseases, such as Type 2 diabetes, obesity, and cardiovascular disease. In this study, a cell-based high-throughput PPARs (PPARŒ±/Œ≤/Œ≥) model was developed for the screening of PPARs agonists. The screening conditions were evaluated through analyzing the expression value of luciferase. Finally, 24\\xa0h of drug acting time, 5 times of the dilution factor of luciferase zymolyte, and about 2\\xa0√ó\\xa010(4) cells/ well on HeLa cells in 96-well plates were used, respectively. Furthermore, the quality of high-throughput screening (HTS) in stability and reliability was evaluated by the Z'-factor. Additionally, different extracts of Rhizoma Coptis and berberine were tested by the developed method. The results suggested that both the EtOAc extract and berberine were able to activate PPARŒ±/Œ≤/Œ≥, and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine. In conclusion, the developed HTS assay is a simple, rapid, stable, and specific method for the screening of PPARs natural agonists.\", 'output': 'EtOAc', 'text_length': 1238, '__index_level_0__': 45078}\n",
      "{'dataset': 'chemdner', 'split_data': 'test', 'task': 'ie', 'instruction': 'Extract chemical substances, including pharmaceutical compounds and active ingredients, from the text.', 'input': 'Neuroprotective Effects of Cilostazol on Retinal Ganglion Cell damage in Diabetic Rats.', 'output': 'Cilostazol', 'text_length': 199, '__index_level_0__': 45198}\n",
      "{'dataset': 'chemdner', 'split_data': 'test', 'task': 'ie', 'instruction': 'Detect and extract names of chemicals, drugs, and molecular entities found in the given text.', 'input': 'Dual action spirobicycloimidazolidine-2,4-diones: antidiabetic agents and inhibitors of aldose reductase-an enzyme involved in diabetic complications.', 'output': 'aldose', 'text_length': 249, '__index_level_0__': 45339}\n",
      "{'dataset': 'chemdner', 'split_data': 'test', 'task': 'ie', 'instruction': 'Identify all chemical entities (e.g., compounds, drugs, molecules) mentioned in the following text.', 'input': 'SEVERE HYPOGLYCEMIC EPISODES: A PERSISTENT THREAT FOR CHILDREN WITH TYPE 1 DIABETES MELLITUS AND THEIR FAMILIES.', 'output': '', 'text_length': 211, '__index_level_0__': 45327}\n",
      "{'dataset': 'chemdner', 'split_data': 'test', 'task': 'ie', 'instruction': 'Extract chemical substances, including pharmaceutical compounds and active ingredients, from the text.', 'input': 'Comparison of tissue metal concentrations in Zucker lean, Zucker obese, and Zucker diabetic fatty rats and the effects of chromium supplementation on tissue metal concentrations.', 'output': 'chromium', 'text_length': 288, '__index_level_0__': 44983}\n",
      "Task: alternative_diet, Sampled: 50\n",
      "{'dataset': 'diabetes_food_hub', 'split_data': 'test', 'task': 'alternative_diet', 'instruction': 'Based on the previous meal, suggest the next meal to maintain a balanced diet.', 'input': 'Onions, cooked, from fresh, made with oil', 'output': \"Bountiful Harvest Vegetable Salad is recommended. The reason is The 'Bountiful Harvest Vegetable Salad' contains a variety of fresh vegetables and nuts that can provide essential nutrients such as fiber, vitamins, and minerals that are lacking in 'Onions, cooked, from fresh, made with oil'. However, individuals should be cautious of the potential high fat content from the nuts and oil used in the salad.\", 'text_length': 525, '__index_level_0__': 49895}\n",
      "{'dataset': 'diabetes_food_hub', 'split_data': 'test', 'task': 'alternative_diet', 'instruction': 'Based on the previous meal, suggest the next meal to maintain a balanced diet.', 'input': 'Cheese, Mozzarella, part skim', 'output': \"Spinach Pesto Chicken Salad Wrap is recommended. The reason is 'Spinach Pesto Chicken Salad Wrap' complements 'Cheese, Mozzarella, part skim' by providing a good source of protein, potassium, and fiber which are lacking in the consumed food. However, caution should be exercised in monitoring sodium intake as the wrap may contain added salt from ingredients like garlic and pepper.\", 'text_length': 489, '__index_level_0__': 49128}\n",
      "{'dataset': 'diabetes_food_hub', 'split_data': 'test', 'task': 'alternative_diet', 'instruction': 'Based on the previous meal, suggest the next meal to maintain a balanced diet.', 'input': 'Ginger root, pickled', 'output': \"Roasted and Spiced Chickpeas is recommended. The reason is 'Roasted and Spiced Chickpeas' complement 'Ginger root, pickled' by providing a good source of protein, fiber, and potassium, which are lacking in the pickled ginger. However, caution should be taken with the total fat content in the chickpeas, especially for those watching their fat intake.\", 'text_length': 449, '__index_level_0__': 49541}\n",
      "{'dataset': 'diabetes_food_hub', 'split_data': 'test', 'task': 'alternative_diet', 'instruction': 'Based on the previous meal, suggest the next meal to maintain a balanced diet.', 'input': 'Tomatoes, raw', 'output': 'Cowboy Caviar is recommended. The reason is Cowboy Caviar complements Tomatoes, raw because it contains a variety of ingredients such as beans, corn, avocado, and bell peppers, which provide a diverse range of nutrients that can help address the deficiencies found in raw tomatoes. However, caution should be taken with the dressing used in Cowboy Caviar, as it may contain added sugars or unhealthy fats that could negate the nutritional benefits of', 'text_length': 541, '__index_level_0__': 50344}\n",
      "{'dataset': 'diabetes_food_hub', 'split_data': 'test', 'task': 'alternative_diet', 'instruction': 'Based on the previous meal, suggest the next meal to maintain a balanced diet.', 'input': 'Cucumber pickles, dill', 'output': \"Southwest-Style Turkey Meatloaf is recommended. The reason is 'Southwest-Style Turkey Meatloaf' complements 'Cucumber pickles, dill' by providing a balanced combination of protein, fiber, and essential nutrients. However, individuals should be cautious of the sodium content in the meatloaf, especially if they are watching their sodium intake.\", 'text_length': 444, '__index_level_0__': 49147}\n",
      "Task: generation, Sampled: 50\n",
      "{'dataset': 'meddialog', 'split_data': 'test', 'task': 'generation', 'instruction': 'What is lump on shin that is sore to touch and swollen?', 'input': \"I have a painful red lump on my left shin and it's been there for about a week now. I've just arranged a doctors appointment for Monday as it feels that it's getting worse. IIt's sore to the touch and feels quite warm and swollen. It's been feeling more tender in the last day or so and, I've been feeling quite tired recently. I've read the symptoms of Cellulitis and it seems plasuible to me. I'm 35, relatively healthy and I don't smoke or use drugs. I drink socially, but not heavily/frequently.My question is whether I should keep to the doctors appointment in a few days or whether I should seek more urgent medical help. It aches to walk but isn't excrutiatingly painful. I'd say that the lump has got bigger in the last few days but doesn't  seem to have spread elsewhere and hasn't grown rapidly.I'm happy to wait until Monday but would also like to know what to do in the meantime? I presume I should keep weight off of it, take over the counter painkillers and rub in an antiseptic lotion, but not sure and would appreciate the advice. Thanks\", 'output': 'hi this is dr.subhadeep.thanks for the opportunity for helping you.as per your description this fits your assumption of cellulitis though I would like to get few more informations1) did you get your sugars checked recently. if not kindly get your sugars checked, fasting blood sugars as well as post-prandial blood sugar levels.if you have recently developed diabete then your immunity will be lower and you might get cellulitis due to streptococcal infection or klebsiella or pseudomonas infection.2) kindly get a total count done which will guide you regarding the extent of infection and help in considering your decision to wait till your appointment.kindly enlighten me about any history of injury over the affected site.as u have told that the lump is tender,warm and non spreading it fits the diagnosis of evolving abscess secondary to cellulitis.in that case incision and drainage may be required once the abscess localises.kindly start with the following group of drugs for the time being:t. amoxicillin+clavulanic acid combination 625 mgx3 times. these will either resolve or localise the abscess,one H2 receptor blockerx2 times before food,a painkiller,t.chymotrypsin x3 times to reduce inflammation. you can get an USG of the affected site to be sure of diagnosis.all the above mentioned medications are to be taken for 5 days.if the abscess/cellulitis is not showing improvement in 3 days post medication with high total count,bld.sugar levels and USG proving evolving abscess then incision and drainage to be considered under spinal or local as per your pain tolerance and size of swellingkindly let me know if the consultation is beneficial.regards', 'text_length': 2771, '__index_level_0__': 44299}\n",
      "{'dataset': 'meddialog', 'split_data': 'test', 'task': 'generation', 'instruction': 'What does the lipid profile test with total bilirubin 1.1mg/dl indicate?', 'input': 'Total bilirubin 1.1mg/dl; conjugated (D. Bilirubin) 0.3 mg; Unconjugated 0.8 mg; S.g.o.t 72 u/l; s.g.p.t 102 u/l; alkaline phophatase 182 u/l; total protein 8.2 gm/dl; albumin 3.7 gm/dl; globulin 4.5 gm/dl; a/g ratio 0.82; g.g.t.p 86 u/l Plasma glucose fasting 424 mg/dl; total cholesterol 131 mg/dl. Pt ratio INR 1.11 Tsh 19.27 Please advice what will I do.', 'output': 'Welcome to Healthcare Magic. Thank you for posting your query.I can understand your query.Let me analyse your report.1. Total bilirubin - raised2. SGOT - raised3. SGPT - raised4. Albumin - low normal5. Plasma fasting glucose - alarmingly raised6. INR - normal7. TSH - raised8. Cholesterol - normalThe reports are suggestive of hepatitis . At the same time what is alarming is the fasting glucose. It is very high. You need immediate intervention through insulin or other medications. You also have hypothyroidism.I would suggest you to immediately visit a clinician. He/she can examine you , recheck the blood glucose and correlate clinically.Get an ultrasound of the abdomen done to look at the liver and gallbladder .Get a postprandial blood glucose and HBA1C done to look at the blood sugar control .Avoid oily, spicy food. Avoid sweets.Regularly exercise for 30 minutes a  day.I would start tablet Thyronorm . Your doctor can guide on the exact dosage.Hope this helps.Write back to us.Regards.', 'text_length': 1427, '__index_level_0__': 43738}\n",
      "{'dataset': 'meddialog', 'split_data': 'test', 'task': 'generation', 'instruction': 'Have PCOS, have fibroid, had missed abortion. Harmful to take homeopathy as well as allopathy?', 'input': 'Hi, I am 30 years, married for 4 years and no children, I have PCOD and doctor has suggested me with G-reg Sr 500. I have Fibroid and my left fallopian tube is blocked due to hydrosalpinx and i am taking homeopathy medicine for the same. Is it harmful to take both homeopathy and Alopathy medicine? and the biggest question whether will i be able to conceive? I was pregnant after 6 months of my marriage but unfortunately i had a missed abortion after 3 months.', 'output': 'Hello!!!! It is NOT harmful to take homoeopathy and Allopathy medicine togather,BUT  you should not take at a time.Atleast make a gap of 15-30minuts.G-Reg Sr-500 is the brand name.It contains 500mg of metformin,which is actually meant for Diabetics.However it is sometimes given to certain cases of women suffering from INFERTILITY due to PCOD if their blood insulin level is determined and documented to be high.Very frequently Metformin causes gastro-intestinal disturbances such as nausea,vomiting,diarrhoea,abdominal pain and loss of appetite,If you have any side effect than consult your Doctor. For your biggest question I would say it is POSSIBLE to conceive for you BUT its very difficult.For that you have to consult regularly to your Gynacologist and Homoeopath also.Homoeopathy will Definitely help in your case to CONCEIVE and PREVENT ABORTION .All the BEST.', 'text_length': 1426, '__index_level_0__': 44248}\n",
      "{'dataset': 'meddialog', 'split_data': 'test', 'task': 'generation', 'instruction': 'How can lower backache while suffering from diabetes be treated?', 'input': 'I am a 66 yr. old woman with type 2 diabetes. Just had 3 days of urination every 30 to 45 minutes day & night. Now I have pain in mid to lower back that has moved to mostly left side & am only urinating 5 to 6 times a day & have to force it. I had passed a kidney stone in 2015 & have another in kidney. I was off my meds for a month due to preps for colonoscopy & I got off track with everything. Started testing & pills again yesterday. I do not know the symptoms for Ketoacidosis other than they are the same as diabetes. My test strips for KA are old. I am very concerned as this is not normal for me. I did not see my doctor yet because of the weekend.', 'output': 'Hello and Welcome to ‚ÄòAsk A Doctor‚Äô service. I have reviewed your query and here is my advice.  With medicines and with physiotherapy.  Hope I have answered your query. Let me know if I can assist you further.', 'text_length': 930, '__index_level_0__': 44077}\n",
      "{'dataset': 'meddialog', 'split_data': 'test', 'task': 'generation', 'instruction': 'I have been on balanitis treatment without a positive result. Please help', 'input': 'Hi doctor, My doctor told me that I have balanitis. He prescribed Clotrimazole and Beclomethasone cream, Itraconazole capsules (one capsule every day) and Levocetirizine dihydrochloride (one tablet for every night) for 10 days. I have finished all medicines in 10 days. First three days I felt that I have benefited, but still I am not cured. Why?', 'output': 'Hello. The treatment which you are taking is entirely correct. Continue it for another two to three weeks. Undergo a test for diabetes as balanitis is a recurrent problem in a diabetes patient. Also, please attach some photo of the area so that it will be easy to diagnose the condition and provide effective treatment. For further information consult a dermatologist online --> https://www.icliniq.com/ask-a-doctor-online/dermatologist', 'text_length': 856, '__index_level_0__': 43882}\n",
      "Task: nli, Sampled: 50\n",
      "{'dataset': 'bionli', 'split_data': 'test', 'task': 'nli', 'instruction': 'Please classify the relationship between the given premise and hypothesis into one of the following labels: entailment, contradiction, or neutral. return only the label.', 'input': '[PRE] We examined whether AICAR or leptin rapidly rescued skeletal muscle insulin resistance via increased palmitate oxidation, reductions in intramuscular lipids, and/or restoration of insulin-stimulated AS60 phosphorylation. Incubation with palmitate (2 mM, 0-18 h) induced insulin resistance in soleus muscle. From 12-18 h, palmitate was removed or AICAR or leptin was provided while 2 mM palmitate was maintained. Palmitate oxidation, intramuscular triacylglycerol, diacylglycerol, ceramide, AMPK phosphorylation, basal and insulin-stimulated glucose transport, plasmalemmal GLUT4, and Akt and AS160 phosphorylation were examined at 0, 6, 12, and 18 h. Palmitate treatment (12 h) increased intramuscular lipids (triacylglycerol +54%, diacylglycerol +11%, total ceramide +18%, C16:0 ceramide +60%) and AMPK phosphorylation (+118%), whereas it reduced fatty acid oxidation (-60%) and insulin-stimulated glucose transport (-70%), GLUT4 translocation (-50%), and AS160 phosphorylation (-40%). Palmitate removal did not rescue insulin resistance or associated parameters. The AICAR and leptin treatments did not consistently reduce intramuscular lipids, but they did rescue palmitate oxidation and insulin-stimulated glucose transport, GLUT4 translocation, and AS160 phosphorylation. Increased AMPK phosphorylation was associated with these improvements only when AICAR and leptin were present. Hence, across all experiments, AMPK phosphorylation did not correlate with any parameters. In contrast, palmitate oxidation and insulin-stimulated AS160 phosphorylation were highly correlated (r = 0.83). We speculate that AICAR and leptin activate both of these processes concomitantly, involving activation of unknown kinases in addition to AMPK.', 'output': 'entailment', 'text_length': 1920, '__index_level_0__': 45887}\n",
      "{'dataset': 'bionli', 'split_data': 'test', 'task': 'nli', 'instruction': 'Assess whether the given hypothesis follows logically from the premise. Select entailment, contradiction, or neutral.', 'input': '[PRE] If adenosine (ADO) mediates metabolic vasodilation in the heart, increases in interstitial ADO (ISF[ADO]) must accompany increases in coronary vascular conductance. We tested this using ADO release, defined as the difference in [ADO] in coronary venous and arterial plasma multiplied by coronary plasma flow, as an index of ISF[ADO]. Pentobarbital-anesthetized dogs received intravenous norepinephrine or left atrial pacing, and the resulting changes in coronary blood flow (delta CBF), conductance (delta C), myocardial oxygen consumption (delta VO2), and ADO release (delta RADO) were measured. If ISF[ADO] and C are coupled, the ratio delta RADO/delta C should be greater than zero. For dogs receiving atrial pacing, the ratios delta RADO/delta C, delta RADO/delta CBF, and delta RADO/delta VO2 equal -2.4 +/- 2.2 nmol . mmHg-1 . ml-1, -0.022 +/- 0.020 nmol/ml, and -0.13 +/- 0.12 nmol/ml, respectively. These values do not differ from zero. For dogs receiving norepinephrine, delta RADO/delta C, delta RADO/delta CBF, and delta RADO/delta VO2 equal 9.7 +/- 1.8, 0.051 +/- 0.017, and 0.44 +/- 0.13, respectively. These values are greater than zero (P less than 0.05). These differences between atrial pacing and norepinephrine infusion rate observed despite similar changes in C, CBF, and VO2.', 'output': 'contradiction', 'text_length': 1432, '__index_level_0__': 45753}\n",
      "{'dataset': 'bionli', 'split_data': 'test', 'task': 'nli', 'instruction': 'Please classify the relationship between the given premise and hypothesis into one of the following labels: entailment, contradiction, or neutral. return only the label.', 'input': '[PRE] We examined the potential function of Src in human pancreatic carcinoma. Overexpression of kinase-activated SrcY527F resulted in a significant increase of insulin-like growth factor I (IGF-I)-dependent cell proliferation in the cell line PANC-1. Western blotting and competition binding studies demonstrated 2.3 +/- 0.2-fold increase in IGF-I receptor expression and 2.8 +/- 0.4-fold increase in IGF-I-specific binding sites/cell. SrcY527F transfection alone did not change receptor affinity or basal receptor tyrosine phosphorylation, whereas IGF-I-stimulated receptor phosphorylation was increased by 2.1 +/- 0.5-fold. IGF-I mRNA expression and protein secretion did not change to exclude autocrine activation.', 'output': 'entailment', 'text_length': 897, '__index_level_0__': 45861}\n",
      "{'dataset': 'bionli', 'split_data': 'test', 'task': 'nli', 'instruction': 'Please classify the relationship between the given premise and hypothesis into one of the following labels: entailment, contradiction, or neutral. return only the label.', 'input': '[PRE] The presence of Arg972 insulin receptor substrate-1 (IRS-1) is associated with impaired insulin/IRS-1 signaling to activate phosphatidylinositol-3 kinase (PI3K). Tumor necrosis factor-Œ± (TNF-Œ±), an inflammatory cytokine with a central role in the pathogenesis of rheumatoid arthritis (RA), induces apoptosis in osteoblasts, which are the principal cell type responsible for bone loss in RA. In our previous study, an association between Arg972 IRS-1 and a high risk and severity of RA was identified. In the present study, the effects of Arg972 IRS-1 and IRS-1 on TNF-Œ±-induced apoptosis in human osteoblasts were examined. Normal and RA osteoblasts were stably transfected with Arg972 IRS-1 and IRS-1. In addition, cells were stably transduced with IRS-1-shRNA to knock down IRS1. Following stimulation with 10 nM insulin for 30 min, the stable overexpression of Arg972 IRS-1 and knock down of IRS-1 significantly decreased IRS-1-associated PI3K activity and Akt activation/phosphorylation at serine 473 (ser473) and enhanced TNF-Œ±-induced apoptosis in normal and in RA osteoblasts. By contrast, the stable overexpression of IRS-1 significantly increased the levels of IRS-1-associated PI3K activity and Akt phosphorylation (ser473) and inhibited TNF-Œ±-induced apoptosis, which was eliminated by pretreatment with 50 ¬µn BJM120, a selective PI3K inhibitor, for 30 min.', 'output': 'entailment', 'text_length': 1553, '__index_level_0__': 45921}\n",
      "{'dataset': 'bionli', 'split_data': 'test', 'task': 'nli', 'instruction': 'Please classify the relationship between the given premise and hypothesis into one of the following labels: entailment, contradiction, or neutral. return only the label.', 'input': '[PRE] Insulin-like growth factor binding proteins (IGFBPs) may participate in regulating ovarian function by modifying effects of insulin-like growth factors (IGFs) or by directly affecting ovarian steroidogenesis in both normal and pathological circumstances. The latter include hyperinsulinemic insulin resistant states, such as polycystic ovary syndrome. We examined regulation of IGFBP-1 production in human granulosa cells by insulin and IGF-I. The cells were obtained during in vitro fertilization, plated in McCoy-5A tissue culture medium supplemented with 10% fetal calf serum (10(5) cells/0.5 mL), and incubated at 37 C, 90% humidity, 5% CO2 for 48 h. After additional 24 h incubation without fetal calf serum, 1, 10, or 100 ng/mL of insulin or IGF-I were added with or without 2 h preincubation with 10 micrograms/mL monoclonal anti insulin receptor antibody IR-47-9. After 48 h incubation with insulin or IGF-I, the medium was collected and IGFBP-1 and progesterone concentrations were measured, using kits from Diagnostic Systems Laboratories, Webster, TX. Progesterone concentration ranged between 50-100 ng/mL/10(5) cells, without consistent stimulatory effect of either insulin or IGF-I. Control cells produced 7.0 +/- 1.7 ng/mL of IGFBP-1. Incubation with 1 or 10 ng/mL of insulin resulted in culture medium IGFBP-1 concentrations of 7.1 +/- 1.3 ng/mL and 5.4 +/- 0.7 ng/mL, respectively (P = NS). Incubation with 100 ng/mL of insulin reduced IGFBP-1 culture medium concentration to 1.6 +/- 0.3 ng/mL (P < 0.01, compared with controls). 1, 10, and 100 ng/mL of IGF-I inhibited IGFBP-1 concentrations in the conditioned culture medium to 1.3 +/- 0.3 ng/mL, 0.4 +/- 0.1 ng/mL and 0.3 +/- 0.1 ng/mL, respectively (P < 0.01, compared with controls). Preincubation with antiinsulin receptor antibody IR-47-9 alleviated inhibitory effect of insulin, but not of IGF-I on IGFBP-1 production. After preincubation with IR-47-9, IGFBP-1 culture medium concentrations were 5.9 +/- 0.8 ng/mL, 4.9 +/- 1.2 ng/mL, and 4.8 +/- 1.3 ng/mL for 1, 10, and 100 ng/mL of insulin, respectively. The latter number was significantly higher than IGFBP-1 concentration in the medium collected from cells incubated with 100 ng/mL of insulin without IR-47-9 (1.6 +/- 0.3 ng/mL, P < 0.01) and not significantly different from the control cells. For cells preincubated with IR-47-9 and then incubated with 1, 10, or 100 ng/mL of IGF-I, the IGFBP-1 conditioned culture medium concentrations were 1.7 +/- 0.1 ng/mL, 0.5 +/- 0.2 ng/mL, and 0.3 +/- 0.1 ng/mL, respectively. None of these were significantly different from the IGFBP-1 concentrations in the medium collected from cells incubated with the respective concentrations of IGF-I without preincubation with IR-47-9.', 'output': 'entailment', 'text_length': 2933, '__index_level_0__': 45927}\n",
      "Task: qa_objective_3, Sampled: 50\n",
      "{'dataset': 'pubmedqa', 'split_data': 'test', 'task': 'qa_objective_3', 'instruction': 'Choose the correct anser (Yes, No, or Maybe) for the given question based on the proviced context.', 'input': 'Question: Do leptin-resistant obese mice form biliary crystals on a high cholesterol diet? Context: Human obesity is associated with leptin resistance and cholesterol gallstone formation. Previously, we demonstrated that leptin-resistant (Lep(db)) obese mice fed a low cholesterol diet have enlarged gallbladders, but a decreased cholesterol saturation index, despite elevated serum cholesterol. Obese humans, however, consume a high cholesterol diet. Therefore, we hypothesized that on a high cholesterol diet, leptin-resistant mice would have cholesterol saturated bile and would form biliary crystals. Eight-week old female lean control (n = 70) and leptin-resistant (n = 72) mice were fed a 1% cholesterol diet for 4 weeks. All animals then had cholecystectomies. Bile was collected, grouped into pools to determine cholesterol saturation index (CSI), and examined for cholesterol crystals. Serum cholesterol and leptin were also measured. Gallbladder volumes for Lep(db) mice were enlarged compared with the lean mice (35.8 microl versus 19.1 microl, P < 0.001), but the CSI for the Lep(db) mice was lower than for the lean animals (0.91 versus 1.15, P < 0.03). The obese animals did not form cholesterol crystals, whereas the lean animals averaged 2.2 crystals per high-powered field (hpf) (P < 0.001). Serum cholesterol and leptin were also elevated (P < 0.001) in the obese animals.', 'output': 'no', 'text_length': 1490, '__index_level_0__': 45456}\n",
      "{'dataset': 'pubmedqa', 'split_data': 'test', 'task': 'qa_objective_3', 'instruction': 'Choose the correct anser (Yes, No, or Maybe) for the given question based on the proviced context.', 'input': 'Question: Does tranilast attenuate the up-regulation of thioredoxin-interacting protein and oxidative stress in an experimental model of diabetic nephropathy? Context: Diabetic nephropathy is the leading cause of kidney failure in the developed world. Tranilast has been reported to not only act as an anti-inflammatory and anti-fibrotic compound, but it also exerts anti-oxidative stress effects in diabetic nephropathy. Thioredoxin-interacting protein (Txnip) is the endogenous inhibitor of the anti-oxidant thioredoxin and is highly up-regulated in diabetic nephropathy, leading to oxidative stress and fibrosis. In this study, we aimed to investigate whether tranilast exerts its anti-oxidant properties through the inhibition of Txnip. Heterozygous Ren-2 rats were rendered diabetic with streptozotocin. Another group of rats were injected with citrate buffer alone and treated as non-diabetic controls. After 6 weeks of diabetes, diabetic rats were divided into two groups: one group gavaged with tranilast at 200 mg/kg/day and another group with vehicle. Diabetic rats had a significant increase in albuminuria, tubulointerstitial fibrosis, peritubular collagen IV accumulation, reactive oxygen species (ROS) and macrophage infiltration (all P < 0.05). These changes were associated with an increase in Txnip mRNA and protein expression in the tubules and glomeruli of diabetic kidney. Treatment with tranilast for 4 weeks significantly attenuated Txnip up-regulation in diabetic rats and this was associated with a reduction in ROS, fibrosis and macrophage infiltration (all P < 0.05).', 'output': 'yes', 'text_length': 1694, '__index_level_0__': 45377}\n",
      "{'dataset': 'pubmedqa', 'split_data': 'test', 'task': 'qa_objective_3', 'instruction': 'Choose the correct anser (Yes, No, or Maybe) for the given question based on the proviced context.', 'input': 'Question: Is the concentration of cyclosporine metabolites significantly lower in kidney transplant recipients with diabetes mellitus? Context: Diabetes mellitus is prevalent among kidney transplant recipients. The activity of drug metabolizing enzymes or transporters may be altered by diabetes leading to changes in the concentration of parent drug or metabolites. This study was aimed to characterize the effect of diabetes on the concentration of cyclosporine (CsA) and metabolites. Concentration-time profiles of CsA and metabolites (AM1, AM9, AM4N, AM1c, AM19, and AM1c9) were characterized over a 12-hour dosing interval in 10 nondiabetic and 7 diabetic stable kidney transplant recipients. All patients were male, had nonfunctional CYP3A5*3 genotype, and were on combination therapy with ketoconazole. The average daily dose (¬±SD) of CsA was 65 ¬± 21 and 68 ¬± 35 mg in nondiabetic and diabetic subjects, respectively (P = 0.550). Cyclosporine metabolites that involved amino acid 1 (AM1, AM19, AM1c) exhibited significantly lower dose-normalized values of area under the concentration-time curve in patients with diabetes. Moreover, during the postabsorption phase (‚â•3 hours after dose), metabolite-parent concentration ratios for all metabolites, except AM4N, was significantly lower in diabetic patients. The pharmacokinetic parameters of ketoconazole were similar between the 2 groups thus excluding inconsistent ketoconazole exposure as a source of altered CsA metabolism.', 'output': 'yes', 'text_length': 1584, '__index_level_0__': 45389}\n",
      "{'dataset': 'pubmedqa', 'split_data': 'test', 'task': 'qa_objective_3', 'instruction': 'Choose the correct anser (Yes, No, or Maybe) for the given question based on the proviced context.', 'input': 'Question: Does omega-3 fatty acid supplementation combined with acute aerobic exercise alter the improved post-exercise insulin response in normoglycemic , inactive and overweight men? Context: The aim of this study was to determine if omega-3 (n-3) supplementation combined with acute aerobic exercise would improve glucose and insulin responses in normoglycemic, inactive, overweight men. In a random order, ten inactive and normoglycemic men (30.6\\xa0¬±\\xa010\\xa0years, 85.4\\xa0¬±\\xa011\\xa0kg, 26.7\\xa0¬±\\xa04 BMI) completed a rest (R) and exercise trial (EX) without n-3 supplementation. Following 42\\xa0days of n-3 supplementation, participants again completed a rest (R\\xa0+\\xa0n-3) and exercise trial (EX\\xa0+\\xa0n-3) with continued n-3 supplementation. The exercise trial consisted of 3\\xa0days of ~70\\xa0% VO2peak for 60\\xa0min/session. N-3 supplementation entailed 4.55\\xa0g/day of n-3 (EPA 2.45\\xa0g, DHA 1.61\\xa0g). A 75\\xa0g oral glucose tolerance (OGTT) test was administered 14-16\\xa0h after each trial. Relative to R (35,278\\xa0¬±\\xa09169\\xa0pmol/L), EX without n-3 reduced the incremental area under the curve for insulin (iAUCinsulin) during an OGTT by 21.3\\xa0% (27765\\xa0¬±\\xa04925\\xa0pmol/L, p\\xa0=\\xa00.018) and 20.6\\xa0% after the EX\\xa0+\\xa0n-3 trial (27,999\\xa0¬±\\xa08370\\xa0pmol/L; p\\xa0=\\xa00.007). In addition, EX (96\\xa0¬±\\xa021\\xa0pmol/L; p\\xa0=\\xa00.006) reduced C-peptide by 13.5\\xa0% when compared to R (111\\xa0¬±\\xa026\\xa0pmol/L). No difference was observed between R and n-3 trials for iAUCinsulin and iAUCC-peptide. Only EX improved insulin sensitivity index by 5.6\\xa0% (p\\xa0=\\xa00.02) when compared to R.', 'output': 'no', 'text_length': 1585, '__index_level_0__': 45436}\n",
      "{'dataset': 'pubmedqa', 'split_data': 'test', 'task': 'qa_objective_3', 'instruction': 'Choose the correct anser (Yes, No, or Maybe) for the given question based on the proviced context.', 'input': 'Question: Is quality of recording of data from patients with type 2 diabetes a valid indicator of quality of care . A cross-sectional study? Context: The quality of recording of clinical data in diabetes care in general practices is very variable. It has been suggested that better recording leads to improved glycaemic control. The purpose of this study was to assess the completeness of recording by GPs of data from type 2 diabetes patients; to compare recorded and missing data; and to investigate the association between completeness and glycaemic control. A cross-sectional survey was carried out in 52 general practices. Medical records were scrutinized for the presence of 11 variables. Examining patients through an active approach completed incomplete records. We compared recorded and unrecorded items. Completeness of recording was determined at both patient and practice levels. Fifty-two general practices with 1641 type 2 diabetes patients cared for by the GP participated. The frequency of absence of any particular item ranged from 20 to 70%. Weight, systolic blood pressure and HbA(1c) were slightly lower in patients with those items missing on their files, and more such patients were non-smokers (P < 0.05). The percentage of patients with unrecorded variables that exceeded target values ranged from 39 to 75. Neither at practice level nor at patient level was any association between the completeness of the data recording and HbA(1c) found.', 'output': 'no', 'text_length': 1564, '__index_level_0__': 45445}\n",
      "Task: summarization, Sampled: 50\n",
      "{'dataset': 'pubmed', 'split_data': 'test', 'task': 'summarization', 'instruction': 'Summarize the key findings of the given PubMed abstract into structured fields: Objective, Methods, Results, and Conclusion.', 'input': 'subjects were recruited by a newspaper advertisement and from previous studies . a total of 117 subjects were eligible and randomized ( supplementary fig . \\n 1 ) . recruitment took place from april 2007 to september 2008 , with the last follow - up visit on 18 december 2008 . \\n eligible participants were men or postmenopausal women with type 2 diabetes who were taking antidiabetic agents other than acarbose , with medications stable for the previous 3 months and who had hba1c values at screening between 6.5 and 8.0% ( table 1 ) . \\n no participants had clinically significant cardiovascular , renal , or liver disease ( alanine aminotransferase more than three times the upper limit of normal ) or a history of cancer . \\n subjects were accepted after surgery or myocardial infarction if they had an event - free 6-month period before the study . \\n one subject had changed medications within 3 months before the start of the study . nevertheless , all randomized subjects were retained for the intention - to - treat analyses . \\n baseline characteristics of study participants data are n ( % ) or * mean ( sd ) . \\n p value is for overall f test for between - groups differences using the generalized linear model anova . \\n p values for fisher exact test where appropriate were calculated separately for distribution of each medication , since participants were from multiple nationalities or on multiple medications . \\n a difference in superscript letters signifies a significant difference in percentage changes using the q statistic . \\n the study was a 3-month randomized parallel study with two supplements and three treatments consisting of the following : a full portion of mixed nuts , a half portion of both nuts and muffins , or a full portion of muffins . \\n after stratification by sex and hba1c ( < 7.1% ) , randomization was carried out using subject identification by a statistician who was geographically separate from the center at which subjects were seen . \\n however , equal emphasis was placed on the potential importance for health of both supplements . \\n the analytical technicians were blinded to treatment , as was the statistician up to and during the preliminary assessment of the primary outcome of hba1c . \\n participants were seen in the center for screening at week 1 , baseline , and weeks 2 , 4 , 8 , 10 , and 12 of the study . at baseline and throughout the study , they received instructions on how to incorporate the supplement into their diets . at each center visit \\n , participants were weighed in indoor clothing without shoes , and a fasting blood sample was taken . \\n only the baseline and week 12 body weight data were used in the final analysis . also at each visit , blood pressure was measured seated on three occasions at 1-min intervals using an omron ( hem 907 xl ) automatic sphygmomanometer ( omron healthcare , burlington , ontario , canada ) , and the average of the three measurements was taken . \\n in addition , participants brought with them their 7-day food record covering the week before the visit , and this record was discussed with the dietitian . during the study , participants were asked to constantly maintain their oral antidiabetic medications and to have a form signed by their family physicians supporting their study involvement . \\n if patients experienced symptoms of hypoglycemia with blood glucose levels < 3.50 mmol / l ( one patient on full - nut supplement ) and provided that hypoglycemia was not explained by specific circumstances such as missed meals or increased physical activity , medications were reduced according to a predetermined protocol by the participants physician . \\n if hba1c rose to > 8.5% on two successive occasions , participants were to be withdrawn from the study and referred back to their own physician . \\n only two subjects were withdrawn : one in the muffin group and the other on the half - nut dose . both had recruitment hba1c levels of 8.0% , which rose above 8.5% on two successive occasions ( supplementary fig . \\n michael s hospital and the university of toronto , and written consent was obtained from all participants . \\n participants were counseled to substitute the supplement calories where possible for the carbohydrate foods in their original diets . \\n general dietary advice conformed to the national cholesterol education program adult treatment panel iii and the american diabetes association guidelines to reduce saturated fat and cholesterol intakes ( supplementary table 1 ) . \\n of the participants , 43% were obese ( 50/117 , bmi > 30 kg / m ) and wished to lose weight . \\n they were informed that this was not a weight - loss study but were given advice on portion size and fat intake to help them meet their weight - reduction objectives . \\n compliance was assessed from the mean of the five 7-day diet records per treatment ( weeks 2 , 4 , 8 , 10 , and 12 ) . \\n the nuts supplied consisted of a mixture of unsalted and mostly raw almonds , pistachios , walnuts , pecans , hazelnuts , peanuts , cashews , and macadamias . \\n the muffin was developed to be a healthy whole - wheat product , sweetened with apple concentrate , with no sugar added . \\n the muffin had similar protein content to the nuts , by the inclusion of egg white and skim milk powder . \\n the calories from mufas in the nuts were the same by design as the carbohydrate calories in the muffin ( supplementary table 2 ) . \\n energy requirements were calculated for each participant as referenced previously ( 3 ) , using the harris - benedict equation , with allowance for physical activity . \\n those participants with energy requirements of > 2,400 calories received supplements of 630 kcal ( 100 g nuts [ n = 0 ] ; four muffins [ n = 1 ] ; or 50 g nuts and two muffins [ n = 1 ] ) ; individuals whose requirements were 1,6002,400 kcal received supplements of 475 kcal ( 75 g nuts [ n = 38 ] ; 37.5 g nuts plus one and a half muffins [ n = 36 ] ; or three muffins [ n = 36 ] ) ; and individuals whose requirements were < 1,600 kcal received supplements of 315 kcal ( 50 g nuts [ n = 2 ] ; 25 g nuts and one muffin [ n = 1 ] ; or two muffins [ n = 2 ] ) ( supplementary table 2 ) . \\n hba1c was analyzed within 2 days of collection on whole blood collected in edta vacutainer tubes and measured by a designated high - performance liquid chromatography ( hplc ) method ( tosoh g7 automated hplc analyzer ; tosoh bioscience , grove city , oh ) ( cv 1.7% ) . \\n blood glucose was measured in the hospital routine analytical laboratory by a glucose oxidase method . \\n serum samples stored at 70c were analyzed for lipids , and apolipoproteins ( apo ) and oxidative products were analyzed at the end of the study . \\n oxidized ldl was measured chemically as conjugated dienes and thiobarbituric acid  reactive substances in the ldl fraction ( 11,12 ) , and oxidized serum proteins were measured as protein thiols ( 13 ) . \\n diets were analyzed in 115 participants with baseline data using a computer program based on the data from the u.s . \\n department of agriculture ( 3 ) and international glycemic index tables ( 14 ) , with additional measurements made on local foods . \\n the initial power calculation was based on an assumption of a 20% dropout and an effect size of 0.8% hba1c units with an sd of effect of 1.235% (  = 0.05 , 1- = 0.8 ) , for which 30 subjects per group were required . \\n the effect size of the change in hba1c was adjusted to 0.45% hba1c units , similar to a modest effect of acarbose with an sd of effect of 0.60% hba1c units ( 15 ) . \\n these values were also in line with the hba1c data of the completer and intention - to - treat groups , respectively , from the recent low glycemic index study . for the comparison of nuts with muffins , 40 subjects \\n no prior adjustment was made for the multiple comparisons necessary for assessment of a dose response . to establish significance for the three comparisons using the bonferroni correction , \\n the power was , therefore , designed to assess the primary outcome of the difference in change in hba1c between full - nut dose versus muffins . \\n the significance of treatment differences was assessed by the contrast statement in sas version 9.2 ( 16 ) , which allows comparisons of repeated measures over time based on a t test statistic with equal weighting for each value . in this study , \\n the three values for the last month ( end of weeks 8 , 10 , and 12 ) were expressed individually as changes from the mean baseline ( mean of weeks 1 and 0 ) . \\n the primary analysis was an intention - to - treat analysis , including all randomized subjects ( n = 117 ) with the baseline observation carried forward for subjects who did not have at least one value in the last month ( i.e. , end of weeks 8 , 10 , and 12 ) ( n = 14 ) . \\n subjects who were randomized but did not start ( n = 1 ) had their screening value used as baseline , and this value was carried forward ( supplementary fig . \\n using the bonferroni correction , for three - way comparisons , these differences were significant when the p value was < 0.0175 . \\n where only start and end values were available ( diet , markers of oxidative stress , and body weight ) , significance was assessed by the least square means procedure in sas with a tukey adjustment for multiplicity of comparisons . \\n pearson correlations were used to examine the relation of nut intake to changes in hba1c , lipids , and apolipoproteins . \\n nut consumption was defined as the difference in total tree nut , peanut , and nut butter intake in grams per day between the pretreatment and end of treatment week assessed from the 7-day diet records . \\n the dose - response analyses on nut and mufa intakes ( % energy ) and change in study outcomes were performed by regression analyses pooling the responses across the three treatment groups . \\n the study was a 3-month randomized parallel study with two supplements and three treatments consisting of the following : a full portion of mixed nuts , a half portion of both nuts and muffins , or a full portion of muffins . \\n after stratification by sex and hba1c ( < 7.1% ) , randomization was carried out using subject identification by a statistician who was geographically separate from the center at which subjects were seen . \\n however , equal emphasis was placed on the potential importance for health of both supplements . \\n the analytical technicians were blinded to treatment , as was the statistician up to and during the preliminary assessment of the primary outcome of hba1c . \\n participants were seen in the center for screening at week 1 , baseline , and weeks 2 , 4 , 8 , 10 , and 12 of the study . at baseline and throughout the study , they received instructions on how to incorporate the supplement into their diets . at each center visit \\n , participants were weighed in indoor clothing without shoes , and a fasting blood sample was taken . \\n only the baseline and week 12 body weight data were used in the final analysis . also at each visit , blood pressure was measured seated on three occasions at 1-min intervals using an omron ( hem 907 xl ) automatic sphygmomanometer ( omron healthcare , burlington , ontario , canada ) , and the average of the three measurements was taken . \\n in addition , participants brought with them their 7-day food record covering the week before the visit , and this record was discussed with the dietitian . during the study , participants were asked to constantly maintain their oral antidiabetic medications and to have a form signed by their family physicians supporting their study involvement . \\n if patients experienced symptoms of hypoglycemia with blood glucose levels < 3.50 mmol / l ( one patient on full - nut supplement ) and provided that hypoglycemia was not explained by specific circumstances such as missed meals or increased physical activity , medications were reduced according to a predetermined protocol by the participants physician . \\n if hba1c rose to > 8.5% on two successive occasions , participants were to be withdrawn from the study and referred back to their own physician . \\n only two subjects were withdrawn : one in the muffin group and the other on the half - nut dose . \\n both had recruitment hba1c levels of 8.0% , which rose above 8.5% on two successive occasions ( supplementary fig . \\n michael s hospital and the university of toronto , and written consent was obtained from all participants . \\n participants were counseled to substitute the supplement calories where possible for the carbohydrate foods in their original diets . \\n general dietary advice conformed to the national cholesterol education program adult treatment panel iii and the american diabetes association guidelines to reduce saturated fat and cholesterol intakes ( supplementary table 1 ) . \\n of the participants , 43% were obese ( 50/117 , bmi > 30 kg / m ) and wished to lose weight . \\n they were informed that this was not a weight - loss study but were given advice on portion size and fat intake to help them meet their weight - reduction objectives . \\n compliance was assessed from the mean of the five 7-day diet records per treatment ( weeks 2 , 4 , 8 , 10 , and 12 ) . \\n the nuts supplied consisted of a mixture of unsalted and mostly raw almonds , pistachios , walnuts , pecans , hazelnuts , peanuts , cashews , and macadamias . \\n the muffin was developed to be a healthy whole - wheat product , sweetened with apple concentrate , with no sugar added . \\n the muffin had similar protein content to the nuts , by the inclusion of egg white and skim milk powder . \\n the calories from mufas in the nuts were the same by design as the carbohydrate calories in the muffin ( supplementary table 2 ) . \\n energy requirements were calculated for each participant as referenced previously ( 3 ) , using the harris - benedict equation , with allowance for physical activity . \\n those participants with energy requirements of > 2,400 calories received supplements of 630 kcal ( 100 g nuts [ n = 0 ] ; four muffins [ n = 1 ] ; or 50 g nuts and two muffins [ n = 1 ] ) ; individuals whose requirements were 1,6002,400 kcal received supplements of 475 kcal ( 75 g nuts [ n = 38 ] ; 37.5 g nuts plus one and a half muffins [ n = 36 ] ; or three muffins [ n = 36 ] ) ; and individuals whose requirements were < 1,600 kcal received supplements of 315 kcal ( 50 g nuts [ n = 2 ] ; 25 g nuts and one muffin [ n = 1 ] ; or two muffins [ n = 2 ] ) ( supplementary table 2 ) . \\n hba1c was analyzed within 2 days of collection on whole blood collected in edta vacutainer tubes and measured by a designated high - performance liquid chromatography ( hplc ) method ( tosoh g7 automated hplc analyzer ; tosoh bioscience , grove city , oh ) ( cv 1.7% ) . \\n blood glucose was measured in the hospital routine analytical laboratory by a glucose oxidase method . \\n serum samples stored at 70c were analyzed for lipids , and apolipoproteins ( apo ) and oxidative products were analyzed at the end of the study . \\n oxidized ldl was measured chemically as conjugated dienes and thiobarbituric acid  reactive substances in the ldl fraction ( 11,12 ) , and oxidized serum proteins were measured as protein thiols ( 13 ) . \\n diets were analyzed in 115 participants with baseline data using a computer program based on the data from the u.s . \\n department of agriculture ( 3 ) and international glycemic index tables ( 14 ) , with additional measurements made on local foods . \\n the initial power calculation was based on an assumption of a 20% dropout and an effect size of 0.8% hba1c units with an sd of effect of 1.235% (  = 0.05 , 1- = 0.8 ) , for which 30 subjects per group were required . \\n the effect size of the change in hba1c was adjusted to 0.45% hba1c units , similar to a modest effect of acarbose with an sd of effect of 0.60% hba1c units ( 15 ) . \\n these values were also in line with the hba1c data of the completer and intention - to - treat groups , respectively , from the recent low glycemic index study . for the comparison of nuts with muffins , 40 subjects \\n no prior adjustment was made for the multiple comparisons necessary for assessment of a dose response . to establish significance for the three comparisons using the bonferroni correction , p < 0.0175 was required . \\n the power was , therefore , designed to assess the primary outcome of the difference in change in hba1c between full - nut dose versus muffins . \\n the significance of treatment differences was assessed by the contrast statement in sas version 9.2 ( 16 ) , which allows comparisons of repeated measures over time based on a t test statistic with equal weighting for each value . in this study , \\n the three values for the last month ( end of weeks 8 , 10 , and 12 ) were expressed individually as changes from the mean baseline ( mean of weeks 1 and 0 ) . \\n the primary analysis was an intention - to - treat analysis , including all randomized subjects ( n = 117 ) with the baseline observation carried forward for subjects who did not have at least one value in the last month ( i.e. , end of weeks 8 , 10 , and 12 ) ( n = 14 ) . \\n subjects who were randomized but did not start ( n = 1 ) had their screening value used as baseline , and this value was carried forward ( supplementary fig . \\n using the bonferroni correction , for three - way comparisons , these differences were significant when the p value was < 0.0175 . where only start and end values were available ( diet , markers of oxidative stress , and body weight ) , significance was assessed by the least square means procedure in sas with a tukey adjustment for multiplicity of comparisons . \\n pearson correlations were used to examine the relation of nut intake to changes in hba1c , lipids , and apolipoproteins . \\n nut consumption was defined as the difference in total tree nut , peanut , and nut butter intake in grams per day between the pretreatment and end of treatment week assessed from the 7-day diet records . \\n the dose - response analyses on nut and mufa intakes ( % energy ) and change in study outcomes were performed by regression analyses pooling the responses across the three treatment groups . \\n of the participants , 39 of 40 ( 97.5% ) completed the full - nut dose ( i.e. , provided a blood sample in the final month ) , compared with 32 of 38 ( 84% ) of those taking the half - nut dose and 32 of 39 ( 82% ) on muffins . in the half - nut dose group , \\n one subject dropped out after randomization but was unaware of his treatment allocation , and one participant was withdrawn because of two consecutive hba1c levels > 8.5% . in the muffin group , \\n no treatment differences were seen at baseline in diet , blood pressure , or anthropometric measurements ( tables 1 and 2 and supplementary table 1 ) . during the study , mufa intake , expressed as percent of total energy , \\n increased significantly after full - nut dose consumption ( supplementary tables 1 and 2 ) compared with muffins ( 8.7% , 95% ci 7.110.4 , p < 0.001 ) . \\n mean study measurements and significance of treatment differences in the intention - to - treat analysis data are means ( 95% ci ) . \\n * baseline is an average of weeks 1 and 0 and end point is an average of weeks 8 , 10 , and 12 , except for body weight ( week 0 ) . \\n mean treatment differences ( 95% ci ) were determined and p values were estimated by contrast using average baseline and the difference from week 8 , 10 , and 12 . \\n treat analysis , oral hypoglycemic medication dosages increased in one participant in the half - nut dose group , with reductions for two participants . \\n three participants ( one in each group ) had their avandia switched to actos after media alerts . \\n the mean hba1c fell 0.21% absolute hba1c units ( 95% ci 0.30 to 0.11 , p < 0.001 ) on the full - nut supplement ; 0.07% absolute hba1c units ( 0.19 to 0.05 , p = 0.270 ) on the half - nut dose supplement ; and 0.05% absolute hba1c units ( 0.16 to 0.06 , p = 0.355 ) on the muffin supplement ( fig . \\n the reduction in hba1c on full - nut dose was significantly different from the half - nut dose ( p = 0.004 ) and muffins dose ( p = 0.001 ) ( fig . \\n the significance of the difference between full - nut dose and muffins in hba1c remained after adjustment for duration of diabetes or body weight using an ancova model ( p = 0.023 and p = 0.004 , respectively ) . \\n no significant changes from baseline were seen in blood glucose or body weight , and there were no significant differences in responses between treatments ( table 2 and supplementary tables 1 and 3 ) . \\n through regression analysis , the full - dose ( of 100 g / day ) nut intake corresponded to a 0.26% ( 95% ci 0.41 to 0.11 ) reduction in absolute hba1c units . \\n mean hba1c measurements in participants with type 2 diabetes consuming full - nut dose , half - nut dose , or muffins . \\n two participants in the full - nut dose group increased and one participant on the half - nut dose decreased lipid medications during the study . there were no changes in lipid medications in the muffin group . \\n significant between - treatment differences were seen with greater cholesterol reductions for the full - nut dose compared with muffins for total cholesterol ( 0.24 mmol / l , 95% ci 0.44 to 0.04 , p < 0.001 ) ; ldl cholesterol ( 0.22 mmol / l , 0.41 to 0.03 , p < 0.001 ) ( supplementary fig . \\n 2 ) ; and total cholesterol : hdl cholesterol ( 0.23 , 0.47 to 0.02 , p = 0.006 ) ( table 2 and supplementary table 3 ) . \\n all three diets significantly raised the hdl cholesterol ( full - nut dose : 0.04 mmol / l , 0.010.08 , p = 0.017 ; half - nut dose : 0.03 mmol / l , 0.000.06 , p = 0.025 ; and muffins : 0.03 mmol / l , 0.010.05 , p = 0.012 ) . \\n nut intake related negatively to total cholesterol ( r = 0.19 , n = 115 , p = 0.039 ) and ldl cholesterol ( r = 0.24 , n = 115 , p = 0.011 ) . through a regression analysis , \\n adjustment for lipid medications still resulted in a significant ldl cholesterol difference between full - nut dose and muffins ( p = 0.007 ) . \\n apob showed a greater reduction on full - nut dose versus muffins ( p < 0.001 ) and half - nut dose versus muffins ( p = 0.012 ) as did the apob : apoa1 ratio ( full - nut dose versus muffins , p = 0.004 , and half - nut dose versus muffins , p = 0.001 ) ( table 2 ) . \\n nut intake related to a reduction in apob ( r = 0.26 , n = 115 , p = 0.006 ) . \\n no significant differences were seen between treatments for crp ( table 2 and supplementary table 3 ) or measures of oxidative damage ( data not shown ) . \\n blood pressure difference was not significant with or without adjustment for blood pressure medication use . \\n in the intention - to - treat analysis , oral hypoglycemic medication dosages increased in one participant in the half - nut dose group , with reductions for two participants . \\n three participants ( one in each group ) had their avandia switched to actos after media alerts . \\n the mean hba1c fell 0.21% absolute hba1c units ( 95% ci 0.30 to 0.11 , p < 0.001 ) on the full - nut supplement ; 0.07% absolute hba1c units ( 0.19 to 0.05 , p = 0.270 ) on the half - nut dose supplement ; and 0.05% absolute hba1c units ( 0.16 to 0.06 , p = 0.355 ) on the muffin supplement ( fig . \\n the reduction in hba1c on full - nut dose was significantly different from the half - nut dose ( p = 0.004 ) and muffins dose ( p = 0.001 ) ( fig . \\n 1 ) . the significance of the difference between full - nut dose and muffins in hba1c remained after adjustment for duration of diabetes or body weight using an ancova model ( p = 0.023 and p = 0.004 , respectively ) . \\n no significant changes from baseline were seen in blood glucose or body weight , and there were no significant differences in responses between treatments ( table 2 and supplementary tables 1 and 3 ) . \\n nut intake related negatively to change in hba1c ( r = 0.20 , n = 115 , p = 0.033 ) . through regression analysis , the full - dose ( of 100 g / day ) \\n nut intake corresponded to a 0.26% ( 95% ci 0.41 to 0.11 ) reduction in absolute hba1c units . \\n mean hba1c measurements in participants with type 2 diabetes consuming full - nut dose , half - nut dose , or muffins . \\n two participants in the full - nut dose group increased and one participant on the half - nut dose decreased lipid medications during the study . there were no changes in lipid medications in the muffin group . \\n significant between - treatment differences were seen with greater cholesterol reductions for the full - nut dose compared with muffins for total cholesterol ( 0.24 mmol / l , 95% ci 0.44 to 0.04 , p < 0.001 ) ; ldl cholesterol ( 0.22 mmol / l , 0.41 to 0.03 , p < 0.001 ) ( supplementary fig . 2 ) ; and total cholesterol : hdl cholesterol ( 0.23 , 0.47 to 0.02 , p = 0.006 ) ( table 2 and supplementary table 3 ) . \\n all three diets significantly raised the hdl cholesterol ( full - nut dose : 0.04 mmol / l , 0.010.08 , p = 0.017 ; half - nut dose : 0.03 mmol / l , 0.000.06 , p = 0.025 ; and muffins : 0.03 mmol / l , 0.010.05 , p = 0.012 ) . \\n nut intake related negatively to total cholesterol ( r = 0.19 , n = 115 , p = 0.039 ) and ldl cholesterol ( r = 0.24 , n = 115 , p = 0.011 ) . through a regression analysis , the full - dose nut intake \\n adjustment for lipid medications still resulted in a significant ldl cholesterol difference between full - nut dose and muffins ( p = 0.007 ) . \\n apob showed a greater reduction on full - nut dose versus muffins ( p < 0.001 ) and half - nut dose versus muffins ( p = 0.012 ) as did the apob : apoa1 ratio ( full - nut dose versus muffins , p = 0.004 , and half - nut dose versus muffins , p = 0.001 ) ( table 2 ) . \\n nut intake related to a reduction in apob ( r = 0.26 , n = 115 , p = 0.006 ) . \\n no significant differences were seen between treatments for crp ( table 2 and supplementary table 3 ) or measures of oxidative damage ( data not shown ) . \\n blood pressure difference was not significant with or without adjustment for blood pressure medication use . \\n increased mixed nut consumption as a source of unsaturated ( monounsaturated and polyunsaturated ) fat intake to replace dietary starch favorably affected both hba1c and serum lipids . \\n these data provide a specific food option for individuals wishing to lower the carbohydrate content of the diet in type 2 diabetes . \\n recently , there has been renewed interest in reducing carbohydrate content in the diet of diabetic patients . in 1994 , on the basis of emerging evidence ( 17 ) , the american diabetes association first suggested the possibility of exchanging dietary carbohydrate for mufa in dietary recommendations for type 2 diabetes ( 18 ) . \\n although not all studies have shown beneficial effects of mufas in diabetes ( 19 ) , general interest has persisted , especially in the context of the mediterranean diet . \\n however , low carbohydrate intakes have also been achieved on the atkins diet by increasing animal fats and proteins . \\n this influential dietary pattern is reflected in the relatively lower prestudy carbohydrate intakes of 45% in the current study rather than the 5060% once recommended ( 20,21 ) . \\n cohort studies have provided additional support showing that higher vegetable fat and protein intakes are associated with a reduced risk of developing diabetes and chd ( 2 ) . \\n furthermore , neither in the current study nor in previous reports has nut consumption been associated with weight gain ( 22 ) . if anything , nuts appear to be well suited as part of weight - reducing diets . \\n the reduction in hba1c was achieved despite baseline hba1c concentrations , which on entry were close to the target of < 7.0% in participants who were already treated with one or more ( average 1.5 ) antihyperglycemic medications . \\n furthermore , a reduction in ldl cholesterol was achieved even though the majority of subjects ( 84/117 , or 72% ) were already taking statins and had low mean baseline ldl cholesterol concentrations of 2.03 \\n mmol / l ( 95% ci 1.902.16 ) . the full - nut dose reduced hba1c by two - thirds of the reduction recognized as clinically meaningful by the u.s . food and drug administration ( > 0.3% absolute hba1c units ) in the development of antihyperglycemic drugs ( 23 ) . \\n in addition , the number of participants who achieved an hba1c concentration of > 7% ( 19 prestudy participants , down to 13 poststudy participants ) was significantly greater on the nut treatment than on the muffin treatment ( 20 prestudy participants , remaining at 20 poststudy participants , mantel - haenszel test , p = 0.040 ) . based on data from the uk prospective diabetes study and the advance study ( 24 ) , the hba1c reduction for the full - nut dose would translate into a predicted 78% reduction in microvascular complications . \\n methodological weaknesses included use of a 7-day diet history with the errors and inaccurateness associated with self - reported data , lack of blinding for participants and dietitians , and the attempt to demonstrate a dose response to nuts when the primary objective of establishing whether nuts improved glycemic control had not first been demonstrated . \\n in addition , in the current study , nut consumption was substantial ( 37.5 g for the half - nut dose and 75 g/2,000 kcal ) for the full - nut dose . \\n however , the baseline nut intake was 12 g / day , and the compliance levels were high ( i.e. , 95.7 and 97.3% for the full - nut and half - nut groups , respectively ) . \\n therefore , we believe that , with the appropriate advice , nut intake at these levels can be achieved and maintained . furthermore , the resulting relative increase in mufa intake was modest at 8.7% of total calories for the full - nut dose . \\n the strengths of the study include its novelty as one of the first studies to assess nuts in type 2 diabetes coupled with measurement of hba1c and blood lipids at three time points in the last month to increase the validity of the assessment of blood lipids and glycemic control . \\n there was good compliance with the supplement and a dropout rate of 12% , which was lower than that seen in many other longer - term diet trials ( 25 ) . \\n finally , there is a requirement for pharmacological interventions aimed at improving glycemic control to demonstrate that they have no negative impact on chd ( 23 ) . in this respect , \\n we have no explanation for the lack of antioxidant effects of nuts seen with previous studies but may relate to antioxidants in wheat bran and apple concentrate used in the muffins . \\n we conclude that mixed , unsalted , raw , or dry - roasted nuts have benefits for both blood glucose control and blood lipids and may be used to increase vegetable oil and protein intake in the diets of type 2 diabetic patients as part of a strategy to improve diabetes control without weight gain .', 'output': 'objectivefat intake , especially monounsaturated fatty acid ( mufa ) , has been liberalized in diabetic diets to preserve hdl cholesterol and improve glycemic control , yet the exact sources have not been clearly defined . \\n therefore , we assessed the effect of mixed nut consumption as a source of vegetable fat on serum lipids and hba1c in type 2 diabetes.research design and methodsa total of 117 type 2 diabetic subjects were randomized to one of three treatments for 3 months . \\n supplements were provided at 475 kcal per 2,000-kcal diet as mixed nuts ( 75 g / day ) , muffins , or half portions of both . \\n the primary outcome was change in hba1c.resultsthe relative increase in mufas was 8.7% energy on the full - nut dose compared with muffins . using an intention - to - treat analysis ( n = 117 ) , full - nut dose ( mean intake 73 g / day ) reduced hba1c ( 0.21% absolute hba1c units , 95% ci 0.30 to 0.11 , p < 0.001 ) with no change after half - nut dose or muffin . \\n full - nut dose was significantly different from half - nut dose ( p = 0.004 ) and muffin ( p = 0.001 ) , but no difference was seen between half - nut dose and muffins . \\n ldl cholesterol also decreased significantly after full - nut dose compared with muffin . \\n the ldl cholesterol reduction after half - nut dose was intermediate and not significantly different from the other treatments . \\n apolipoprotein ( apo ) b and the apob : apoa1 ratio behaved similarly . \\n nut intake related negatively to changes in hba1c ( r = 0.20 , p = 0.033 ) and ldl cholesterol ( r = 0.24 , p = 0.011).conclusionstwo ounces of nuts daily as a replacement for carbohydrate foods improved both glycemic control and serum lipids in type 2 diabetes .', 'text_length': 32672, '__index_level_0__': 44801}\n",
      "{'dataset': 'pubmed', 'split_data': 'test', 'task': 'summarization', 'instruction': 'Summarize the key findings of the given PubMed abstract into structured fields: Objective, Methods, Results, and Conclusion.', 'input': '', 'output': \"klinefelter syndrome ( ks ) is characterized in adults by the combination of a tall stature , small testes , gynecomastia , and azoospermia . \\n this case is described in a north african population of the mediterranean region of north africa . \\n we report the case of a male 16 years old , of arab ethnic origin , and diagnosed with this syndrome , who had a small height in relation to a growth hormone ( gh ) deficiency and a history of absence seizures ( generalized myoclonic epilepsy ) . \\n the patient 's size was < 2.8 standard deviation ( sd ) with weight < 3 sd . \\n gh deficiency was isolated and confirmed by two dynamic tests ( insulin  hypoglycemia tolerance test and clonidine ) with normal hypothalamic magnetic resonance imaging ( mri ) . \\n gh supplementation using recombinant gh was advocated , while gonadotropin treatment was deferred.small size in children or adolescents should not eliminate the diagnosis of klinefelter syndrome  on the contrary , the presence of any associated sign ( brain maturation , delay in puberty , aggressiveness ) should encourage one to request a karyotype for the diagnosis and appropriate care of any case of ks that can be associated with gh deficiency , or which is in a variant form ( isochromosome xq , 49,xxxxy ) .\", 'text_length': 1393, '__index_level_0__': 44561}\n",
      "{'dataset': 'pubmed', 'split_data': 'test', 'task': 'summarization', 'instruction': 'Summarize the key findings of the given PubMed abstract into structured fields: Objective, Methods, Results, and Conclusion.', 'input': '-thalassemia major is a hereditary hemolytic anemia that is treated with multiple blood transfusions . \\n a major complication of this treatment is iron overload , which leads to cell death and organ dysfunction . \\n iron accumulates initially in the reticuloendothelial system ( bone marrow , spleen , and liver ) and then in the hepatocytes , the heart ( myocytes ) , and the endocrine glands . \\n the turnover of iron in the hepatocytes , myocytes , and endocrine glands is very low . \\n chelation therapy has been used to eliminate it , methods to estimate total body iron stores are required , and serum ferritin acts as a reliable marker but can yield false results in the presence of inflammation and liver disease . \\n liver is the primary site for iron storage in patients with hemochromatosis or transfusion - dependent anemia ; therefore , liver iron concentration ( lic ) accurately reflects total body iron stores . \\n this procedure carries a 0.5% complication risk and it is also disliked by patients . clinical management of these patients is also based on the assessment of liver iron stores for several reasons . \\n impairment of the endocrine and exocrine functions of the pancreas is a common complication in patients with beta - thalassemia major . \\n the incidence of impaired glucose tolerance and diabetes in thalassemia major patients varied from 9% to 15% depending on the age of assessment , the intensity of chelation , transfusion , and related patient compliance . \\n the etiology of diabetes in -thalassemia is increased peripheral resistance to insulin and direct toxic effect of excess iron in the acinar and beta cells of the pancreas resulting in insulin deficiency . \\n magnetic resonance imaging ( mri ) represents the most available noninvasive technique to assess hepatic iron content and shows a good correlation with biopsy results [ 11 , 12 ] . \\n it is the best noninvasive method for measuring the level of iron in the liver for the purposes of confirming the diagnosis , determining the severity and monitoring therapy with high sensitivity , specificity , and positive and negative predictive values . \\n the study was conducted at the radiology and pediatrics departments , zagazig university , in the time frame of december 2010 to december 2011 , and included 50 thalassemia major pediatric patients ( 33 males and 17 females ) , whose age ranged between 9 and 16 years , referred from the pediatric hematologic clinic , in addition to 15 healthy controls . \\n they were on regular blood transfusion 12 times / year and received desferrioxamine as chelation therapy 4 days per week . \\n group c : included thalassemic diabetic patients ( 10/50).splenectomized patients were 37/50 of all our patients . all patients underwent mri with 1.5 tesla scanner ( philips medical system ) . \\n t1 and t2wis were obtained in the axial planes plus breath hold gradient echo sequence using a body coil to avoid signal drop - off and to ensure the highest uniformity in the signal - to - noise ratio throughout the scanned volume . \\n the used t2 * gradient echo pulse sequence in the axial plane was obtained with 25 slices to cover the whole abdomen using the following : te = 510  m / sec tr = 50120  m / sec , flip angle = 20 , fov = 350400  mm , matrix ( frequency  phase ) 256  256 pixels , slice thickness = 57  mm with 1  mm interval , in - phase and out - phase mr imaging was also performed in five cases , using te 4.2  m / sec and 2.1  m / sec , respectively , to differentiate between siderosis and steatosis . \\n  te = 510 \\n m / sec tr = 50120  m / sec , matrix ( frequency  phase ) 256  256 pixels , slice thickness = 57  mm with 1  mm interval , in - phase and out - phase mr imaging was also performed in five cases , using te 4.2  m / sec and 2.1  m / sec , respectively , to differentiate between siderosis and steatosis . \\n the results were tabulated with statistical analysis of ( spss version 19 ) data expressed as mean  sd or number and percentage . \\n we compared the clinically classified groups of our cases as regards the mean age at diagnosis with laboratory assessment of their serum ferritin level which was significantly higher in patients with abnormal glucose tolerance ( groups b and c ) compared to nondiabetic patients ( group a ) ( p < 0.05 ) ( table 1 ) . \\n tissue iron overload was detected in the different groups of thalassemic patients on the basis of decreased signal intensity of the involved organ parenchyma on t2*gre sequence as a result of the paramagnetic susceptibility of iron and was compared to the signal intensity on t2wi of the same patient and relative to the studied control cases ( figure 1 ) . \\n hepatic siderosis was diagnosed in 45/50 ( 90% ) of thalassemic patients and pancreatic siderosis in 21/50 of patients ( 42% ) . \\n thalassemic patients with impaired glucose tolerance ( group b ) and who are diabetic ( group c ) showed significant reduction in the signal intensity of the liver and the pancreas compared to those with normal glucose tolerance ( group a ) ( table 2 ) ( figure 2 ) . \\n patients with impaired glucose tolerance ( 14 patients ) showed normal signal intensity of the pancreatic parenchyma in 10/14 patients and hypointense signal of the pancreatic parenchyma in 4/14 patients while all thalassemic diabetic patients showed significant drop in the pancreatic parenchyma signal intensity ( table 2 ) . on t2wi , \\n the hepatic siderosis was detected in 28/50 ( 56% ) patients by the hypointensity of the hepatic parenchyma relative to the healthy control hepatic parenchymal signal ( 11 cases from group a , 17 cases from groups b and c ) while pancreatic siderosis was detected in 9 out of 50 patients ( 18% ) , 4 cases were with impaired glucose tolerance and 5 cases were diabetic . \\n these findings confirmed that t2*gre sequence is highly specific and more sensitive to the magnetic susceptibility of the deposited iron than seen on ct2wis as hepatic siderosis was diagnosed in 90% of cases and pancreatic siderosis in 42% of cases by t2*gre images compared to 56% and 18% , respectively , by ct2wi . \\n the drop of the signal intensity of both hepatic and pancreatic parenchymas occurred in both diabetic and impaired glucose tolerance patient groups with no statistically significant difference ( p > 0.05 ) . \\n the drop of signal intensity of the liver and pancreas on t2*gre was accentuated in splenectomized thalassemic patients as seen in 35/37 and 21/37 patients , respectively , compared with those with preserved spleen , particularly in patients with abnormal glucose tolerance ( table 3 ) ( figure 3 ) . \\n in- and out - phases mr sequences were used in 5/50 patients to exclude suspected fatty parenchymal infiltration that results in drop of normal si on the out - phase sequence and we did not detect any case of steatosis in our study ( figures 1 and 3 ) . \\n magnetic resonance ( mr ) imaging is the most sensitive and specific imaging modality in the diagnosis of parenchymal iron overload in thalassemic patients on regular blood transfusion . \\n the susceptibility effect caused by the accumulation of iron leads to signal loss in the affected tissues , particularly with the t2 * weighted sequences , which makes the diagnosis of iron overload possible in a noninvasive way , thereby avoiding repeated biopsies . \\n the accumulation of iron ions in the tissues , because of the superparamagnetic properties of the iron , causes local distortion in the magnetic fields and relaxation of the spins which results in shortening of the longitudinal relaxation time ( t1 ) and the transverse relaxation time ( t2 ) , and particularly the transverse relaxation time as affected by magnetic field inhomogeneity ( t2 * ) . \\n this effect causes a loss of signal intensity in the affected organs that is proportional to the iron deposition . \\n dual sequences mr imaging ( gradient in and out phase ) demonstrates decreased signal intensity in the affected tissues on the in - phase images compared with the out - phase images . \\n this occurs because the echo time of the in - phase sequence is usually higher than that of the out - phase sequence ; therefore , the in - phase pulse sequence is more sensitive to iron deposits because of the increased t2 * effect . in the current study , \\n the single breath t2 * gradient echo sequence was preferred for its short scanning time making it more convenient in young age and the resulting signal intensity was compared to that on t2wi . \\n dual phase imaging including in- and out - phase gradient mr imaging was used in five cases to differentiate tissue iron overload from suspected steatosis which demonstrates signal intensity drop in the out - phase sequence and we did not detect any cases of hepatic steatosis in our study .   in the present study , \\n there is significantly lower signal intensity of the liver ( 45/50 ) and pancreas ( 21/50 ) in thalassemic patients compared to controls on t2*gre images and in the in - phase sequence in consistency with matter et al . , 2010 . \\n the pancreatic siderosis that resulted in drop of mr signal intensity subsequent to iron overload occurred in 42% of our patients whereas higher percentage was reported by noetzli et al . \\n , 2009 , who reported that iron overload in the pancreas occurs in up to 75100% of thalassemic major cases . \\n t2*gre sequence was found to be sensitive to parenchymal iron overload and more specific than conventional t2wi which is diagnosed only in 28/50 ( 56% ) hepatic siderosis cases and 9/50 ( 18% ) pancreatic siderosis cases compared to 45/50 ( 90% ) and 21/50 ( 42% ) cases detected by t2*gre sequence , respectively . \\n our study also detected lower signal intensity of the liver and pancreas in thalassemic patients with abnormal glucose tolerance ( including groups b and c ) compared to patients with normal glucose tolerance ( group a ) in agreement with matter et al . \\n no significant difference between diabetic and impaired glucose tolerance patients in the dropped signal intensity of the liver and pancreas on t2*gre was detected in the study performed by mong et al . \\n , 2001 , who explained the presence of other causative factors for diabetes as genetic predisposition and immune damage . \\n the reduction in the signal intensity of the liver in thalassemic patients with abnormal glucose tolerance ( groups b and c ) compared to nondiabetic patients ( group a ) was in agreement with papakonstantinou et al . , 2007 . \\n this is an important point that reflects the importance of hepatic iron deposition in the development of insulin resistance in consistency with chern et al . , 2001 , \\n thirty seven patients undergone splenectomy , confirmed by ultrasonography , and all of them showed significant reduction in the signal intensity of the liver and pancreas compared to those with intact spleen . \\n this finding was explained by the study made by matter et al . , 2010 , by decreased extrahepatic iron buffering capacity in splenectomized patients with accelerated iron deposition in the liver and pancreas . \\n hepatic and pancreatic siderosis is a major problem in thalassemic patients and could be detected noninvasively by the drop of signal intensity on t2 * weighted gradient echo mri in the in - phase sequence . \\n it was more evident in patients with abnormal glucose tolerance and is accelerated after splenectomy especially in the pancreas . \\n we recommend t2*gre sequence in the protocol of mri regular followup of thalassemic patients and for those under intensive chelation regimen as noninvasive tool to assess improvement of the hepatic and pancreatic siderosis .', 'output': 'background . mri has emerged for the noninvasive assessment of iron overload in various tissues . \\n the aim of this paper is to evaluate hepatic and pancreatic iron overload by t2 weighted gradient echo mri in young beta - thalassemia major patients and to correlate it with glucose disturbance and postsplenectomy status . \\n subjects and methods . \\n 50 thalassemic patients , in addition to 15 healthy controls . \\n all patients underwent clinical assessment and laboratory investigations . out of 50 thalassemic patients , \\n 37 patients were splenectomized . \\n mri was performed for all subjects . \\n results . \\n all patients showed significant reduction in the signal intensity of the liver and the pancreas on t2grd compared to controls , thalassemic patients who had abnormal glucose tolerance ; diabetic and impaired glucose tolerance patients displayed a higher degree of pancreatic and hepatic siderosis and more t2 drop in their signal intensity than those with normal blood sugar level . \\n splenectomized thalassemic patients had significantly lower signal intensity of the liver and pancreas compared to nonsplenectomized patients . \\n conclusion . \\n t2 gradient echo mri is noninvasive highly sensitive method in assessing hepatic and pancreatic iron overload in thalassemic patients , more evident in patients with abnormal glucose tolerance , and is accelerated in thalassemic splenectomized patients .', 'text_length': 13174, '__index_level_0__': 44362}\n",
      "{'dataset': 'pubmed', 'split_data': 'test', 'task': 'summarization', 'instruction': 'Summarize the key findings of the given PubMed abstract into structured fields: Objective, Methods, Results, and Conclusion.', 'input': \"cushing 's syndrome ( cs ) is a complex endocrine disorder with potential for serious consequences if not adequately treated . \\n the incidence of cs varies in different studies from 0.7 to 2.4 per million populations per year . \\n a more recent study reported a prevalence of 79 per million and incidence of 1.8 per million per year for cs . \\n nearly 80% of the cases of endogenous hypercortisolism are adrenocorticotropic hormone ( acth ) dependent , the acth source being pituitary in about 70 - 80% and ectopic in 10 - 15% \\n . the acth source may remain occult in few cases for many years in spite of extensive investigations . \\n primary adrenal disease ( adrenal adenoma , adrenal carcinoma ) accounts for about 15 - 20% of cases . \\n cs is more common among certain high - risk groups , e.g. , 2 - 5% among patients with type 2 diabetes mellitus with poor blood glucose control and 0.5 - 1% among hypertensive patients . \\n cs patients experience significant clinical burden as a result of the physical illness , associated comorbidities like hypertension , diabetes mellitus , vulnerability to infections and associated psychopathology . \\n identification and management of this complex problem poses a greater challenge in a resource - poor country like india . \\n presented here is the profile of patients with cs attending this tertiary care center since 1985 . \\n patients referred to the endocrine services of this hospital for evaluation / management of cs , from january 1985 to july 2012 , are included in this study . \\n all subjects had detailed clinical evaluation , including review of past medical records and medications . \\n the protocol for evaluation of patients with suspected cs has changed considerably during the study period . in the 80s , patients with suspected cs had plasma cortisol measurement 6 h for 2 days to assess diurnal variation followed by low - dose ( 0.5 mg 6 h for 2 days ) dexamethasone suppression test . \\n those confirmed to have hypercortisolism underwent computed tomography ( ct ) scan of the adrenal glands to exclude adrenal pathology . \\n those without an adrenal mass lesion underwent high - dose dexamethasone suppression test ( hddst ) with 8 mg dexamethasone ( 2 mg 6 h for 2 days ) . those who showed more than 50% \\n suppression underwent ct ( or magnetic resonance imaging ( mri ) since the late 80 's , 0.5 tesla ) scan for pituitary gland . \\n those with non - suppressible cortisol on hddst and those without a lesion on ct / mri underwent further investigations to exclude an ectopic acth source . those who had an adenoma ( micro or macro ) \\n radioimmunoassay for acth and cortisol became freely available ( on a commercial basis during the mid 80 's ) in this hospital from the year 2000 . \\n subsequently , late night salivary cortisol estimation , intravenous hddst , ga dota - toc / fdg pet - ct scan and bilateral internal jugular vein sampling for acth and corticotrophin releasing hormone ( crh ) stimulation test have been added . \\n now ( after year 2000 ) , two or more screening tests ( ondst , lddst , late night salivary cortisol ) are performed in addition to measurement of basal serum cortisol and plasma acth . \\n those with discordant results and those with low serum cortisol in the absence of history of steroid use are re - evaluated subsequently to exclude the possibility of cyclical hypercortisolism . \\n acth dependent cs ( plasma acth > 10 pg / ml ) patients underwent hddst and mri of pituitary ( 1.5 tesla since 2007 ) with dynamic sequences with gadolinium . \\n acth dependent cs patients with normal or inconclusive ( lesion < 5 mm ) findings on mri sella were further investigated to localize the ectopic source of acth with contrast - enhanced ct scan of the neck , chest , abdomen and pelvis . \\n crh stimulation test , bilateral internal jugular vein sampling for acth and ga dota - toc / fdg pet - ct scan were performed as additional tests for the more recent cases . \\n subjects with acth dependent cs where no pituitary or ectopic acth producing tumor could be identified were explained the pros and cons of pituitary exploration , bilateral adrenalectomy and medical therapy and given the option for choosing one of these modalities of treatment . \\n some patients with cushing 's disease who were severely symptomatic ( significant myopathy , multiple vertebral fractures , etc . \\n estimation of plasma acth is performed using two monoclonal antibodies specific for acth ( acth : 9 - 12 and acth : 36 - 39 ) . \\n the measuring range of acth assay is 1 - 2000 pg / ml with inter - assay and intra - assay cv < 6% . \\n mri is performed on a 1.5 t scanner ( siemens avanto or sonata , erlangen , germany ) . \\n t1w spin echo sequences are obtained in the coronal and sagittal planes using thin slices ( 3 mm ) . \\n following contrast administration , both dynamic and routine images are performed . for dynamic imaging , \\n besides descriptive statistics , the two groups were compared by applying the student t - test for continuous data . \\n qualitative data were compared by applying the chi - square / fishers test , p < 0.05 was considered as significant . \\n three hundred and sixty - four patients were diagnosed to have cs ( 250 females and 114 males , age ranging from 6 months to 65 years [ 28 years + 12 years ] ) during these 27 years . \\n nearly 70% of the patients were in the 10 - 40 year age group [ figure 1 ] . \\n age and gender distribution of patients in different age groups one hundred and twenty - one of these patients were diagnosed prior to 2000 ( 88 females and 33 males , age ranging from 6 months to 56 years [ mean 27.0812 ] ) [ table 1 ] . among them , 25 patients had acth independent hypercortisolism ( 13 adrenal carcinoma , 11 adenoma and one primary pigmented nodular adrenal disease [ ppnad ] ) . \\n five patients had ectopic acth syndrome ( eas ) ( four diagnosed during initial evaluation and one during follow - up ) . among the other 91 patients , 61 had cd ( 12 pituitary macroadenoma , 42 microadenoma and seven normal pituitary on imaging [ developed pituitary tumor during follow - up after bilateral adrenelectomy ] ) ; source of acth excess \\n eleven of the twelve with pituitary macroadenoma had pituitary surgery as the initial therapy , seven of them required radiotherapy ( external irradiation in five , gamma knife in two ) and six of these seven required bilateral adrenelectomy . \\n one of these 12 patients underwent external irradiation for pituitary and bilateral total adrenelectomy at another center . \\n one patient with microadenoma had a cerebellopontine angle tumor and another had breast carcinoma with secondaries ; the other 40 patients underwent pituitary surgery . \\n bilateral total adrenalectomy was performed subsequently in 17 of these , four required additional pituitary surgery and/or radiotherapy . \\n nineteen of the thirty patients with normal pituitary had bilateral adrenalectomy , two died of septicemia with chest infection and nine were lost to follow - up . \\n cushing 's syndrome patients evaluated during different periods one hundred and ninety - one patients were diagnosed to have cs ( 131 females and 60 males , age ranging from 2 years to 65 years [ 28.711.8 ] ) between january 2000 and december 2009 . of these , \\n dependent , 121 were due to cd ( 14 macroadenoma ) , 13 eas ( 11 during initial evaluation and two on follow - up ) and 17 occult acth source . \\n 23 were adrenal carcinomas , 15 were adrenal adenoma , one was aimah and one was ppnad . \\n fifty - two patients ( 34 females and 18 males , age ranging from 12 years to 55 years [ 26.7  11.16 years ] ) were diagnosed to have cs between january 2010 and july 2012 . \\n forty - six patients had acth dependent cs while six had acth independent hypercortisolism ( four adrenal adenoma and two ppnad ) . among the 46 acth \\n dependent cs patients , four had eas ( one thymic carcinoid and three bronchial carcinoid ) , 33 cd ( four macroadenoma ) and nine with occult acth source . \\n altogether 293 ( 80.5% ) were acth dependent cs , 71 ( 19.5% ) were acth independent [ table 2 ] . among 293 acth dependent cases , 215 ( 73% ) were due to cd ( 30 [ 14% ] pituitary macroadenoma ) , 22 ( 7.5% ) were due to eas and in 56 ( 19% ) , the acth source could not be identified ( occult acth source ) . \\n source of eas was bronchial carcinoid ( seven cases ) , thymic carcinoid ( six cases ) , pancreatic neuroendocrine tumor ( four cases including one case of insulinoma ) , men 2 ( medullary ca thyroid with ectopic acth secretion ) ( one case ) and four cases of metastatic carcinoma ( one each of squamous cell carcinoma , adenocarcinoma , small cell carcinoma and metastatic neuroendocrine tumor with unknown primary [ tumorlets ] ) . \\n adrenal carcinoma ( 36 ) , adrenal adenoma ( 30 ) , ppnad ( 4 ) and acth independent macronodular adrenal hyperplasia ( 1 ) accounted for the 71 acth independent cs cases . \\n figure 4 shows the age and gender distribution of patients with adrenal adenoma and adrenal carcinoma . \\n etiology of cushing 's syndrome in different age groups etiology of ectopic adrenocorticotropic hormone syndrome in different age groups age wise distribution of cases of adrenal adenomas and carcinomas hypertension and diabetes mellitus were the predominant presenting symptoms . \\n age and clinical profile of cd patients with pituitary macroadenoma was not significantly different from those with smaller pituitary lesions [ table 2 ] . \\n prevalence of hypertension , diabetes mellitus and obesity were 77% , 57% and 60% , respectively , among cd patients with pituitary macroadenoma , while it was 72% , 67% and 72% among those with pituitary microadenoma . \\n mean plasma acth was higher [ figure 5 ] and a lower number of patients showed > 50% suppression with hddst in the group with macroadenoma ( not statistically significant ) . \\n profile of patients with cushing 's syndrome plasma adrenocorticotropic hormone ( pg / ml ) in cushing 's syndrome patients with pituitary micro adenoma ( 1 ) , macro adenoma ( 2 ) , eas ( 3 ) , adrenal adenoma ( 4 ) and adrenal carcinoma ( 5 ) obesity was less common among eas and adrenal carcinoma patients . \\n plasma acth was higher among patients with eas compared with patients with cd . among cd patients , \\n ninety - one ( 26% ) patients had skin infections , 15 patients had wound infections , nine patients had chest infection and four of these died of septicemia prior to any surgical intervention . \\n fifteen patients had tuberculosis , which included two adrenal tuberculosis and two intestinal tuberculosis with perforation and peritonitis . \\n one of the patients with adrenal tuberculosis was misdiagnosed as adrenal adenoma and subjected to adrenalectomy . \\n sixty - four patients had fractures , which included fracture hip in one patient , multiple rib and vertebral fractures . \\n two patients with vertebral fractures had paraparesis and one had paraplegia ; all three were males with age ranging from 13 years to 26 years . \\n seven patients had avascular necrosis of bone , and the most common site was head of femur , others being head of humerus and carpel bones . \\n there were three patients with cd who developed pituitary apoplexy , two of them required surgery for hypercortisolism while one was asymptomatic without surgery . \\n complaints were of cyclical nature in three patients ( two f , one m ) , with length of cycles ranging from 2 weeks to 2 years . \\n the first patient had normal cortisol levels during evaluation at our hospital , and mri revealed pituitary microdenoma with hemorrhage . \\n the second patient had several such episodes during a 6-year period , where she had weight gain followed by symptomatic hypocortisolism and weight loss of 16 - 20 kg . \\n she lost 25 kg ( 103 - 78 kg ) during the next 1 year , which was followed by weight gain and increase in plasma cortisol and acth . \\n the third patient was a 19-year - old male admitted with overt features of cs and no history of steroid use . \\n initial evaluation revealed low plasma cortisol , but repeat evaluation few weeks later revealed acth dependent hypercortisolism . \\n source of acth could not be identified in both these patients ; they underwent bilateral adrenalectomy and are on follow - up . \\n two women with cs ( one with cd and another with unknown acth source ) had venous thrombosis . \\n the first patient had axillary vein thrombosis some years after cure of hypercortisolism while the other had a large thrombus extending from the inferior vena cava to the right atrium at the time of diagnosis of cs . \\n x - ray of the chest of this patient showed miliary shadows that were mistaken for miliary tuberculosis . \\n one young male patient had dialated cardiomyopathy , which recovered within 1 year of bilateral adrenalectomy . \\n one patient had carcinoma breast with secondaries in the liver at the time of diagnosis of cs and two women developed breast carcinoma several years after cure of hypercortisolism . \\n introduction of sensitive assays for acth and cortisol , higher resolution imaging techniques and better understanding of the etiology have changed the diagnostic and therapeutic strategy for patients with cs . \\n availability of acth assay has made it possible to distinguish between acth dependent and acth independent cs . however , identifying the acth source ( pituitary versus ectopic ) still continues to be a challenge . \\n the present study included 364 cs patients evaluated during the last 27 years in the endocrine services of this hospital . \\n seventy - one ( 19.5% ) had primary adrenal disease while 293 ( 80.5% ) were acth dependent . \\n unilateral adrenal disease ( adrenal carcinoma 36 , adenoma 30 ) accounted for most of the adrenal cs . \\n there were four cases of ppnad and one case of aimah . among the cases of acth dependent \\n cs , 215 ( 73.4% ) were due to cd , 22 ( 7.5% ) were due to eas and 56 ( 19.1% ) had occult acth source . \\n cd was the most common cause ( 59% ) for cs in the present study , although it was less than in other published series . \\n table 3 compares the profile of cs patients in the present study with some large published series . \\n our patients were younger compared with cs patients in the italian multicentric study and the euro cushings registry ( mean age 28 years vs. 36 years and 43 years ) . \\n duration of symptoms prior to diagnosis was 3.2 years , which was longer compared with 29 months in the italian multicenter study . \\n macroadenomas are reported in 4 - 10% of the cases with cd . in the present study , 30 ( 14% ) of the 215 patients with cd had pituitary macroadenoma , proportion of patients with macroadenoma was higher among the earlier group ( 20% vs. 12% ) compared with patients diagnosed more recently . \\n there was a significant female preponderance in all etiological groups except eas , like other published series . \\n the number of patients diagnosed cs per year ( 8 vs. 19 ) and percentage of patients with eas ( 5 vs. 17 ) was more after year 2000 . \\n the percentage of patients with pituitary macroadenoma among cd patients was higher ( 20% vs. 12% ) during the earlier period . \\n etiology of cushing 's syndrome : comparison with some published series common co - morbidities with cs are obesity , hypertension , diabetes mellitus , osteoporosis , infections and neurocognitive dysfunction . \\n those with weight loss were patients with a very long duration of symptoms , uncontrolled diabetes mellitus and infections like tuberculosis . \\n we did not observe significant difference in the clinical profile of patients with different etiology for cortisol excess except that obesity was less common among the eas and adrenal carcinoma group and psychiatric problems were more common among eas compared with the other groups . \\n acth independent cs is mostly due to unilateral adrenal tumors ; adenomas are more common than carcinomas . in this present study , \\n it is difficult to say whether adrenal carcinoma is more common among indian patients or if this is a reflection of referral bias . \\n cyclicity / periodic hormonogenesis have been reported , although rarely , in patients with cs . \\n some of the hypotheses suggested to explain this phenomenon are episodic hemorrhage , synchronous growth and death of tumor cells , fluctuations in the hypothalamus  pituitary  adrenal axis , etc . \\n , cyclicity has been defined as occurrence of three peaks and two troughs of hypercortisolemia . \\n skeletal fractures , avascular necrosis of bones , venous thrombosis , and cardiac dysfunction are well documented in patients with cs . \\n one of our patients had extensive ivc thrombosis with miliary shadows in the lungs that was mistaken for milliary tuberculosis . \\n three patients had breast carcinoma ( one at the time of diagnosis and two during follow - up ) and two had accoustic neuroma . \\n it is not possible to say whether there is a causal link or whether it is a coincidence , as these are not uncommon diseases . \\n the strength of this study is the large number of patients studied at a single center by the same investigators and the long - term follow - up . \\n that is one possible reason for the higher number of cases with occult acth source . \\n cushing 's disease was the most common cause for cs ; 14% patients with cd had pituitary macroadenoma . \\n etiology of acth / cortisol excess could not be established in 56 ( 15% ) cs patients . \\n patients in this study were young , had long duration of illness , multiple metabolic abnormalities and coexisting infections .\", 'output': \"background : there is little published literature on the profile of patients with cushing 's syndrome ( cs ) from india . \\n the aim of this study was to compile data of cs patients treated at this hospital.materials and methods : patients referred to the endocrine services of this hospital for diagnosis / treatment of cs from january 1985 to july 2012 were the subjects for this study . \\n all patients had detailed medical history , physical examination and biochemical and hormonal assays ( which changed with availability of tests and changing views ) . \\n assays for plasma adrenocorticotropic hormone ( acth ) ( late 90s ) , salivary cortisol estimation , ijv sampling for acth and corticotrophin releasing hormone stimulation tests were added on later . \\n imaging included computed tomography ( ct ) , magnetic resonance imaging ( since the late 80 's ) and 68ga dota - toc / fdg pet - ct ( 2008).results : three hundred sixty - four patients ( 250 females , 114 males , age 6 months to 65 years , mean 28 years + 12 years ) were diagnosed to have cs during this period . \\n two hundred and ninety - three patients ( 80.5% ) were acth dependent ( cd 215 , ectopic acth syndrome 22 , occult acth source 56 ) while 71 ( 19.5% ) were acth independent ( adrenal carcinoma 36 , adenoma 30 , primary pigmented nodular adrenal disease 4 , aimah 1 ) . \\n pituitary macro adenoma was seen in 14% of the cd cases . \\n the most common presenting complaints were hypertension and diabetes mellitus . \\n a total of 63% patients complained of weight gain while 15% had lost weight . \\n myopathy , infections , skeletal fractures and psychiatric problems were the other common observations in our patients.conclusion:the clinical spectrum was broad . \\n cd was the most common cause for cs .\", 'text_length': 19461, '__index_level_0__': 44590}\n",
      "{'dataset': 'pubmed', 'split_data': 'test', 'task': 'summarization', 'instruction': 'Summarize the key findings of the given PubMed abstract into structured fields: Objective, Methods, Results, and Conclusion.', 'input': \"syndrome of inappropriate secretion of antidiuretic hormone ( siadh ) , also known as the syndrome of inappropriate antidiuresis ( siad ) , is one of the most common causes of hyponatremia1 ) . \\n impaired water excretion in the absence of renal insufficiency , glucocorticoid deficiency , hypothyroidism and decreased effective arterial blood volume are the hallmarks of this syndrome . although a growing number of drugs have been reported to produce siadh , most published reports concern vasopressin and its analogues such as thiazide and thiazide - like diuretics , chlorpropamide , carbamazepine , antipsychotics , antidepressants and nonsteroidal anti - inflammatory drugs . \\n old age seems a risk factor of siadh following the use of many of these drugs . \\n a combined use of these drugs , excessive fluid intake , and other underlying conditions which limit free water excretion will increase the risk3 ) . \\n sodium valproic acid ( vpa ) , known as a carboxylic acid , is being used for an anti - epileptic in idiopathic and symptomatic generalized epilepsies and for some symptomatic focal epilepsies as well as trigeminal neuralgia , migraine and bipolar disorders4 ) . \\n its mechanism is unknown ; however it is probably associated with the metabolism of the gaba neurotransmitter . the toxic effect it provokes \\n there are several vpa - related idiosyncrasies ; the most noteworthy are alopecia , bone marrow aplasia , immune - mediated hepatotoxicity and pancreatitis5 ) . here \\n we describe a patient with hyponatremia caused during the treatment with the antiepileptic drug , i.e. , sodium valproic acid ( vpa ) . \\n the clinical course indicated that vpa contributed to an siadh6 ) . to our knowledge , this is a rare case of example in the medical literature in english which shows an association between vpa and siadh . \\n he had suffered from generalized tonic clonic epilepsy that occurred after a craniectomy due to right epidural hematoma . \\n the patient was treated with sodium valproate in a dose of 900 mg / day for 9 months . \\n he had been removed a brain tumor 4 years before and he had craniectomy for an epidural hematoma 10 months ago . \\n he was admitted to our hospital with a reported seizure , dizziness , nausea and vomiting for the day . \\n his vital signs , physical and neurological examination on arrival were within normal limits except drowsy consciousness . \\n significant laboratory findings were : sodium of 111 ( 135 - 145 ) mmol / l , potassium of 2.6(3.5 - 5.0 ) mmol / l , chloride 66 ( 95 - 110 ) mmol / l and serum osmolarity of 245 ( 280 - 300 ) mosm / kg . \\n urine sodium and urine osmolarity were 58 mmol / l and 751 ( 50 - 1,200 ) mosm / kg , respectively . \\n ante meridiem cortisol level , thyroid stimulating hormone , and free thyroxine level were within normal limits . \\n the results of her rapid acth stimulation tests were also within normal ranges ( table 1 ) . \\n valproic acid level was revealed to be within therapeutic range ( 62.76 g / ml ; an optimum therapeutic range 50 to 100 g / ml ) . \\n the diagnosis of siadh was made based on hyponatremia , and low serum and high urine osmolality . \\n no other causes of hyponatremia , including diuretic therapy , tumors and respiratory system disease , were present . \\n the sodium valproate treatment was discontinued , and hypertonic saline was infused because of his symptomatic and profound hyponatremia . his serum sodium concentration increased to 131 \\n the symptoms resolved immediately after the correction of hyponatremia . during the next 48 hours , normal saline infusion was given , and serum sodium level was restored to 134 mmol / l . \\n the patient presented with hyponatremia , hypoosmolality , impaired excretion of water , which are all features of siadh7 ) and of generalized tonic clonic convulsions . \\n we consider these seizures to be caused by hyponatremia due to siadh ; because other symptoms differed from those of the initial convulsive episode and serum vpa level which was useful to assess the patient compliance was within the target therapeutic range . \\n other causes of hyponatremia such as volume depletion , hypothyroidism , renal or adrenal insufficiency and diuretic abuse , and vomiting were excluded . \\n the correction of the patient 's hyponatremia , combined with the discontinuation of sodium valproate , resulted in the resolution of his hyponatremia . \\n this is the first report in korea on such an adverse reaction to this medication . \\n use of vpa could lead to gastrointestinal discomfort , weight gain , hair loss , tremor and sedation , but these side effects seems rather uncommon , mild , and transient during vpa monotherapy8 ) . \\n potentially hazardous reactions such as hepatitis and pancreatitis have occurred in a few patients on vpa , generally in multidrug therapy8 ) . \\n ( consider including this in the introduction before noting side effects are quoted ) , we could find only a few patients who reported hyponatremia at different times after sodium valproate use9 - 13 ) . \\n the mechanism by which valproic acid could cause hyponatremia or siadh has not been fully elucidated . \\n most cases of drug - induced hyponatremia involve the elderly , and could be related to an altered antidiuretic hormone ( adh ) regulation or action of adh on kidneys12 ) . \\n we speculate that dopaminergic , serotonergic and noradrenergic systems may play a role in siadh due to sodium valproate14 ) . \\n another hypothesis is that valproic acid has a direct effect on tubular cell function , because a few cases of tubular dysfunction in association with valproic acid with a positive dechallenge have been described5 ) . \\n thus , we consider this episode of siadh to be due to a combination of factors including serotonergic stimulation of adh , reduced sensitivity of the hypothalamic osmoreceptors , and reduced renal ability to conserve salt and water . \\n hyponatremia accompanied by cns disorders has shown to increase delayed cerebral ischemia and mortality rates15 ) . \\n therefore , we suggest that patients who have high risk of hyponatremia are recommended to measure the baseline electrolyte levels before starting therapy with sodium valproate16 ) , and to monitor for electrolyte levels throughout the full course of treatment .\", 'output': \"we report a rare case of the concurrent manifestation of central diabetes insipidus ( cdi ) and type 2 diabetes mellitus ( dm ) . \\n a 56 year - old man was diagnosed as a type 2 dm on the basis of hyperglycemia with polyuria and polydipsia at a local clinic two months ago and started an oral hypoglycemic medication , but resulted in no symptomatic improvement at all . upon admission to the university hospital , \\n the patient 's initial fasting blood sugar level was 140 mg / dl , and he showed polydipsic and polyuric conditions more than 8 l urine / day . despite the hyperglycemia controlled with metformin and diet , his symptoms persisted . \\n further investigations including water deprivation test confirmed the coexisting cdi of unknown origin , and the patient 's symptoms including an intense thirst were markedly improved by desmopressin nasal spray ( 10 g / day ) . \\n the possibility of a common origin of cdi and type 2 dm is raised in a review of the few relevant adult cases in the literature .\", 'text_length': 7416, '__index_level_0__': 44727}\n",
      "Task: qa_objective_1, Sampled: 50\n",
      "{'dataset': 'medqa', 'split_data': 'test', 'task': 'qa_objective_1', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': 'A 65-year-old man presents to the emergency department with back pain. The patient states that he has gradually worsening back pain that seems to have worsened after moving furniture the other day. He also states that while he walks, he feels numbness and weakness in his legs. The only time the patient states his back pain is improved is when he is riding his bike or pushing a cart at the grocery store. The patient has a past medical history of osteoporosis, dyslipidemia, and diabetes. He drinks 3 alcoholic drinks every day and has a 44 pack-year smoking history. His temperature is 99.5¬∞F (37.5¬∞C), blood pressure is 157/108 mmHg, pulse is 90/min, respirations are 17/min, and oxygen saturation is 98% on room air. Physical exam is notable for a non-tender spine with normal mobility in all 4 directions. Radiography of the spine and basic labs are ordered. Which of the following is the most likely diagnosis? Please select one of the following: A) Compression fracture, B) Herniated nucleus pulposus, C) Musculoskeletal strain, D) Spinal stenosis.', 'output': 'D) Spinal stenosis', 'text_length': 1166, '__index_level_0__': 43203}\n",
      "{'dataset': 'medqa', 'split_data': 'test', 'task': 'qa_objective_1', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': 'A 58-year-old man presents to his primary care physician with a 3-week history of increasing pain in his legs and feet. Specifically, he says that he has been getting electric shock sensations that started in his feet, but have progressed up his leg. In addition, the pain is accompanied by numbness and tingling in his hands and feet bilaterally. His past medical history is significant for poorly controlled type 2 diabetes mellitus. Given these symptoms, his physician prescribes a new drug to help him cope with these symptoms. Which of the following is the mechanism of action for the medication that was most likely prescribed in this case? Please select one of the following: A) Increased duration of GABA channel opening, B) Increased frequency of GABA channel opening, C) Selective serotonin reuptake inhibitor, D) Serotonin norepinephrine reuptake inhibitor.', 'output': 'D) Serotonin norepinephrine reuptake inhibitor', 'text_length': 1006, '__index_level_0__': 43309}\n",
      "{'dataset': 'medqa', 'split_data': 'test', 'task': 'qa_objective_1', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': \"A 65-year-old woman comes to the physician for the evaluation of several episodes of urinary incontinence over the past several months. She reports that she was not able to get to the bathroom in time. During the past 6 months, her husband has noticed that she is starting to forget important appointments and family meetings. She has type 2 diabetes mellitus treated with metformin. The patient had smoked a pack of cigarettes daily for 45 years. Her vital signs are within normal limits. On mental status examination, she is confused and has short-term memory deficits. She walks slowly taking short, wide steps. Muscle strength is normal. Deep tendon reflexes are 2+ bilaterally. Which of the following is the most likely underlying cause of this patient's urinary incontinence? Please select one of the following: A) Detrusor-sphincter dyssynergia, B) Inability to suppress voiding, C) Loss of sphincter function, D) Impaired detrusor contractility.\", 'output': 'B) Inability to suppress voiding', 'text_length': 1077, '__index_level_0__': 43326}\n",
      "{'dataset': 'medqa', 'split_data': 'test', 'task': 'qa_objective_1', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': 'A 70-year-old male presents to his primary care physician for complaints of fatigue. The patient reports feeling tired during the day over the past 6 months. Past medical history is significant for moderately controlled type II diabetes. Family history is unremarkable. Thyroid stimulating hormone and testosterone levels are within normal limits. Complete blood cell count reveals the following: WBC 5.0, hemoglobin 9.0, hematocrit 27.0, and platelets 350. Mean corpuscular volume is 76. Iron studies demonstrate a ferritin of 15 ng/ml (nl 30-300). Of the following, which is the next best step? Please select one of the following: A) MRI abdomen, B) Blood transfusion, C) CT abdomen, D) Colonoscopy.', 'output': 'D) Colonoscopy', 'text_length': 807, '__index_level_0__': 43314}\n",
      "{'dataset': 'medqa', 'split_data': 'test', 'task': 'qa_objective_1', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': 'A 59-year-old man presents to the emergency department with right-sided weakness and an inability to speak for the past 2 hours. His wife says he was gardening in his backyard when he suddenly lost balance and fell down. The patient has a past medical history of hypertension, diabetes mellitus, and coronary artery disease. Two years ago, he was admitted to the coronary intensive care unit with an anterolateral myocardial infarction. He has not been compliant with his medications since he was discharged. On physical examination, his blood pressure is 110/70 mm Hg, pulse is 110/min and irregular, temperature is 36.6¬∞C (97.8¬∞F), and respiratory rate is 18/min. Strength is 2/5 in both his right upper and right lower extremities. His right calf is edematous with visible varicose veins. Which of the following is the best method to detect the source of this patient‚Äôs stroke? Please select one of the following: A) Duplex ultrasound of his right leg, B) Carotid duplex, C) Head CT without contrast, D) ECG.', 'output': 'D) ECG', 'text_length': 1109, '__index_level_0__': 43275}\n",
      "Task: re, Sampled: 50\n",
      "{'dataset': 'ddi', 'split_data': 'test', 'task': 're', 'instruction': \"Analyze the sentence with two drugs labeled as @DRUG_A$ and @DRUG_B$. Extract the interaction between @DRUG_A$ and @DRUG_B$ from the input sentence by selecting only one of the following options: 'DDI-effect', 'DDI-mechanism', 'DDI-advise', 'DDI-false', and 'DDI-int'. 'DDI-effect': Choose this when the interaction describes an effect or a pharmacodynamic mechanism. 'DDI-mechanism': Choose this for interactions explained by pharmacokinetic mechanisms. 'DDI-advise': Choose this when the sentence provides a recommendation or advice about the drug interaction. 'DDI-false': Choose this if there is no actual drug-drug interaction in the sentence. 'DDI-int': Choose this when a drug-drug interaction is mentioned without additional detail.\", 'input': 'Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG_A$, chloral hydrate, @DRUG_B$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.', 'output': 'DDI-false', 'text_length': 1592, '__index_level_0__': 43615}\n",
      "{'dataset': 'ddi', 'split_data': 'test', 'task': 're', 'instruction': \"Analyze the sentence with two drugs labeled as @DRUG_A$ and @DRUG_B$. Extract the interaction between @DRUG_A$ and @DRUG_B$ from the input sentence by selecting only one of the following options: 'DDI-effect', 'DDI-mechanism', 'DDI-advise', 'DDI-false', and 'DDI-int'. 'DDI-effect': Choose this when the interaction describes an effect or a pharmacodynamic mechanism. 'DDI-mechanism': Choose this for interactions explained by pharmacokinetic mechanisms. 'DDI-advise': Choose this when the sentence provides a recommendation or advice about the drug interaction. 'DDI-false': Choose this if there is no actual drug-drug interaction in the sentence. 'DDI-int': Choose this when a drug-drug interaction is mentioned without additional detail.\", 'input': 'Again, @DRUG_A$ neutralized the increase in glycemia after @DRUG_B$ overload both in diabetic and non-diabetic rats.', 'output': 'DDI-false', 'text_length': 865, '__index_level_0__': 43585}\n",
      "{'dataset': 'ddi', 'split_data': 'test', 'task': 're', 'instruction': \"Analyze the sentence with two drugs labeled as @DRUG_A$ and @DRUG_B$. Extract the interaction between @DRUG_A$ and @DRUG_B$ from the input sentence by selecting only one of the following options: 'DDI-effect', 'DDI-mechanism', 'DDI-advise', 'DDI-false', and 'DDI-int'. 'DDI-effect': Choose this when the interaction describes an effect or a pharmacodynamic mechanism. 'DDI-mechanism': Choose this for interactions explained by pharmacokinetic mechanisms. 'DDI-advise': Choose this when the sentence provides a recommendation or advice about the drug interaction. 'DDI-false': Choose this if there is no actual drug-drug interaction in the sentence. 'DDI-int': Choose this when a drug-drug interaction is mentioned without additional detail.\", 'input': 'Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG_A$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG_B$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.', 'output': 'DDI-false', 'text_length': 1575, '__index_level_0__': 43641}\n",
      "{'dataset': 'ddi', 'split_data': 'test', 'task': 're', 'instruction': \"Analyze the sentence with two drugs labeled as @DRUG_A$ and @DRUG_B$. Extract the interaction between @DRUG_A$ and @DRUG_B$ from the input sentence by selecting only one of the following options: 'DDI-effect', 'DDI-mechanism', 'DDI-advise', 'DDI-false', and 'DDI-int'. 'DDI-effect': Choose this when the interaction describes an effect or a pharmacodynamic mechanism. 'DDI-mechanism': Choose this for interactions explained by pharmacokinetic mechanisms. 'DDI-advise': Choose this when the sentence provides a recommendation or advice about the drug interaction. 'DDI-false': Choose this if there is no actual drug-drug interaction in the sentence. 'DDI-int': Choose this when a drug-drug interaction is mentioned without additional detail.\", 'input': 'Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG_A$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG_B$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.', 'output': 'DDI-false', 'text_length': 1594, '__index_level_0__': 43666}\n",
      "{'dataset': 'ddi', 'split_data': 'test', 'task': 're', 'instruction': \"Analyze the sentence with two drugs labeled as @DRUG_A$ and @DRUG_B$. Extract the interaction between @DRUG_A$ and @DRUG_B$ from the input sentence by selecting only one of the following options: 'DDI-effect', 'DDI-mechanism', 'DDI-advise', 'DDI-false', and 'DDI-int'. 'DDI-effect': Choose this when the interaction describes an effect or a pharmacodynamic mechanism. 'DDI-mechanism': Choose this for interactions explained by pharmacokinetic mechanisms. 'DDI-advise': Choose this when the sentence provides a recommendation or advice about the drug interaction. 'DDI-false': Choose this if there is no actual drug-drug interaction in the sentence. 'DDI-int': Choose this when a drug-drug interaction is mentioned without additional detail.\", 'input': 'Oral @DRUG_A$: Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for @DRUG_B$ or oral hypoglycemic agents.', 'output': 'DDI-false', 'text_length': 937, '__index_level_0__': 43595}\n",
      "Task: qa_objective_2, Sampled: 50\n",
      "{'dataset': 'medmcqa', 'split_data': 'test', 'task': 'qa_objective_2', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': 'A 70-year-old man with a history of diabetes presents with severe pain in his right ear. The patient was diagnosed with external otitis. Further tests suggested that the patient suffered bone and nerve damage. Clinical laboratory analysis showed that the isolated microorganism produced a distinct blue pigment as well as an ADP-ribosylation toxin. What is the most likely causative agent? Please select one of the following: A) Staphylococcus epidermidis, B) Staphylococcus aureus, C) Pseudomonas aeruginosa, D) Enterococcus faecalis.', 'output': 'C) Pseudomonas aeruginosa', 'text_length': 652, '__index_level_0__': 43412}\n",
      "{'dataset': 'medmcqa', 'split_data': 'test', 'task': 'qa_objective_2', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': 'A 58-year-old diabetic came with chest pain, ECG shows ST elevation in II, III and AVF leads. Inference would be Please select one of the following: A) Inferior wall MI, B) Anterior wall MI, C) Lateral wall MI, D) Posterior wall MI.', 'output': 'A) Inferior wall MI', 'text_length': 343, '__index_level_0__': 43371}\n",
      "{'dataset': 'medmcqa', 'split_data': 'test', 'task': 'qa_objective_2', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': 'Site of diabetic foot ulcera) Medial Malleolusb) Lateral malleolusc) Heeld) Head of metatarsale) Head of toes Please select one of the following: A) cd, B) bc, C) bd, D) ac.', 'output': 'A) cd', 'text_length': 270, '__index_level_0__': 43464}\n",
      "{'dataset': 'medmcqa', 'split_data': 'test', 'task': 'qa_objective_2', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': 'Insulin resistance state causing hyperglycemia is present in ? Please select one of the following: A) Acromegaly, B) Osteomalacia, C) Liver cell carcinoma, D) Somatostatinoma.', 'output': 'A) Acromegaly', 'text_length': 280, '__index_level_0__': 43329}\n",
      "{'dataset': 'medmcqa', 'split_data': 'test', 'task': 'qa_objective_2', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': 'A diabetic female on INH and Rifampicin for TB developed DVT. She was started on Warfarin, PT is not raised, and next step should be: Please select one of the following: A) Increase the dose of Warfarin, B) Replace Warfarin with Acenocoumarol, C) Switch Ethambutol for Rifampicin, D) Use LMW heparin.', 'output': 'D) Use LMW heparin', 'text_length': 410, '__index_level_0__': 43335}\n"
     ]
    }
   ],
   "source": [
    "import random\n",
    "import numpy as np\n",
    "import pandas as pd  # pandas ÏûÑÌè¨Ìä∏ Ï∂îÍ∞Ä\n",
    "from datasets import load_dataset, Dataset, DatasetDict\n",
    "\n",
    "# ÏãúÎìú Í∞í ÏÑ§Ï†ï\n",
    "SEED = 42\n",
    "\n",
    "# PythonÏùò random Î™®Îìà ÏãúÎìú Í≥†Ï†ï\n",
    "random.seed(SEED)\n",
    "\n",
    "# NumPy ÏãúÎìú Í≥†Ï†ï\n",
    "np.random.seed(SEED)\n",
    "\n",
    "# 1. Îç∞Ïù¥ÌÑ∞ÏÖã Î°úÎìú\n",
    "dataset_name = \"passionMan/diabetes_v11\"\n",
    "train_dataset = load_dataset(dataset_name, split=\"train\")\n",
    "test_dataset = load_dataset(dataset_name, split=\"test\")\n",
    "\n",
    "# 2. Ï§ëÎ≥µ ÌôïÏù∏ÏùÑ ÏúÑÌïú train Îç∞Ïù¥ÌÑ∞Ïùò (input, output) ÏÑ∏Ìä∏ ÏÉùÏÑ±\n",
    "train_pairs = set((row[\"input\"], row[\"output\"]) for row in train_dataset)\n",
    "\n",
    "# 3. Í∞Å taskÎ≥Ñ ÏÉòÌîå Í∞úÏàò ÏÑ§Ï†ï\n",
    "task_sample_limits = {\n",
    "    'qa_objective_1': 50,\n",
    "    'qa_objective_2': 50,\n",
    "    'qa_objective_3': 50,\n",
    "    'nli': 50,\n",
    "    're': 50,\n",
    "    'ie': 50,\n",
    "    \"summarization\": 50,\n",
    "    \"generation\": 50,\n",
    "    'alternative_diet': 50,\n",
    "    'daily_diets': 50,\n",
    "}\n",
    "default_sample_limit = 50  # ÎÇòÎ®∏ÏßÄ taskÎäî 100Í∞úÏî© ÏÉòÌîåÎßÅ\n",
    "\n",
    "# 4. taskÎ≥Ñ ÏÉòÌîåÎßÅ Îç∞Ïù¥ÌÑ∞ Ï¥àÍ∏∞Ìôî\n",
    "task_sampled_data = {}\n",
    "# task_countsÎ•º task_sample_limitsÎ°ú Ï¥àÍ∏∞Ìôî\n",
    "task_counts = {task: 0 for task in task_sample_limits}\n",
    "\n",
    "# 5. TaskÎ≥Ñ ÏÉòÌîåÎßÅ\n",
    "# ÌÖåÏä§Ìä∏ Îç∞Ïù¥ÌÑ∞ÏÖãÏùÑ ÏÖîÌîåÎßÅÌïòÏó¨ ÎûúÎç§ ÏÉòÌîåÎßÅ Î≥¥Ïû•\n",
    "test_dataset = test_dataset.shuffle(seed=SEED)\n",
    "\n",
    "for row in test_dataset:\n",
    "    task = row[\"task\"]\n",
    "    dataset_value = row.get(\"dataset\")  # dataset Ïª¨Îüº Í∞í ÌôïÏù∏\n",
    "    input_output_pair = (row[\"input\"], row[\"output\"])\n",
    "\n",
    "    # qa_objective ÏÑ∏Î∂ÑÌôî\n",
    "    if task == \"qa_objective\":\n",
    "        if dataset_value == \"medqa\":\n",
    "            task = \"qa_objective_1\"  # medqaÎ°ú ÏÑ∏Î∂ÑÌôî\n",
    "        elif dataset_value == \"medmcqa\":\n",
    "            task = \"qa_objective_2\"  # medmcqaÎ°ú ÏÑ∏Î∂ÑÌôî\n",
    "        else:\n",
    "            continue  # medqa, medmcqaÍ∞Ä ÏïÑÎãàÎ©¥ Í±¥ÎÑàÎõ∞Í∏∞\n",
    "\n",
    "    # Ìï¥Îãπ taskÏùò ÏÉòÌîåÎßÅ Ï†úÌïú ÌôïÏù∏\n",
    "    sample_limit = task_sample_limits.get(task, default_sample_limit)\n",
    "\n",
    "    # ÏÉòÌîåÎßÅ Ï°∞Í±¥ ÌôïÏù∏\n",
    "    if task_counts.get(task, 0) < sample_limit and input_output_pair not in train_pairs:\n",
    "        if task not in task_sampled_data:\n",
    "            task_sampled_data[task] = []\n",
    "        task_sampled_data[task].append(row)\n",
    "        task_counts[task] += 1\n",
    "\n",
    "    # Î™®Îì† taskÏùò ÏÉòÌîåÎßÅÏù¥ ÏôÑÎ£åÎêòÎ©¥ Ï¢ÖÎ£å\n",
    "    if all(task_counts.get(task, 0) >= task_sample_limits.get(task, default_sample_limit) for task in task_sample_limits):\n",
    "        break\n",
    "\n",
    "# 6. Í≤∞Í≥º Ï∂úÎ†• Î∞è ÌôïÏù∏\n",
    "for task, samples in task_sampled_data.items():\n",
    "    print(f\"Task: {task}, Sampled: {len(samples)}\")\n",
    "    for sample in samples[:5]:  # Ï≤´ 5Í∞ú ÏÉòÌîåÎßå Ï∂úÎ†•\n",
    "        print(sample)\n",
    "\n",
    "# 7. ÌïÑÏöî Ïãú ÏÉòÌîåÎßÅÎêú Îç∞Ïù¥ÌÑ∞ Ï†ÄÏû•\n",
    "# pandasÎ•º ÏÇ¨Ïö©ÌïòÏó¨ Î¶¨Ïä§Ìä∏Ïùò ÎîïÏÖîÎÑàÎ¶¨Î•º Îç∞Ïù¥ÌÑ∞ÌîÑÎ†àÏûÑÏúºÎ°ú Î≥ÄÌôò ÌõÑ DatasetÏúºÎ°ú Î≥ÄÌôò\n",
    "sampled_dataset = DatasetDict({\n",
    "    task: Dataset.from_pandas(pd.DataFrame(samples)) for task, samples in task_sampled_data.items()\n",
    "})\n",
    "\n",
    "# Ï†ÄÏû• (ÌïÑÏöîÏãú Ï£ºÏÑù Ï†úÍ±∞)\n",
    "# sampled_dataset.save_to_disk(\"sampled_test_dataset\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Task: qa_objective_2, Sampled: 50\n",
      "{'dataset': 'medmcqa', 'split_data': 'test', 'task': 'qa_objective_2', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': 'Dopamine agonist used in diabetes Please select one of the following: A) Metformin, B) Bromocriptine, C) Cabergoline, D) Vanadium salts.', 'output': 'B) Bromocriptine', 'text_length': 244, '__index_level_0__': 36490}\n",
      "{'dataset': 'medmcqa', 'split_data': 'test', 'task': 'qa_objective_2', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': 'A 58-year-old diabetic came with chest pain, ECG shows ST elevation in II, III and AVF leads. Inference would be Please select one of the following: A) Inferior wall MI, B) Anterior wall MI, C) Lateral wall MI, D) Posterior wall MI.', 'output': 'A) Inferior wall MI', 'text_length': 343, '__index_level_0__': 36501}\n",
      "{'dataset': 'medmcqa', 'split_data': 'test', 'task': 'qa_objective_2', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': 'A diabetic female on INH and Rifampicin for TB developed DVT. She was started on Warfarin, PT is not raised, and next step should be: Please select one of the following: A) Increase the dose of Warfarin, B) Replace Warfarin with Acenocoumarol, C) Switch Ethambutol for Rifampicin, D) Use LMW heparin.', 'output': 'D) Use LMW heparin', 'text_length': 410, '__index_level_0__': 36465}\n",
      "{'dataset': 'medmcqa', 'split_data': 'test', 'task': 'qa_objective_2', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': 'Which is the initial Imaging modality of choice for Insulinoma? Please select one of the following: A) USG, B) CT abdomen, C) Somatostatin Receptor Scan (SRS), D) E.U.S.', 'output': 'D) E.U.S', 'text_length': 269, '__index_level_0__': 36517}\n",
      "{'dataset': 'medmcqa', 'split_data': 'test', 'task': 'qa_objective_2', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': 'Arrange the insulin in order of their duration of action (shoest first and longest last) a. NPH b. Glargine c. Detemir d. Degludec Please select one of the following: A) d<a<c<b, B) a<c<b<d, C) b<a<d<c, D) c<d<a<b.', 'output': 'B) a<c<b<d', 'text_length': 316, '__index_level_0__': 36472}\n",
      "Task: re, Sampled: 50\n",
      "{'dataset': 'ddi', 'split_data': 'test', 'task': 're', 'instruction': \"Analyze the sentence with two drugs labeled as @DRUG_A$ and @DRUG_B$. Extract the interaction between @DRUG_A$ and @DRUG_B$ from the input sentence by selecting only one of the following options: 'DDI-effect', 'DDI-mechanism', 'DDI-advise', 'DDI-false', and 'DDI-int'. 'DDI-effect': Choose this when the interaction describes an effect or a pharmacodynamic mechanism. 'DDI-mechanism': Choose this for interactions explained by pharmacokinetic mechanisms. 'DDI-advise': Choose this when the sentence provides a recommendation or advice about the drug interaction. 'DDI-false': Choose this if there is no actual drug-drug interaction in the sentence. 'DDI-int': Choose this when a drug-drug interaction is mentioned without additional detail.\", 'input': 'Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG_A$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG_B$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.', 'output': 'DDI-false', 'text_length': 1575, '__index_level_0__': 36771}\n",
      "{'dataset': 'ddi', 'split_data': 'test', 'task': 're', 'instruction': \"Analyze the sentence with two drugs labeled as @DRUG_A$ and @DRUG_B$. Extract the interaction between @DRUG_A$ and @DRUG_B$ from the input sentence by selecting only one of the following options: 'DDI-effect', 'DDI-mechanism', 'DDI-advise', 'DDI-false', and 'DDI-int'. 'DDI-effect': Choose this when the interaction describes an effect or a pharmacodynamic mechanism. 'DDI-mechanism': Choose this for interactions explained by pharmacokinetic mechanisms. 'DDI-advise': Choose this when the sentence provides a recommendation or advice about the drug interaction. 'DDI-false': Choose this if there is no actual drug-drug interaction in the sentence. 'DDI-int': Choose this when a drug-drug interaction is mentioned without additional detail.\", 'input': 'Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG_A$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG_B$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.', 'output': 'DDI-false', 'text_length': 1594, '__index_level_0__': 36809}\n",
      "{'dataset': 'ddi', 'split_data': 'test', 'task': 're', 'instruction': \"Analyze the sentence with two drugs labeled as @DRUG_A$ and @DRUG_B$. Extract the interaction between @DRUG_A$ and @DRUG_B$ from the input sentence by selecting only one of the following options: 'DDI-effect', 'DDI-mechanism', 'DDI-advise', 'DDI-false', and 'DDI-int'. 'DDI-effect': Choose this when the interaction describes an effect or a pharmacodynamic mechanism. 'DDI-mechanism': Choose this for interactions explained by pharmacokinetic mechanisms. 'DDI-advise': Choose this when the sentence provides a recommendation or advice about the drug interaction. 'DDI-false': Choose this if there is no actual drug-drug interaction in the sentence. 'DDI-int': Choose this when a drug-drug interaction is mentioned without additional detail.\", 'input': 'Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG_A$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG_B$.', 'output': 'DDI-false', 'text_length': 1585, '__index_level_0__': 36811}\n",
      "{'dataset': 'ddi', 'split_data': 'test', 'task': 're', 'instruction': \"Analyze the sentence with two drugs labeled as @DRUG_A$ and @DRUG_B$. Extract the interaction between @DRUG_A$ and @DRUG_B$ from the input sentence by selecting only one of the following options: 'DDI-effect', 'DDI-mechanism', 'DDI-advise', 'DDI-false', and 'DDI-int'. 'DDI-effect': Choose this when the interaction describes an effect or a pharmacodynamic mechanism. 'DDI-mechanism': Choose this for interactions explained by pharmacokinetic mechanisms. 'DDI-advise': Choose this when the sentence provides a recommendation or advice about the drug interaction. 'DDI-false': Choose this if there is no actual drug-drug interaction in the sentence. 'DDI-int': Choose this when a drug-drug interaction is mentioned without additional detail.\", 'input': 'Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG_A$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG_B$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.', 'output': 'DDI-false', 'text_length': 1594, '__index_level_0__': 36796}\n",
      "{'dataset': 'ddi', 'split_data': 'test', 'task': 're', 'instruction': \"Analyze the sentence with two drugs labeled as @DRUG_A$ and @DRUG_B$. Extract the interaction between @DRUG_A$ and @DRUG_B$ from the input sentence by selecting only one of the following options: 'DDI-effect', 'DDI-mechanism', 'DDI-advise', 'DDI-false', and 'DDI-int'. 'DDI-effect': Choose this when the interaction describes an effect or a pharmacodynamic mechanism. 'DDI-mechanism': Choose this for interactions explained by pharmacokinetic mechanisms. 'DDI-advise': Choose this when the sentence provides a recommendation or advice about the drug interaction. 'DDI-false': Choose this if there is no actual drug-drug interaction in the sentence. 'DDI-int': Choose this when a drug-drug interaction is mentioned without additional detail.\", 'input': 'Oral @DRUG_A$: Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for @DRUG_B$ or oral hypoglycemic agents.', 'output': 'DDI-false', 'text_length': 937, '__index_level_0__': 36725}\n",
      "Task: qa_objective_1, Sampled: 50\n",
      "{'dataset': 'medqa', 'split_data': 'test', 'task': 'qa_objective_1', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': 'A 43-year-old type 1 diabetic woman who is poorly compliant with her diabetes medications presented to the emergency department with hemorrhage from her nose. On exam, you observe the findings shown in figure A. What is the most likely explanation for these findings? Please select one of the following: A) Cryptococcal infection, B) Candida infection, C) Rhizopus infection, D) Gram negative bacterial infection.', 'output': 'C) Rhizopus infection', 'text_length': 526, '__index_level_0__': 36399}\n",
      "{'dataset': 'medqa', 'split_data': 'test', 'task': 'qa_objective_1', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': 'A 27-year-old man presents to the emergency department with his family because of abdominal pain, excessive urination, and drowsiness since the day before. He has had type 1 diabetes mellitus for 2 years. He ran out of insulin 2 days ago. The vital signs at admission include: temperature 36.8¬∞C (98.2¬∞F), blood pressure 102/69 mm Hg, and pulse 121/min. On physical examination, he is lethargic and his breathing is rapid and deep. There is a mild generalized abdominal tenderness without rebound tenderness or guarding. His serum glucose is 480 mg/dL. Arterial blood gas of this patient will most likely show which of the following? Please select one of the following: A) ‚Üë pH, ‚Üë bicarbonate, and normal pCO2, B) ‚Üì pH, normal bicarbonate and ‚Üë pCO2, C) ‚Üì pH, ‚Üì bicarbonate and ‚Üë anion gap, D) ‚Üì pH, ‚Üì bicarbonate and normal anion gap.', 'output': 'C) ‚Üì pH, ‚Üì bicarbonate and ‚Üë anion gap', 'text_length': 965, '__index_level_0__': 36372}\n",
      "{'dataset': 'medqa', 'split_data': 'test', 'task': 'qa_objective_1', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': 'A newborn male is evaluated one minute after birth. He was born at 38 weeks gestation to a 28-year-old gravida 3 via vaginal delivery. The patient‚Äôs mother received sporadic prenatal care, and the pregnancy was complicated by gestational diabetes. The amniotic fluid was clear. The patient‚Äôs pulse is 70/min, and his breathing is irregular with a slow, weak cry. He whimpers in response to a soft pinch on the thigh, and he has moderate muscle tone with some flexion of his extremities. His body is pink and his extremities are blue. The patient is dried with a warm towel and then placed on his back on a flat warmer bed. His mouth and nose are suctioned with a bulb syringe.\\n\\nWhich of the following is the best next step in management? Please select one of the following: A) Chest compressions and bag-mask ventilation, B) Positive pressure ventilation and reassessment of Apgar score at 5 minutes, C) Supplemental oxygen via nasal cannula and reassessment of Apgar score at 5 minutes, D) Endotracheal intubation and mechanical ventilation.', 'output': 'B) Positive pressure ventilation and reassessment of Apgar score at 5 minutes', 'text_length': 1211, '__index_level_0__': 36325}\n",
      "{'dataset': 'medqa', 'split_data': 'test', 'task': 'qa_objective_1', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': 'A 65-year-old man presents to the emergency department with back pain. The patient states that he has gradually worsening back pain that seems to have worsened after moving furniture the other day. He also states that while he walks, he feels numbness and weakness in his legs. The only time the patient states his back pain is improved is when he is riding his bike or pushing a cart at the grocery store. The patient has a past medical history of osteoporosis, dyslipidemia, and diabetes. He drinks 3 alcoholic drinks every day and has a 44 pack-year smoking history. His temperature is 99.5¬∞F (37.5¬∞C), blood pressure is 157/108 mmHg, pulse is 90/min, respirations are 17/min, and oxygen saturation is 98% on room air. Physical exam is notable for a non-tender spine with normal mobility in all 4 directions. Radiography of the spine and basic labs are ordered. Which of the following is the most likely diagnosis? Please select one of the following: A) Compression fracture, B) Herniated nucleus pulposus, C) Musculoskeletal strain, D) Spinal stenosis.', 'output': 'D) Spinal stenosis', 'text_length': 1166, '__index_level_0__': 36333}\n",
      "{'dataset': 'medqa', 'split_data': 'test', 'task': 'qa_objective_1', 'instruction': 'Select the most appropriate answer for the given medical question from the provided options.', 'input': 'A 45-year-old man comes to the physician for his routine health maintenance examination. He was diagnosed with diabetes mellitus 4 years ago. His medical history is otherwise unremarkable. He takes no medications other than daily metformin. He has consumed a can of beer every night for the past 10 years. His blood pressure is 145/90 mm Hg. His body mass index is 31 kg/m2. Physical examination shows no abnormalities. Laboratory studies show:\\nPartial thromboplastin time (activated) 30 seconds (N=25-40 seconds)\\nProthrombin time 13 seconds (N=11-15 seconds)\\nInternational normalized ratio 1.2\\nSerum albumin 4 g/dL\\nBilirubin, total 0.9 mg/dL\\nDirect 0.2 mg/dL\\nAlkaline phosphatase 45 U/L\\nAspartate aminotransferase (AST, GOT) 43 U/L\\nAlanine aminotransferase (ALT, GPT) 56 U/L\\nŒ≥-Glutamyltransferase (GGT) 43 U/L (N=5-50 U/L)\\nHepatitis A antibody Negative\\nHepatitis B surface antigen Negative\\nHepatitis C antibody Negative\\nLiver biopsy shows excessive intracellular fat accumulation, hepatocyte ballooning, and perivenular infiltration of lymphocytes and neutrophils without significant fibrosis. Which of the following best describes these findings? Please select one of the following: A) Alcoholic fatty liver, B) Alcoholic hepatitis, C) Nonalcoholic-fatty-liver-disease-induced cirrhosis, D) Nonalcoholic steatohepatitis.', 'output': 'D) Nonalcoholic steatohepatitis', 'text_length': 1445, '__index_level_0__': 36452}\n",
      "Task: nli, Sampled: 50\n",
      "{'dataset': 'bionli', 'split_data': 'test', 'task': 'nli', 'instruction': 'Please classify the relationship between the given premise and hypothesis into one of the following labels: entailment, contradiction, or neutral. return only the label.', 'input': '[PRE] Hereditary hemochromatosis (HH) is mostly caused by mutations in the iron-regulatory gene HFE. The disease is associated with iron overload, resulting in liver cirrhosis/cancer, cardiomegaly, kidney dysfunction, diabetes, and arthritis. Fe2+-induced oxidative damage is suspected in the etiology of these symptoms. Here we examined, using Hfe-/- mice, whether disruption of uric acid (UA) homeostasis plays any role in HH-associated arthritis. We detected elevated levels of UA in serum and intestine in Hfe-/- mice compared with controls. Though the expression of xanthine oxidase, which generates UA, was not different in liver and intestine between wild type and Hfe-/- mice, the enzymatic activity was higher in Hfe-/- mice. We then examined various transporters involved in UA absorption/excretion. Glut9 expression did not change; however, there was an increase in Mrp4 and a decrease in Abcg2 in Hfe-/- mice. As ABCG2 mediates intestinal excretion of UA and mutations in ABCG2 cause hyperuricemia, we examined the potential connection between iron and ABCG2. We found p53-responsive elements in hABCG2 promoter and confirmed with chromatin immunoprecipitation that p53 binds to this promoter. p53 protein was reduced in Hfe-/- mouse intestine. p53 is a heme-binding protein and p53-heme complex is subjected to proteasomal degradation.', 'output': 'entailment', 'text_length': 1527, '__index_level_0__': 38127}\n",
      "{'dataset': 'bionli', 'split_data': 'test', 'task': 'nli', 'instruction': 'Please classify the relationship between the given premise and hypothesis into one of the following labels: entailment, contradiction, or neutral. return only the label.', 'input': '[PRE] We examined the potential function of Src in human pancreatic carcinoma. Overexpression of kinase-activated SrcY527F resulted in a significant increase of insulin-like growth factor I (IGF-I)-dependent cell proliferation in the cell line PANC-1. Western blotting and competition binding studies demonstrated 2.3 +/- 0.2-fold increase in IGF-I receptor expression and 2.8 +/- 0.4-fold increase in IGF-I-specific binding sites/cell. SrcY527F transfection alone did not change receptor affinity or basal receptor tyrosine phosphorylation, whereas IGF-I-stimulated receptor phosphorylation was increased by 2.1 +/- 0.5-fold. IGF-I mRNA expression and protein secretion did not change to exclude autocrine activation.', 'output': 'entailment', 'text_length': 897, '__index_level_0__': 38115}\n",
      "{'dataset': 'bionli', 'split_data': 'test', 'task': 'nli', 'instruction': 'Please classify the relationship between the given premise and hypothesis into one of the following labels: entailment, contradiction, or neutral. return only the label.', 'input': '[PRE] Both rosiglitazone and metformin increase hepatic insulin sensitivity, but their mechanism of action has not been compared in humans. The objective of this study was to compare the effects of rosiglitazone and metformin treatment on liver fat content, hepatic insulin sensitivity, insulin clearance, and gene expression in adipose tissue and serum adiponectin concentrations in type 2 diabetes. A total of 20 drug-naive patients with type 2 diabetes (age 48 +/- 3 years, fasting plasma glucose 152 +/- 9 mg/dl, BMI 30.6 +/- 0.8 kg/m2) were treated in a double-blind randomized fashion with either 8 mg rosiglitazone or 2 g metformin for 16 weeks. Both drugs similarly decreased HbA1c, insulin, and free fatty acid concentrations. Body weight decreased in the metformin (84 +/- 4 vs. 82 +/- 4 kg, P < 0.05) but not the rosiglitazone group. Liver fat (proton spectroscopy) was decreased with rosiglitazone by 51% (15 +/- 3 vs. 7 +/- 1%, 0 vs. 16 weeks, P = 0.003) but not by metformin (13 +/- 3 to 14 +/- 3%, NS). Rosiglitazone (16 +/- 2 vs. 20 +/- 1 ml.kg(-1).min(-1), P = 0.02) but not metformin increased insulin clearance by 20%. Hepatic insulin sensitivity in the basal state increased similarly in both groups. Insulin-stimulated glucose uptake increased significantly with rosiglitazone but not with metformin. Serum adiponectin concentrations increased by 123% with rosiglitazone but remained unchanged during metformin treatment. The decrease of serum adiponectin concentrations correlated with the decrease in liver fat (r = -0.74, P < 0.001). Rosiglitazone but not metformin significantly increased expression of peroxisome proliferator-activated receptor-gamma, adiponectin, and lipoprotein lipase in adipose tissue.', 'output': 'entailment', 'text_length': 1911, '__index_level_0__': 38130}\n",
      "{'dataset': 'bionli', 'split_data': 'test', 'task': 'nli', 'instruction': 'Please classify the relationship between the given premise and hypothesis into one of the following labels: entailment, contradiction, or neutral. return only the label.', 'input': '[PRE] We studied the effects of fatty acid oxidation on insulin secretion of db/db mice and underlying molecular mechanisms of these effects. At 2-3 months of age, db/db mice were markedly obese, hyperglycemic, and hyperinsulinemic. Serum free fatty acid (FFA) levels were increased in 2-month-old (1.5 +/- 0.1 vs. 1.1 +/- 0.1 mmol/l, P < 0.05) and 3-month-old (1.9 +/- 0.1 vs. 1.2 +/- 0.1 mmol/l, P < 0.01) mice compared with the age and sex-matched db/+ mice serving as controls. Glucose-induced insulin release from db/db islets was markedly decreased compared with that from db/+ islets and was specifically ameliorated (by 54% in 2-month-old and 38% in 3-month-old mice) by exposure to a carnitine palmitoyltransferase I inhibitor, etomoxir (1 micromol/l). Etomoxir failed to affect the insulin response to alpha-ketoisocaproate. The effect of etomoxir on glucose-induced insulin release was lost after culturing db/db islets in RPMI medium containing 22 mmol/l glucose but no fatty acid. Culture of db/+ islets with 0.125 mmol/l palmitate led to a decrease in glucose-induced insulin secretion, which was partially reversible by etomoxir. Both islet glucose oxidation and the ratio of glucose oxidation to utilization were decreased in db/db islets. Etomoxir significantly enhanced glucose oxidation by 60% and also the ratio of oxidation to glucose utilization (from 27 +/- 2.5 to 37 +/-3.0%, P < 0.05). Pyruvate dehydrogenase (PDH) activity was decreased in islets of db/db mice (75 +/-4.2 vs. 91 +/- 2.9 nU/ng DNA, P < 0.01), whereas PDH kinase activity was increased (rate of PDH inactivation -0.25 +/- 0.02 vs. - 0.11 +/- 0.02/min, P < 0.0 1). These abnormalities were partly but not wholly reversed by a 2-h preexposure to etomoxir.', 'output': 'contradiction', 'text_length': 1926, '__index_level_0__': 38056}\n",
      "{'dataset': 'bionli', 'split_data': 'test', 'task': 'nli', 'instruction': 'Please classify the relationship between the given premise and hypothesis into one of the following labels: entailment, contradiction, or neutral. return only the label.', 'input': '[PRE] Diabetes is characterized by progressive beta cell dysfunction and loss due in part to oxidative stress that occurs from gluco/lipotoxicity. Treatments that directly protect beta cell function and survival in the diabetic milieu are of particular interest. A growing body of evidence suggests that osteocalcin, an abundant non-collagenous protein of bone, supports beta cell function and proliferation. Based on previous gene expression data by microarray, we hypothesized that osteocalcin protects beta cells from glucose-induced oxidative stress. To test our hypothesis we cultured isolated rat islets and INS-1E cells in the presence of normal, high, or high glucose\\xa0¬±\\xa0osteocalcin for up to 72\\xa0h. Oxidative stress and viability/mitochondrial function were measured by H2O2 assay and Alamar Blue assay, respectively. Caspase 3/7 activity was also measured as a marker of apoptosis. A functional test, glucose stimulated insulin release, was conducted and expression of genes/protein was measured by qRT-PCR/western blot/ELISA. Osteocalcin treatment significantly reduced high glucose-induced H2O2 levels while maintaining viability/mitochondrial function. Osteocalcin also significantly improved glucose stimulated insulin secretion and insulin content in rat islets after 48\\xa0h of high glucose exposure compared to untreated islets. As expected sustained high glucose down-regulated gene/protein expression of INS1 and BCL2 while increasing TXNIP expression. Interestingly, osteocalcin treatment reversed the effects of high glucose on gene/protein expression.', 'output': 'contradiction', 'text_length': 1750, '__index_level_0__': 38057}\n",
      "Task: qa_objective_3, Sampled: 50\n",
      "{'dataset': 'pubmedqa', 'split_data': 'test', 'task': 'qa_objective_3', 'instruction': 'Choose the correct anser (Yes, No, or Maybe) for the given question based on the proviced context.', 'input': 'Question: Is insulin sensitization by voluntary exercise in aging rats mediated through hepatic insulin sensitizing substance ( HISS )? Context: Food in the upper gastrointestinal tract potentiates the glucose uptake response to insulin. Meal-induced insulin sensitization (MIS) occurs as a result of insulin-mediated release of hepatic insulin sensitizing substance (HISS) that increases glucose uptake in peripheral tissues. HISS release decreases with age, and exercise causes metabolic improvements in aging, therefore it is important to analyze the effect of exercise on age-associated decline in HISS-action. The aim of this study is to test the hypothesis that improved insulin sensitivity, by voluntary running-wheel exercise in aging rats, is attained by preserving the HISS response. We also investigate the possible association of exercise-mediated beneficial changes in metabolic conditions and body composition with improved HISS-action. We measured insulin- and HISS-sensitivity in 9, 14 and 21-week old rats with/without exercise. Metabolic markers were also determined in age-matched control and exercised rats. Exercise significantly improved HISS-dependent glucose uptake in all age groups. The direct action of insulin was minimally altered by age or exercise. Body composition and metabolic conditions were beneficially changed with exercise-induced improvements in the HISS response.', 'output': 'yes', 'text_length': 1505, '__index_level_0__': 37891}\n",
      "{'dataset': 'pubmedqa', 'split_data': 'test', 'task': 'qa_objective_3', 'instruction': 'Choose the correct anser (Yes, No, or Maybe) for the given question based on the proviced context.', 'input': 'Question: Do diabetic patients with prior specialist care have better glycaemic control than those with prior primary care? Context: To compare glycaemic control, as reflected in the A1c level, of diabetic patients with primary care vs. with specialist care. The study used administrative data from eastern Ontario, Canada, and a database containing the results of all A1c tests from this region between 1 September 1999 and 1 September 2000. To avoid referral bias, diabetic patients with an index specialist visit were selected and separated into those with exclusively primary care previously (n = 974) and those with prior specialist care (n = 3533). We compared A1c levels measured within 30 days of the index visit and hence attributable to the prior care. To control for confounding between the groups, both multiple linear regression and propensity score-based matching were used. After controlling for confounders, patients with prior specialist care had significantly lower A1c levels (P < 0.0001). Other predictors of lower A1c included older age, shorter diabetes duration, rural residence and higher neighbourhood income. In propensity score-matched cohorts, the A1c level was 8.3 +/- 2.0% with prior primary care vs. 7.9 +/- 1.6% with prior specialist care (P < 0.0001).', 'output': 'yes', 'text_length': 1385, '__index_level_0__': 37948}\n",
      "{'dataset': 'pubmedqa', 'split_data': 'test', 'task': 'qa_objective_3', 'instruction': 'Choose the correct anser (Yes, No, or Maybe) for the given question based on the proviced context.', 'input': 'Question: Does risk assessment explain high prevalence of gestational diabetes mellitus in a large group of Sardinian women? Context: A very high prevalence (22.3%) of gestational diabetes mellitus (GDM) was recently reported following our study on a large group of Sardinian women. In order to explain such a high prevalence we sought to characterise our obstetric population through the analysis of risk factors and their association with the development of GDM. The prevalence of risk factors and their association with the development of GDM were evaluated in 1103 pregnancies (247 GDM and 856 control women). The association of risk factors with GDM was calculated according to logistic regression. Sensitivity and specificity of risk assessment strategy were also calculated. None of the risk factors evaluated showed an elevated frequency in our population. The high risk patients were 231 (20.9%). Factors with a stronger association with GDM development were obesity (OR 3.7, 95% CI 2.08-6.8), prior GDM (OR 3.1, 95% CI 1.69-5.69), and family history of Type 2 diabetes (OR 2.6, 95% CI 1.81-3.86). Only patients over 35 years of age were more represented in the GDM group (38.2% vs 22.6% in the non-GDM cases, P < 0.001). Type 2 diabetes in second-degree relatives was equally represented in GDM and non-GDM subjects, while prior poor obstetrical outcomes mostly characterized non-GDM women (17.5% vs 10.6%, P < 0.001). The \"average risk\" assessment better characterized non-GDM patients (76.8% vs 57.8%, P < 0.001). The logistic regression analysis confirmed that Type 2 diabetes in second-degree relatives, prior poor obstetrical outcomes and the \"average risk\" definition did not predict the development of GDM.', 'output': 'no', 'text_length': 1823, '__index_level_0__': 38004}\n",
      "{'dataset': 'pubmedqa', 'split_data': 'test', 'task': 'qa_objective_3', 'instruction': 'Choose the correct anser (Yes, No, or Maybe) for the given question based on the proviced context.', 'input': 'Question: Does decreasing Insulin Sensitivity in Women induce Alterations in LH Pulsatility? Context: Obesity is associated with neuroendocrine reproductive alterations and decreased fertility. The objective of the study was to gain insight into the neuroendocrine mechanisms implicated in these alterations. The effects on pulsatile LH secretion of 28 days of a hypercaloric diet were studied in lean and regularly cycling female volunteers. Approximately 50% extra calories (3 g sucrose/kg body weight per day and 1 g fat/kg body weight per day) were added to their individual daily requirements. Spontaneous and insulin-stimulated LH secretion was recorded on 2 different days, before and at the end of the caloric load. The hypercaloric diet induced an average weight gain of 2.0 ¬± 0.3 kg (P < .05), corresponding to a body mass index increase of 0.7 ¬± 0.1 kg/m(2) (P < .05). A concomitant decrease of 11.6% ¬± 4.6% in whole-body insulin sensitivity was also observed (Œ¥ = -1.6 ¬± 0.7 mg/kg ¬∑ min glucose; P < .05). The frequency of spontaneous and insulin-stimulated pulsatile LH secretion was increased by 17.9% ¬± 9.0% and 26.5% ¬± 9.0%, respectively (both P < .05). Spontaneous LH peak amplitude was decreased by 26.5% ¬± 9.0% (Œ¥ = -0.7 ¬± 0.36 U/L; P < .05), a change correlated with insulin sensitivity.', 'output': 'yes', 'text_length': 1408, '__index_level_0__': 37906}\n",
      "{'dataset': 'pubmedqa', 'split_data': 'test', 'task': 'qa_objective_3', 'instruction': 'Choose the correct anser (Yes, No, or Maybe) for the given question based on the proviced context.', 'input': 'Question: Is the homeostasis model assessment of the insulin resistance score predictive of a sustained virological response in chronic hepatitis C patients? Context: To investigate the independent association between the homeostasis model assessment of the insulin resistance (HOMA-IR) score and rapid virological response (RVR) and sustained virological response (SVR) in chronic hepatitis C (CHC). Observational prospective cohort study of 412 CHC patients [59% males; mean age 45 years; genotype 1 (44%), 2 (32%), 3 (19%) and 4 (5%)] treated with pegylated interferon Œ± plus ribavirin. A HOMA-IR ‚â•2.0 was present in 49% and a metabolic syndrome in 4% of patients. By multivariate analysis, independent predictors of SVR were the lack of advanced fibrosis (‚â•F3) in genotype 1 and a lower body mass index in genotype 3 patients. In the subgroup of patients in whom HCV-RNA was evaluated at week 4 (n = 281), independent predictors of RVR were HCV-RNA <700,000 IU/ml, age <40 years and lower aspartate aminotransferase:alanine aminotransferase ratio in genotype 1 and baseline HOMA-IR ‚â§2 in genotype 3 patients. No predictive factor of RVR was identified among genotype 2 patients. RVR was the strongest predictor of SVR among genotype 1 or 3 patients.', 'output': 'no', 'text_length': 1353, '__index_level_0__': 37951}\n",
      "Task: ie, Sampled: 50\n",
      "{'dataset': 'chemdner', 'split_data': 'test', 'task': 'ie', 'instruction': 'Extract all chemical entities (chemical compounds, drugs, and molecules) from the given text.', 'input': 'Central resistance to the actions of insulin and leptin is associated with the onset of obesity and type 2 diabetes mellitus (T2DM), whereas leptin and insulin signaling is essential for both glucose and energy homeostasis. Although it is known that leptin resistance can lead to attenuated insulin signaling, whether insulin resistance can lead to or exacerbate leptin resistance is unknown. To investigate the molecular events underlying crosstalk between these signaling pathways, immortalized hypothalamic neuronal models, rHypoE-19 and mHypoA-2/10, were utilized. Prolonged insulin exposure was used to induce cellular insulin resistance, and thereafter leptin-mediated regulation of signal transduction and gene expression was assessed. Leptin directly repressed agouti-related peptide (AgRP) mRNA levels, but induced urocortin-2 (UCN2), insulin receptor substrate-1 (IRS1), IRS2, and IR transcription, through leptin-mediated phosphatidylinositol-3-kinase (PI3K)/Akt activation. Neuronal insulin resistance, as assessed by attenuated Akt phosphorylation, blocked leptin-mediated signal transduction, and AgRP, UCN2, IRS1, IRS2 and IR synthesis. Insulin resistance caused a substantial decrease in IR protein levels, forkhead box protein 1 (FoxO1) phosphorylation, and an increase in suppressor of cytokine signaling 3 (SOCS3) protein levels. Cellular insulin resistance may cause or exacerbate neuronal leptin resistance, and by extension, obesity. It is essential to unravel the effects of neuronal insulin resistance given that both peripheral, as well as the less widely studied central insulin resistance, may contribute to the development of metabolic, reproductive and cardiovascular disorders. This study provides an improved understanding of the complex cellular crosstalk between insulin-leptin signal transduction that is disrupted during neuronal insulin resistance.', 'output': 'glucose', 'text_length': 1984, '__index_level_0__': 36639}\n",
      "{'dataset': 'chemdner', 'split_data': 'test', 'task': 'ie', 'instruction': 'Extract all chemical entities (chemical compounds, drugs, and molecules) from the given text.', 'input': 'Type 2 diabetes mellitus (T2D) patients often exhibit hyperglucagonemia despite hyperglycemia suggesting defective Œ±-cell function. While endoplasmic reticulum (ER) stress has been suggested to underlie Œ≤-cell dysfunction in T2D, its role in Œ±-cell biology remains unclear. X-box binding protein 1 (XBP1) is a transcription factor that plays a crucial role in the unfolded protein response (UPR) and its deficiency in Œ≤-cells has been reported to impair insulin secretion leading to glucose intolerance. To evaluate the role of XBP1 in Œ±-cells, we created complementary in vivo (Œ±-cell specific XBP1 knockout (Œ±XBPKO) mice) and in vitro (stable XBP1 knock down Œ±-cell line, Œ±XBPKD) models. Œ±XBPKO mice exhibited glucose intolerance, mild insulin resistance and an inability to suppress glucagon secretion following glucose stimulation. Œ±XBPKD cells exhibited activation of IRE1, an upstream activator of XBP1, leading to phosphorylation of JNK. Interestingly, insulin treatment of Œ±XBPKD cells reduced tyrosine phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing serine phosphorylation (pS(307)) of IRS-1. Consequently the Œ±XBPKD cells exhibited blunted suppression of glucagon secretion following insulin treatment in the presence of high glucose. Together, these data indicate that XBP1 deficiency in pancreatic Œ±-cells induces altered insulin signaling and dysfunctional glucagon secretion.', 'output': 'serine', 'text_length': 1520, '__index_level_0__': 36664}\n",
      "{'dataset': 'chemdner', 'split_data': 'test', 'task': 'ie', 'instruction': 'Extract all chemical entities (chemical compounds, drugs, and molecules) from the given text.', 'input': 'Effect of bisphenol-A on insulin signal transduction and glucose oxidation in skeletal muscle of adult male albino rat.', 'output': 'glucose', 'text_length': 219, '__index_level_0__': 36646}\n",
      "{'dataset': 'chemdner', 'split_data': 'test', 'task': 'ie', 'instruction': 'Extract all chemical entities (chemical compounds, drugs, and molecules) from the given text.', 'input': 'The insulin/IGF-1 pathway controls a number of physiological processes in the nematode worm Caenorhabditis elegans, including development, aging and stress response. We previously found that the Akt/PKB ortholog AKT-1 dampens the apoptotic response to genotoxic stress in the germline by negatively regulating the p53-like transcription factor CEP-1. Here, we report unexpected rearrangements to the insulin/IGF-1 pathway, whereby the insulin-like receptor DAF-2 and 3-phosphoinositide-dependent protein kinase PDK-1 oppose AKT-1 to promote DNA damage-induced apoptosis. While DNA damage does not affect phosphorylation at the PDK-1 site Thr350/Thr308 of AKT-1, it increased phosphorylation at Ser517/Ser473. Although ablation of daf-2 or pdk-1 completely suppressed akt-1-dependent apoptosis, the transcriptional activation of CEP-1 was unaffected, suggesting that daf-2 and pdk-1 act independently or downstream of cep-1 and akt-1. Ablation of the akt-1 paralog akt-2 or the downstream target of the insulin/IGF-1 pathway daf-16 (a FOXO transcription factor) restored sensitivity to damage-induced apoptosis in daf-2 and pdk-1 mutants. In addition, daf-2 and pdk-1 mutants have reduced levels of phospho-MPK-1/ERK in their germ cells, indicating that the insulin/IGF-1 pathway promotes Ras signaling in the germline. Ablation of the Ras effector gla-3, a negative regulator of mpk-1, restored sensitivity to apoptosis in daf-2 mutants, suggesting that gla-3 acts downstream of daf-2. In addition, the hypersensitivity of let-60/Ras gain-of-function mutants to damage-induced apoptosis was suppressed to wild-type levels by ablation of daf-2. Thus, insulin/IGF-1 signaling selectively engages AKT-2/DAF-16 to promote DNA damage-induced germ cell apoptosis downstream of CEP-1 through the Ras pathway.', 'output': 'phospho', 'text_length': 1901, '__index_level_0__': 36659}\n",
      "{'dataset': 'chemdner', 'split_data': 'test', 'task': 'ie', 'instruction': 'Extract all chemical entities (chemical compounds, drugs, and molecules) from the given text.', 'input': 'Despite the recent attention focused on the roles of the nucleotide binding and oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome in the pathogenesis of type 2 diabetes, little is known about the ex vivo profile of inflammasome activation in type 2 diabetic patients. In this study, we investigated patterns of NLRP3 inflammasome activation in monocyte-derived macrophages (MDMs) from drug-na√Øve patients with newly diagnosed type 2 diabetes. Type 2 diabetic subjects had significantly increased mRNA and protein expression of NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC), and proinflammatory cytokines in MDMs cultured with autologous sera compared with healthy controls. Upregulated interleukin (IL)-1Œ≤ maturation, IL-18 secretion, and caspase-1 cleavage were observed in MDMs from type 2 diabetic patients after stimulation with various danger molecules (ATP, high-mobility group protein B1, free fatty acids, islet amyloid polypeptide, and monosodium uric acid crystals). Mitochondrial reactive oxygen species and NLRP3 were required for IL-1Œ≤ synthesis in MDMs. Finally, 2 months of therapy with the antidiabetic drug metformin significantly inhibited the maturation of IL-1Œ≤ in MDMs from patients with type 2 diabetes through AMP-activated protein kinase (AMPK) activation. Taken together, these data suggest that NLRP3 inflammasome activation is elevated in myeloid cells from type 2 diabetic patients and that antidiabetic treatment with metformin contributes to modulation of inflammasome activation in type 2 diabetes.', 'output': 'ATP', 'text_length': 1691, '__index_level_0__': 36633}\n"
     ]
    }
   ],
   "source": [
    "import random\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "from datasets import load_dataset, Dataset, DatasetDict\n",
    "\n",
    "# ‚úÖ ÏãúÎìú ÏÑ§Ï†ï\n",
    "SEED = 42\n",
    "random.seed(SEED)\n",
    "np.random.seed(SEED)\n",
    "\n",
    "# ‚úÖ 1. Îç∞Ïù¥ÌÑ∞ÏÖã Î°úÎìú\n",
    "dataset_name = \"passionMan/diabetes_v11\"\n",
    "train_dataset = load_dataset(dataset_name, split=\"train\")\n",
    "test_dataset = load_dataset(dataset_name, split=\"test\")\n",
    "\n",
    "# ‚úÖ 2. Ï§ëÎ≥µ Î∞©ÏßÄÎ•º ÏúÑÌïú (input, output) ÏÑ∏Ìä∏ ÏÉùÏÑ±\n",
    "train_pairs = set((row[\"input\"], row[\"output\"]) for row in train_dataset)\n",
    "\n",
    "# ‚úÖ 3. `qa`, `ner`, `nli`, `ned`Îßå ÏÉòÌîåÎßÅ ÎåÄÏÉÅ\n",
    "task_sample_limits = {\n",
    "    'qa_objective_1': 50,  # medqa\n",
    "    'qa_objective_2': 50,  # medmcqa\n",
    "    'qa_objective_3': 50,  # pubmedqa\n",
    "    'nli': 50,\n",
    "    'ie': 50,\n",
    "    're': 50,\n",
    "}\n",
    "default_sample_limit = 50  # Í∏∞Î≥∏Í∞í 50Í∞ú ÏÉòÌîåÎßÅ\n",
    "\n",
    "# ‚úÖ 4. ÏÉòÌîåÎßÅ Îç∞Ïù¥ÌÑ∞ Ï†ÄÏû•Ïö© ÎîïÏÖîÎÑàÎ¶¨ Ï¥àÍ∏∞Ìôî\n",
    "task_sampled_data = {}\n",
    "task_counts = {task: 0 for task in task_sample_limits}  # ‚úÖ ÌïÑÏöî taskÎßå Ï¥àÍ∏∞Ìôî\n",
    "\n",
    "# ‚úÖ 5. TaskÎ≥Ñ ÏÉòÌîåÎßÅ ÏàòÌñâ\n",
    "test_dataset = test_dataset.shuffle(seed=SEED)\n",
    "\n",
    "for row in test_dataset:\n",
    "    task = row[\"task\"]\n",
    "    dataset_value = row.get(\"dataset\")  # ‚úÖ dataset Ïª¨Îüº Í∞í ÌôïÏù∏\n",
    "    input_output_pair = (row[\"input\"], row[\"output\"])\n",
    "\n",
    "    # ‚úÖ 5-1. `qa_objective`Î•º `medqa`ÏôÄ `medmcqa`Î°ú ÏÑ∏Î∂ÑÌôî\n",
    "    if task == \"qa_objective\":\n",
    "        if dataset_value == \"medqa\":\n",
    "            task = \"qa_objective_1\"  # medqa\n",
    "        elif dataset_value == \"medmcqa\":\n",
    "            task = \"qa_objective_2\"  # medmcqa\n",
    "        elif dataset_value == \"pubmedqa\":\n",
    "            task = \"qa_objective_3\"  # pubmedqa\n",
    "        else:\n",
    "            continue  # ‚úÖ `medqa`, `medmcqa`, `pubmedqa`Í∞Ä ÏïÑÎãàÎ©¥ Í±¥ÎÑàÎõ∞Í∏∞\n",
    "\n",
    "    # ‚úÖ 5-2. `qa`, `ner`, `nli`, `ned` Ïô∏Ïùò taskÎäî Î¨¥Ïãú\n",
    "    if task not in task_sample_limits:\n",
    "        continue  # ‚úÖ ÌïÑÏöî ÏóÜÎäî taskÎäî ÏÉòÌîåÎßÅ ÎåÄÏÉÅÏóêÏÑú Ï†úÏô∏\n",
    "\n",
    "    # ‚úÖ 5-3. ÏÉòÌîåÎßÅ Í∞úÏàò ÌôïÏù∏ Î∞è Ï§ëÎ≥µ Î∞©ÏßÄ\n",
    "    sample_limit = task_sample_limits.get(task, default_sample_limit)\n",
    "    \n",
    "    if task_counts.get(task, 0) < sample_limit and input_output_pair not in train_pairs:\n",
    "        if task not in task_sampled_data:\n",
    "            task_sampled_data[task] = []\n",
    "        task_sampled_data[task].append(row)\n",
    "        task_counts[task] += 1\n",
    "\n",
    "    # ‚úÖ 5-4. Î™®Îì† taskÏùò ÏÉòÌîåÎßÅ Í∞úÏàòÍ∞Ä Ï∂©Ï°±ÎêòÎ©¥ Ï¢ÖÎ£å\n",
    "    if all(task_counts.get(task, 0) >= task_sample_limits.get(task, default_sample_limit) for task in task_sample_limits):\n",
    "        break\n",
    "\n",
    "# ‚úÖ 6. ÏÉòÌîåÎßÅ Í≤∞Í≥º Ï∂úÎ†• (Í∞Å taskÎ≥Ñ 5Í∞ú ÏÉòÌîå ÌôïÏù∏)\n",
    "for task, samples in task_sampled_data.items():\n",
    "    print(f\"Task: {task}, Sampled: {len(samples)}\")\n",
    "    for sample in samples[:5]:  \n",
    "        print(sample)\n",
    "\n",
    "# ‚úÖ 7. ÏÉòÌîåÎßÅÎêú Îç∞Ïù¥ÌÑ∞ DatasetDictÎ°ú Î≥ÄÌôò\n",
    "sampled_dataset = DatasetDict({\n",
    "    task: Dataset.from_pandas(pd.DataFrame(samples)) for task, samples in task_sampled_data.items()\n",
    "})\n",
    "\n",
    "# ‚úÖ 8. ÌïÑÏöîÌïòÎ©¥ Ï†ÄÏû• Í∞ÄÎä• (Ï£ºÏÑù Ìï¥Ï†ú)\n",
    "# sampled_dataset.save_to_disk(\"sampled_test_dataset\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Processing samples:  38%|‚ñà‚ñà‚ñà‚ñä      | 190/500 [41:49<1:31:49, 17.77s/sample]  "
     ]
    }
   ],
   "source": [
    "import json\n",
    "import re\n",
    "from tqdm import tqdm\n",
    "from transformers import TextStreamer\n",
    "\n",
    "FastLanguageModel.for_inference(model)\n",
    "\n",
    "output_file = \"inference_results_test_v1.jsonl\"\n",
    "\n",
    "\n",
    "task_max_new_tokens = {\n",
    "    \"alternative_diet\": 512,\n",
    "    \"daily_diets\": 2048,\n",
    "    # \"dfh_info\": 256,\n",
    "    \"generation\": 8192,\n",
    "    \"ie\": 32,\n",
    "    \"nli\": 32,\n",
    "    \"qa_objective_1\": 128,\n",
    "    \"qa_objective_2\": 128,\n",
    "    \"qa_objective_3\": 128,\n",
    "    \"re\": 64,\n",
    "    \"summarization\": 8192, \n",
    "}\n",
    "\n",
    "\n",
    "# 1. `tqdm`ÏùÑ ÏÇ¨Ïö©ÌïòÏó¨ ÏßÑÌñâ ÏÉÅÌÉú ÌëúÏãú\n",
    "total_samples = sum(len(samples) for samples in sampled_dataset.values())\n",
    "with open(output_file, 'w') as f_out:\n",
    "    with tqdm(total=total_samples, desc=\"Processing samples\", unit=\"sample\") as pbar:\n",
    "        for task, sample in sampled_dataset.items():\n",
    "            for samp in sample:\n",
    "                # Îç∞Ïù¥ÌÑ∞ÏÖã Ïù¥Î¶ÑÏóê Îî∞Î•∏ context length ÏÑ§Ï†ï\n",
    "                task_name = samp.get(\"task\", \"\")\n",
    "                # max_new_tokens = 8192 if dataset_name in [\"meddialog\", \"pubmed\"] else 8\n",
    "                max_new_tokens = task_max_new_tokens.get(task_name, 8)  # Í∏∞Î≥∏Í∞í 8\n",
    "\n",
    "\n",
    "                # ÏûÖÎ†• ÌÜ†ÌÅ∞ ÏÉùÏÑ±\n",
    "                inputs = tokenizer(\n",
    "                    [\n",
    "                        alpaca_prompt.format(\n",
    "                            samp['instruction'],  # instruction\n",
    "                            samp['input'],  # input\n",
    "                            \"\",  # output\n",
    "                        )\n",
    "                    ], return_tensors=\"pt\"\n",
    "                ).to(\"cuda\")\n",
    "\n",
    "                # TextStreamer ÏÑ§Ï†ï\n",
    "                text_streamer = TextStreamer(tokenizer)\n",
    "                \n",
    "                # Î™®Îç∏ ÏÉùÏÑ± Î∞è Ï∂úÎ†•\n",
    "                output_tensor = model.generate(\n",
    "                    **inputs, \n",
    "                    max_new_tokens=max_new_tokens\n",
    "                )\n",
    "                model_output = tokenizer.decode(output_tensor[0], skip_special_tokens=True)\n",
    "\n",
    "                # `### Response:` Îí§Ïùò ÌÖçÏä§Ìä∏ Ï∂îÏ∂ú\n",
    "                response_text = None\n",
    "                response_match = re.search(r\"### Response:\\s*(.+)\", model_output, re.DOTALL)\n",
    "                if response_match:\n",
    "                    response_text = response_match.group(1).strip()\n",
    "                else:\n",
    "                    response_text = \"No valid response found\"\n",
    "\n",
    "                # Î™®Îç∏ Ï∂úÎ†• Í≤∞Í≥ºÎ•º sampÏóê Ï∂îÍ∞Ä\n",
    "                samp['model_output'] = response_text\n",
    "\n",
    "                # JSONL ÌòïÏãùÏúºÎ°ú Ï†ÄÏû•\n",
    "                f_out.write(json.dumps(samp, ensure_ascii=False) + \"\\n\")\n",
    "                \n",
    "                # tqdm ÏßÑÌñâ ÏÉÅÌÉú ÏóÖÎç∞Ïù¥Ìä∏\n",
    "                pbar.update(1)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "meal_kernel",
   "language": "python",
   "name": "meal"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
